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What is coronary heart disease?
Coronary heart disease (CHD) arises from atherosclerosis in the coronary arteries.1,2 
Atherosclerosis is a slowly progressing disease resulting in the formation of atherosclerotic 
plaques and narrowing of the arteries.1,2 Rupture of an atherosclerotic plaque leads to 
thrombus formation and temporal or permanent obstruction of the coronary artery.1,2 
As a consequence, the underlying tissue is no longer supplied with oxygen and nutrients, 
resulting in ischemia and possible necrosis of myocardial tissue.1,2 The patient experiences 
this as chest pain that may radiate to the neck, back, or arms, which is usually accompanied 
with nausea, excessive sweating, shortness of breath and fear of death.3,4 Although 20% 
of the patients (mostly women, diabetics, postoperative patients and elderly people) with 
a temporal or permanent obstruction of one of the coronary arteries lack chest pain and 
experience atypical symptoms.3,4
Acute CHD can appear as an acute myocardial infarction (MI) or unstable angina pectoris 
(UAP).3,4 If a patient experiences chest pain and/or other complaints concerning an 
obstruction of the coronary arteries an electrocardiogram (ECG) should be performed.3,4 
As shown in figure 1, an abnormal ECG is indicative for CHD, but is not sufficient by itself 
to distinguish between acute MI and UAP.5 The most important difference between acute 
MI and UAP is the presence of necrosis of myocardial tissue.3 Therefore, as shown in figure 
1, the final diagnosis of acute MI or UAP depends on the detection of proteins that are 
released in the blood due to myocardial tissue necrosis.4,5 
Figure 1 | A schematic 
representation illustrating 
the steps needed to 
diagnose acute myocardial 
infarction or unstable 
angina pectoris in patients 
experiencing ischemic 
discomfort (adapted from 








1Mortality of coronary heart disease
CHD is the main cause of death worldwide.6 In the Netherlands, 10,400 individuals died 
because of CHD (6000 males and 4400 females), accounting for 7.6% of all deaths in 2010, 
making CHD the second most important cause of death in the Netherlands (see table 1).7
Table 1 | Top ten of diseases with the highest mortality in the Netherlands in 2011 (www.nationaalkompas.nl)7
Disease/illness Males Females Combined
Lung cancer 6.586 3.958 10.544
Coronary heart disease 5.724 4.152 9.876
Dementia (including Alzheimer) 2.544 6.617 9.161
Stroke 3.315 5.165 8.480
Heart failure 2.499 3.999 6.498
COPD 3.466 2.887 6.353
Infections of the lower respiratory tract 2.613 3.068 5.681
Colon cancer 2.619 2.508 5.127
Breast cancer 22 3.261 3.283
Private accidents 1.246 1.575 2.821
All causes of death combined 65.259 70.482 135.741
COPD, Chronic Obstructive Pulmonary Disease
Since 1970 CHD mortality is declining in western countries,8,9 including the Netherlands.10 
This can be explained by technological advances such as bypass surgery and percutaneous 
coronary interventions, which prevent death during an acute manifestation of CHD.11 
Second, there are interventions that prolong survival once CHD is manifest (secondary 
prevention).12 This includes stimulating a healthy lifestyle and medical treatment to reduce 
high cholesterol levels and high blood pressure in individuals diagnosed with CHD.12 And 
finally by primary prevention aimed at preventing CHD in individuals that never had a CHD 
event.12 This can be done by stimulating a healthy lifestyle in the general population but also 
by treating individuals with a high risk for CHD with the same interventions that are used for 
secondary prevention.12,13 For the latter approach to be successful it is important to select 
only the individuals at high risk for CHD. To do so risk scores have been developed to select 
these high risk individuals. 
Risk scores for coronary heart disease
In 1948 the Framingham Heart Study was initiated, the goal of this study was to identify risk 
factors for CHD.14 At that point it was already assumed that CHD was a multifactor disease 
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that developed over a long time.14 The investigators included 5209 individuals, free from 
CHD aged between 30 and 59 years living in Framingham, Massachusetts and hoped that 
they could follow the included individuals for as long as 20 years.14 It was expected that by 
comparing individuals that developed CHD with individuals that remained healthy during 
the course of time, risk factors for CHD could be found.14
In 1957, the first report on the Framingham study was published.15 It was found that older 
age, male sex, high blood pressure, obesity and high cholesterol levels were associated 
with atherosclerotic heart disease.15 Twenty years later a general cardiovascular risk profile 
was proposed.16 This risk profile included the joint effects of gender, age, systolic blood 
pressure, serum cholesterol levels, cigarette smoking, electrocardiographic evidence of 
left ventricular hypertrophy and glucose intolerance.16 The Framingham score currently 
used is simplified,17 and based on a larger and more recent population (i.e. the original 
Framingham cohort plus their offspring).18 This simplified version includes the traditional 
risk factors (TRFs) sex, age, total cholesterol or LDL cholesterol, systolic blood pressure, 
smoking and self-reported diabetes.17 Left ventricular hypertrophy was no longer included, 
since it was highly correlated with hypertension.17 To date several other risk scores have 
been developed to predict the risk for cardiovascular disease19-22 and CHD23-27 in individuals 
free from cardiovascular disease. Of these, the SCORE function is used to assess CHD risk in 
individuals free from cardiovascular disease in the Netherlands.28,29 
The performance of these risk scores can be estimated by the C statistic,30 which is also 
known as the area under the receiver operator characteristic (ROC) curve31 or the C-index in 
case of survival data.32 The C-index estimates the probability that of two randomly chosen 
individuals, the one with a higher score will develop CHD earlier than the one with a lower 
score.32 The C-index can vary between 0.5 (50% of the cases are correctly ranked, meaning 
that the test is not better than flipping a coin) and 1 (all the cases are correctly ranked).32 For 
the Framingham risk score and comparable scores the C-index is around 0.75,33 meaning that 
in 75% of the cases, two randomly chosen individuals are correctly ranked.30 This indicates 
that there is room for improvement of the currently used CHD risks scores, which can be 
done by adding novel risk markers.
Metabolomics and coronary heart disease
Since atherosclerosis is a disease of the arteries it is reasonable to assume that most CHD 
risk factors can be found in blood. However of the risk factors to be found in blood the 
current risk scores only use total cholesterol, HDL-cholesterol and triglyceride levels as risk 
markers. There are a many other compounds to be found in blood, for example free fatty 







1atherosclerosis and thus CHD. By applying metabolomics technology it is possible to acquire 
information about the blood metabolome by identifying and quantifying metabolites in a 
non-biased way.34,35 To date more than 4000 different metabolites are already identified and 
quantified in human blood, and this number is still increasing.36 These metabolites reveal 
information about the metabolic state of an individual and this information might be useful 
for understanding, diagnosing or predicting CHD.
There are different techniques available for identifying and quantifying these metabolites.36 
Proton nuclear magnetic resonance (1H-NMR) spectroscopy and chromatography coupled 
to mass spectrometry (MS) based platforms are mostly used.37,38 See box 1 for a description 
of both techniques and their advantages and disadvantages.37,38 1H-NMR spectroscopy is a 
Box 1 | Techniques used for measuring metabolites at a large scale
The two most commonly used methods to obtain information about a person’s metabolome in one single 
measurement are chromatography coupled to mass spectrometry (MS) and proton nuclear magnetic 
resonance (1H-NMR) spectroscopy.37,38 
With chromatography coupled to MS, the compounds within the samples are first separated by separation 
techniques based on liquid or gas chromatography.41 Next, to identify these compounds the samples are 
placed in the mass spectrometer and ionized, the resulting charged molecules (ions) are than separated 
by their mass to charge ratio.41 Next, these ions fly into the detector, which records the current induced 
when this happens.41 This information is visualized in a mass spectrum.41 Depending on the location and 
the heights of the peaks in the mass spectrum, information about the identity and the abundance of the 
molecules in the biological sample can be deducted.41
1H-NMR spectroscopy is used to find clues about the structure of unknown molecules.37,42 1H stands for 
hydrogen-1, which is the most common hydrogen isotope.42 This hydrogen isotope contains 1 proton and 
1 electron and absorbs electromagnetic radiation at a specific frequency or resonance, depending on the 
force of the magnetic field used.42 In a 1H-NMR spectrometer, the electromagnetic radiation is fixed at a 
specific frequency but the magnetic field can be varied from high to low.42 When hydrogen atoms absorb 
electromagnetic radiation, this is visualized by peaks in the 1H-NMR spectrum.42 The location of the peaks 
depends on the chemical environment (i.e. the other atoms located nearby the hydrogen atom) of the 
hydrogen atoms.42 As a result a high or a low magnetic field is needed for the hydrogen atoms to absorb 
electromagnetic radiation.42 The heights and areas of the peaks reveal information about the number 
of hydrogen atoms in these specific chemical environments.42 Based on this information it is possible to 
identify molecules in a biological sample.42
Table | The advantages and disadvantages of 1H-NMR and chromatography coupled to MS based techniques.43
Method Advantages/Disadvantages
1H-NMR spectroscopy +highly reproducible
+fast
-relatively few metabolites can be identified and quantified
-low sensitivity, only high abundant metabolites can be detected
Chromatography coupled to MS +many different metabolites can be identified and quantified
+high sensitivity, also low abundant metabolites can be detected
-slow
-sample preparation is difficult
12
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robust and reliable technique that is highly reproducible,39 which is a prerequisite for the 
identification of novel biomarkers that may be used for CHD risk prediction improvement.40 
Moreover, 1H-NMR spectroscopy is fast, especially when compared to chromatography 
coupled to MS based platforms. The downside of 1H-NMR spectroscopy is it low sensitivity 
compared to MS based platforms. For example with 1H-NMR spectroscopy it is possible to 
identify and quantify up to 44 different metabolites in blood, whereas with chromatography-
MS based methods up to hundreds of different metabolites can be identified and quantified.36 
Thus with 1H-NMR spectroscopy it is possible to generate a robust and reliable profile of 
the metabolome in large study populations in relatively little time and it is hoped that this 
profile can be used to improve CHD risk prediction beyond TRFs.
Genetics and coronary heart disease
Twin, family and adoption studies showed that CHD has a heritable component.44-47 In a 
Swedish twin-registry study it was found that in males 57% of the variance in death from 
CHD can be explained by heritable factors and for females this was 38%.46 The proportion in 
CHD death explained by a non-shared environment was 43% for males and 62% for females, 
the shared environment did not explain any of the variance found.46  In a Danish twin study 
comparable results were found.47 Thus CHD is caused by a combination of genetic and 
environmental risk factors. Not only CHD, but also CHD risk factors have a large heritable 
component, including smoking,48 blood pressure,49 and blood lipid levels.50 
In 1996, Risch and Merikangas proposed that finding genetic variants associated with 
common complex disease in the common population required large scale testing by 
association analysis.51 With the completion of a physical map of the human genome in 
2001,52 and the identification of more than 1.4 million single nucleotide polymorphisms 
(SNPs)53 it became possible to associate diseases and/or traits with common genetic 
variants on a genome-wide scale. These studies are commonly referred to as genome-wide 
association studies (GWAS). 
In 2009 a catalog with published GWAS came online.54 On 13/12/12 this catalog (http://www.
genome.gov/gwastudies/) contained 1459 publications and 8084 SNPs. Of these studies, 
153 publications are related to CHD or CHD related risk factors (i.e. blood pressure, blood 
lipid levels, diabetes type and anthropomorphic related traits). Together these publications 
contain 914 SNPs associated with CHD or CHD risk factors.
The GWAS approach has delivered many SNPs for complex traits and with the progress 
made through meta-analysis leading to stable risk estimates for each SNP, the usefulness 
of these SNPs for CHD risk prediction should be tested. A limitation of GWAS is that every 







1associated with CHD or its risk factors, SNPs were combined into a genetic risk score (GRS).
56-
58 It was expected that such a GRS, based on SNPs associated with CHD or CHD risk factors is 
associated with incident CHD and perhaps can improve CHD risk prediction beyond the TRFs 
on which current CHD risk scores are based.56-58
Metabolic health
To find risk markers that may improve CHD risk prediction, most studies focus on finding risk 
factors for CHD. One may question if a low CHD risk is simply caused by the absence of risk 
factors or that there are protective factors involved, protecting individuals against CHD even 
in the presence of established CHD risk factors. To answer this question it is relevant to study 
which factors mark metabolic health. 
This can be done in the offspring of long-lived individuals that are characterized by a lower 
prevalence of age-related diseases, including diabetes, hypertension CHD and stroke.59-62 
This indicates that these long-lived individuals have a genetic or familial factor that somehow 
protects them against the development of metabolic diseases, which make them interesting 
for studying which factors are involved in healthy ageing and longevity and thus possible 
markers that are protective against CHD. 
Box 2 | Studies used in this thesis
Cardiovascular Registry Maastricht cohort study - The Cardiovascular Registry Maastricht (CAREMA) cohort 
study was set up to study coronary heart disease (CHD) and associated risk factors.63 The cohort consists 
of 21.148 participants born between 1927 and 1977 who were randomly sampled from Maastricht and 
surrounding communities between 1987 and 1997.63 This cohort was followed until December 2003. During 
this follow-up period, 742 incident CHD cases (i.e. acute myocardial infarction, unstable angina pectoris 
or death due to CHD) occurred.63,64 From the CAREMA cohort a sub-cohort was drawn, consisting of 2221 
participants, including 116 cases. Only the cases experiencing a CHD event and the members of the sub-
cohort are included in the data-analysis.65 This type of study design is called a case-cohort study.65 
Erasmus Rucphen Family study - The Erasmus Rucphen Family (ERF) study is a large, family-based study with 
participants from a genetically isolated community located in the Southwest of the Netherlands.66 The ERF 
study includes individuals that are the living descendants of 22 couples that had at least six children baptized 
in the community church between 1850 and 1900. Participants were thus not selected based on disease 
of interest.66 Participants were classified as a CHD case when they indicated that they had experienced 
a myocardial infarction, underwent a coronary revascularization procedure or if they reported angina 
symptoms during an interview with the study physician. Participants were also classified as a CHD case if 
they showed signs of myocardial infarction on the electrocardiogram. In this study of 2415 participants, 170 
participants were classified as a CHD case and 2157 participants were categorized as controls.
Leiden Longevity Study - This study was set up to investigate if there was evidence of genetic enrichment 
for exceptional survival using a family approach.67 For this study large series of sib pairs aged 90 years and 
over were collected.67 In addition the offspring of the long-lived siblings and the partners of the offspring 
were also collected for further study.67 The recruitment for this study started in July 2002.67 In total 421 




Aims of this thesis
The main goal of this thesis was to assess if CHD risk prediction based on the TRFs could 
be improved by adding novel risk markers. First it was tested if metabolomics data could 
improve CHD risk prediction beyond TRFs. Second it was investigated if genetic markers 
could improve CHD risk prediction. A secondary goal was to find out if a comprehensive 
lipid profile could mark metabolic health as opposite to age-related diseases like CHD in 
middle-aged individuals. Finally, as a first step in understanding more of CHD pathology we 
combined metabolomics data (a comprehensive fatty acid profile) with genetic information 
on the FADS1 gene. See box 2 for the studies used to investigate these questions.
Outline of this thesis
In chapter 2 we investigated if a metabolomics approach could be useful for improving and 
understanding CHD risk prediction beyond TRFs. Therefore we obtained a metabolic profile 
using 1H-NMR spectroscopy in the individuals who entered the Cardiovascular Registry 
Maastricht (CAREMA) cohort study from 1993 until 1997 and were selected for the sub-
cohort or experienced a CHD event during follow-up. Using least absolute shrinkage and 
selection operator (LASSO) regression,68,69 a subset of the most informative metabolites for 
predicting incident CHD was obtained. Subsequently, it was tested if a score based on these 
metabolites was associated with incident CHD within the same case-cohort study. Using the 
Erasmus Rucphen Family (ERF) study it was tested if the selected metabolites were relevant 
for differentiating between prevalent CHD cases and CHD-free controls.
In chapter 3 we compared two methods for data reduction, our own targeted approach 
explained in chapter 2 and a more commonly used method which involves partitioning 
the 1H-NMR spectra into discrete sections and calculate the sum of the spectral intensity 
in each section.70,71 Moreover, we also evaluated the impact of two scaling methods (i.e. 
autoscaling and pareto scaling) which are commonly used as data pre-treatment methods 
in metabolomics data-analysis.72
In chapter 4, as apposite to the development of CHD, factors that promote longevity and 
metabolic health were studied. Therefore offspring of long-lived siblings were compared to 
their same-aged spouses representing the general population. Siblings are considered long-
lived when they are 90 years or older and have a brother or sister who is also 90 years or 
older.67 These long-lived siblings could not be easily compared a control group since most 
subjects in their birth cohort were already deceased. However at middle-age their offspring 
also showed less overall mortality, and metabolic disease compared to the general Dutch 







1aged partners. With this approach it is possible to study the differences between people 
that have a tendency to become long-lived and people with an average life expectancy. 
The focus for this chapter was on lipid metabolism. Thus a comprehensive lipid profile was 
obtained using 1H-NMR spectroscopy.73
In chapter 5 it was investigated if GWAS identified SNPs known to be associated with CHD or 
CHD risk factors (i.e. blood pressure, diabetes type 2, blood lipid levels and anthropomorphic 
related traits) could improve CHD risk prediction beyond traditional CHD risk factors. Based 
on these SNPs GRSs were constructed. First we focused on counted GRSs. The first counted 
GRS was based on SNPs associated with CHD and CHD risk factors, the second one was based 
on SNPs associated with CHD risk factors and the third one was based on SNPs associated 
with CHD only. The fourth GRS was also based on SNPs associated with CHD, but in contrast 
to the counted GRS, we adjusted for the different effect sizes of the CHD associated SNPs. 
The effect sizes for these SNPs were based on two large meta-analysis.74,75 As an exploratory 
approach, we selected a subset of the most informative SNPs using LASSO regression.
In chapter 6, the fatty acid metabolism was explored for gaining more understanding in the 
development of CHD. Lipid metabolism, including fatty acid metabolism plays an important 
role in CHD etiology.  For example, a high intake of polyunsaturated fatty acids reduces 
CHD risk.76-78 The fatty acid intake is often estimated by assessing the fatty acid contents in 
biological tissues.79 This profile, however, does not only reflect dietary intake, but also fatty 
acid metabolism in the body itself,79 in which δ-5 and δ-6 desaturase play an important 
role.80,81 In this chapter we explored the role of δ-5 and δ-6 desaturase in CHD, in addition 




1. Lusis AJ. Atherosclerosis. Nature. Sep 14 
2000;407(6801):233-241.
2. Weber C, Noels H. Atherosclerosis: current patho-
genesis and therapeutic options. Nature medi-
cine. 2011;17(11):1410-1422.
3. Welch TD, Yang EH, Reeder GS, Gersh BJ. Modern 
management of acute myocardial infarction. Cur-
rent problems in cardiology. Jul 2012;37(7):237-
310.
4. Myocardial infarction redefined--a consensus 
document of The Joint European Society of Cardi-
ology/American College of Cardiology Committee 
for the redefinition of myocardial infarction. Euro-
pean heart journal. Sep 2000;21(18):1502-1513.
5. Wright RS, Anderson JL, Adams CD, et al. 2011 
ACCF/AHA focused update incorporated into the 
ACC/AHA 2007 Guidelines for the Management 
of Patients with Unstable Angina/Non-ST-Eleva-
tion Myocardial Infarction: a report of the Amer-
ican College of Cardiology Foundation/American 
Heart Association Task Force on Practice Guide-
lines developed in collaboration with the Amer-
ican Academy of Family Physicians, Society for 
Cardiovascular Angiography and Interventions, 
and the Society of Thoracic Surgeons. Journal 
of the American College of Cardiology. May 10 
2011;57(19):e215-367.
6. World Health Organization. The top 10 causes 
of death. 2013; http://www.who.int/mediacen-
tre/factsheets/fs310/en/. Accessed 26-02-2014, 
2014.
7. Poos M. Sterfte naar doodsoorzaak: Waaraan 
overlijden mensen in Nederland? 2013; http://
www.nationaalkompas.nl/gezondheid-en-ziek-




8. Thom TJ. International Mortality from Heart-Dis-
ease - Rates and Trends. International Journal of 
Epidemiology. 1989;18:S20-S28.
9. Nichols M, Townsend N, Scarborough P, Rayner 
M. Trends in age-specific coronary heart disease 
mortality in the European Union over three de-
cades: 1980-2009. European heart journal. Oct 
2013;34(39):3017-3027.
10. Reitsma JB, Dalstra JA, Bonsel GJ, et al. Cardiovas-
cular disease in the Netherlands, 1975 to 1995: 
decline in mortality, but increasing numbers 
of patients with chronic conditions. Heart. Jul 
1999;82(1):52-56.
11. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel 
S, Murphy A. Growing epidemic of coronary heart 
disease in low- and middle-income countries. Cur-
rent problems in cardiology. Feb 2010;35(2):72-
115.
12. Ford ES, Capewell S. Proportion of the decline in 
cardiovascular mortality disease due to preven-
tion versus treatment: public health versus clinical 
care. Annual review of public health. 2011;32:5-
22.
13. Smolina K, Wright FL, Rayner M, Goldacre MJ. De-
terminants of the decline in mortality from acute 
myocardial infarction in England between 2002 
and 2010: linked national database study. Bmj. 
2012;344:d8059.
14. Dawber TR, Meadors GF, Moore FE, Jr. Epidemio-
logical approaches to heart disease: the Framing-
ham Study. American journal of public health and 
the nation’s health. Mar 1951;41(3):279-281.
15. Dawber TR, Moore FE, Mann GV. Coronary heart 
disease in the Framingham study. American jour-
nal of public health and the nation’s health. Apr 
1957;47(4 Pt 2):4-24.
16. Kannel WB, McGee D, Gordon T. A general cardio-
vascular risk profile: the Framingham Study. The 
American journal of cardiology. Jul 1976;38(1):46-
51.
17. Wilson PW, D’Agostino RB, Levy D, Belanger AM, 
Silbershatz H, Kannel WB. Prediction of coronary 
heart disease using risk factor categories. Circula-
tion. May 12 1998;97(18):1837-1847.
18. Anderson KM, Wilson PW, Odell PM, Kannel 
WB. An updated coronary risk profile. A state-
ment for health professionals. Circulation. Jan 
1991;83(1):356-362.
19. Conroy R. Estimation of ten-year risk of fatal car-
diovascular disease in Europe: the SCORE project. 
European heart journal. 2003;24(11):987-1003.
20. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook 
NR. C-reactive protein and parental history im-
prove global cardiovascular risk prediction: the 
Reynolds Risk Score for men. Circulation. Nov 25 
2008;118(22):2243-2251, 2244p following 2251.
21. Woodward M, Brindle P, Tunstall-Pedoe H, esti-
mation Sgor. Adding social deprivation and family 
history to cardiovascular risk assessment: the AS-
SIGN score from the Scottish Heart Health Extend-
ed Cohort (SHHEC). Heart. Feb 2007;93(2):172-
176.
22. Balkau B, Hu G, Qiao Q, et al. Prediction of the risk 







1cludes glucose as a risk factor. The DECODE Study. Diabetologia. Dec 2004;47(12):2118-2128.
23. Tunstall-Pedoe H. The Dundee coronary risk-disk 
for management of change in risk factors. Bmj. 
Sep 28 1991;303(6805):744-747.
24. Menotti A, Lanti M, Puddu PE, Kromhout D. Cor-
onary heart disease incidence in northern and 
southern European populations: a reanalysis of 
the seven countries study for a European coro-
nary risk chart. Heart. Sep 2000;84(3):238-244.
25. Stevens RJ, Kothari V, Adler AI, Stratton IM, Hol-
man RR, Grp U. The UKPDS risk engine: a model 
for the risk of coronary heart disease in Type II di-
abetes (UKPDS 56). Clin Sci. Dec 2001;101(6):671-
679.
26. Chambless LE, Folsom AR, Sharrett AR, et al. Cor-
onary heart disease risk prediction in the Athero-
sclerosis Risk in Communities (ARIC) study. Jour-
nal of Clinical Epidemiology. 2003;56(9):880-890.
27. Assmann G, Schulte H, Cullen P, Seedorf U. As-
sessing risk of myocardial infarction and stroke: 
new data from the Prospective Cardiovascular 
Munster (PROCAM) study. European journal of 
clinical investigation. Dec 2007;37(12):925-932.
28. Smulders YM, Burgers JS, Scheltens T, et al. Clini-
cal practice guideline for cardiovascular risk man-
agement in the Netherlands. The Netherlands 
journal of medicine. Apr 2008;66(4):169-174.
29. Graham I, Atar D, Borch-Johnsen K, et al. Euro-
pean guidelines on cardiovascular disease pre-
vention in clinical practice: executive summary: 
Fourth Joint Task Force of the European Society 
of Cardiology and Other Societies on Cardiovas-
cular Disease Prevention in Clinical Practice (Con-
stituted by representatives of nine societies and 
by invited experts). European heart journal. Oct 
2007;28(19):2375-2414.
30. Cook NR. Use and misuse of the receiver operat-
ing characteristic curve in risk prediction. Circula-
tion. Feb 20 2007;115(7):928-935.
31. Hanley JA, McNeil BJ. The meaning and use of 
the area under a receiver operating characteristic 
(ROC) curve. Radiology. Apr 1982;143(1):29-36.
32. Harrell FE, Jr., Califf RM, Pryor DB, Lee KL, Rosati 
RA. Evaluating the yield of medical tests. JAMA : 
the journal of the American Medical Association. 
May 14 1982;247(18):2543-2546.
33. Cook NR, Paynter NP, Eaton CB, et al. Comparison 
of the Framingham and Reynolds Risk scores for 
global cardiovascular risk prediction in the multi-
ethnic Women’s Health Initiative. Circulation. Apr 
10 2012;125(14):1748-1756, S1741-1711.
34. Ellis DI, Dunn WB, Griffin JL, Allwood JW, Goo-
dacre R. Metabolic fingerprinting as a diagnostic 
tool. Pharmacogenomics. Sep 2007;8(9):1243-
1266.
35. Nicholson JK, Lindon JC. Systems biology: Meta-
bonomics. Nature. Oct 23 2008;455(7216):1054-
1056.
36. Psychogios N, Hau DD, Peng J, et al. The human 
serum metabolome. PloS one. 2011;6(2):e16957.
37. Beckonert O, Keun HC, Ebbels TM, et al. Meta-
bolic profiling, metabolomic and metabonomic 
procedures for NMR spectroscopy of urine, plas-
ma, serum and tissue extracts. Nature protocols. 
2007;2(11):2692-2703.
38. Dunn WB, Broadhurst D, Begley P, et al. Proce-
dures for large-scale metabolic profiling of serum 
and plasma using gas chromatography and liquid 
chromatography coupled to mass spectrometry. 
Nature protocols. Jul 2011;6(7):1060-1083.
39. Dumas ME, Maibaum EC, Teague C, et al. Assess-
ment of analytical reproducibility of 1H NMR 
spectroscopy based metabonomics for large-scale 
epidemiological research: the INTERMAP Study. 
Analytical chemistry. Apr 1 2006;78(7):2199-
2208.
40. Dent TH. Predicting the risk of coronary heart 
disease. II: the role of novel molecular bio-
markers and genetics in estimating risk, and the 
future of risk prediction. Atherosclerosis. Dec 
2010;213(2):352-362.
41. Mishur RJ, Rea SL. Applications of mass spec-
trometry to metabolomics and metabonomics: 
detection of biomarkers of aging and of age-relat-
ed diseases. Mass spectrometry reviews. Jan-Feb 
2012;31(1):70-95.
42. Keeler J. Understanding NMR Spectroscopy. Wi-
ley; 2013.
43. Mayr M. Metabolomics: ready for the prime 
time? Circulation. Cardiovascular genetics. Oct 
2008;1(1):58-65.
44. Marenberg ME, Risch N, Berkman LF, Floderus 
B, de Faire U. Genetic susceptibility to death 
from coronary heart disease in a study of twins. 
The New England journal of medicine. Apr 14 
1994;330(15):1041-1046.
45. Zdravkovic S, Wienke A, Pedersen NL, Marenberg 
ME, Yashin AI, De Faire U. Heritability of death 
from coronary heart disease: a 36-year follow-up 
of 20 966 Swedish twins. Journal of internal med-
icine. Sep 2002;252(3):247-254.
46. Sundquist K, Winkleby M, Li X, Ji J, Hemminki 
K, Sundquist J. Familial transmission of coro-
18
Chapter 1
nary heart disease: a cohort study of 80,214 
Swedish adoptees linked to their biological and 
adoptive parents. American heart journal. Aug 
2011;162(2):317-323.
47. Wienke A, Holm NV, Skytthe A, Yashin AI. The her-
itability of mortality due to heart diseases: a cor-
related frailty model applied to Danish twins. Twin 
research : the official journal of the International 
Society for Twin Studies. Aug 2001;4(4):266-274.
48. Boomsma DI, Koopmans JR, Van Doornen LJ, Orle-
beke JF. Genetic and social influences on starting 
to smoke: a study of Dutch adolescent twins and 
their parents. Addiction. Feb 1994;89(2):219-226.
49. Evans A, Van Baal GC, McCarron P, et al. The ge-
netics of coronary heart disease: the contribution 
of twin studies. Twin research : the official journal 
of the International Society for Twin Studies. Oct 
2003;6(5):432-441.
50. Beekman M, Heijmans BT, Martin NG, et al. Her-
itabilities of apolipoprotein and lipid levels in 
three countries. Twin research : the official jour-
nal of the International Society for Twin Studies. 
Apr 2002;5(2):87-97.
51. Risch N, Merikangas K. The future of genetic stud-
ies of complex human diseases. Science. Sep 13 
1996;273(5281):1516-1517.
52. McPherson JD, Marra M, Hillier L, et al. A phys-
ical map of the human genome. Nature. Feb 15 
2001;409(6822):934-941.
53. Sachidanandam R, Weissman D, Schmidt SC, et al. 
A map of human genome sequence variation con-
taining 1.42 million single nucleotide polymor-
phisms. Nature. Feb 15 2001;409(6822):928-933.
54. Hindorff LA, Sethupathy P, Junkins HA, et al. Po-
tential etiologic and functional implications of 
genome-wide association loci for human diseases 
and traits. Proceedings of the National Academy 
of Sciences of the United States of America. Jun 9 
2009;106(23):9362-9367.
55. Botstein D, Risch N. Discovering genotypes un-
derlying human phenotypes: past successes for 
mendelian disease, future approaches for com-
plex disease. Nature genetics. Mar 2003;33 Sup-
pl:228-237.
56. Aulchenko YS, Ripatti S, Lindqvist I, et al. Loci in-
fluencing lipid levels and coronary heart disease 
risk in 16 European population cohorts. Nature 
genetics. Jan 2009;41(1):47-55.
57. Paynter NP, Chasman DI, Pare G, et al. Association 
between a literature-based genetic risk score and 
cardiovascular events in women. JAMA : the jour-
nal of the American Medical Association. Feb 17 
2010;303(7):631-637.
58. Morrison AC, Bare LA, Chambless LE, et al. Predic-
tion of coronary heart disease risk using a genetic 
risk score: the Atherosclerosis Risk in Communi-
ties Study. American journal of epidemiology. Jul 
1 2007;166(1):28-35.
59. Adams ER, Nolan VG, Andersen SL, Perls TT, Terry 
DF. Centenarian offspring: start healthier and stay 
healthier. Journal of the American Geriatrics Soci-
ety. Nov 2008;56(11):2089-2092.
60. Westendorp RG, van Heemst D, Rozing MP, et al. 
Nonagenarian siblings and their offspring display 
lower risk of mortality and morbidity than spo-
radic nonagenarians: The Leiden Longevity Study. 
Journal of the American Geriatrics Society. Sep 
2009;57(9):1634-1637.
61. Florez H, Ma Y, Crandall JP, et al. Parental longev-
ity and diabetes risk in the Diabetes Prevention 
Program. The journals of gerontology. Series A, 
Biological sciences and medical sciences. Nov 
2011;66(11):1211-1217.
62. Terry DF, Wilcox MA, McCormick MA, Perls TT. 
Cardiovascular disease delay in centenarian off-
spring. The journals of gerontology. Series A, 
Biological sciences and medical sciences. Apr 
2004;59(4):385-389.
63. Merry AH, Boer JM, Schouten LJ, et al. Validity of 
coronary heart diseases and heart failure based 
on hospital discharge and mortality data in the 
Netherlands using the cardiovascular registry 
Maastricht cohort study. European journal of epi-
demiology. 2009;24(5):237-247.
64. Merry AH, Boer JM, Schouten LJ, et al. Risk pre-
diction of incident coronary heart disease in The 
Netherlands: re-estimation and improvement of 
the SCORE risk function. European journal of pre-
ventive cardiology. Aug 2012;19(4):840-848.
65. Prentice RL. A Case-Cohort Design for Epidemio-
logic Cohort Studies and Disease Prevention Tri-
als. Biometrika. Apr 1986;73(1):1-11.
66. Sayed-Tabatabaei FA, van Rijn MJ, Schut AF, et al. 
Heritability of the function and structure of the 
arterial wall: findings of the Erasmus Rucphen 
Family (ERF) study. Stroke; a journal of cerebral 
circulation. Nov 2005;36(11):2351-2356.
67. Schoenmaker M, de Craen AJ, de Meijer PH, et al. 
Evidence of genetic enrichment for exceptional 
survival using a family approach: the Leiden Lon-
gevity Study. European journal of human genetics 







168. Tibshirani R. The lasso method for variable selec-tion in the Cox model. Statistics in medicine. Feb 
28 1997;16(4):385-395.
69. Tibshirani R. Regression shrinkage and selection 
via the Lasso. J Roy Stat Soc B Met. 1996;58(1):267-
288.
70. De Meyer T, Sinnaeve D, Van Gasse B, et al. Eval-
uation of standard and advanced preprocessing 
methods for the univariate analysis of blood se-
rum 1H-NMR spectra. Analytical and bioanalytical 
chemistry. Oct 2010;398(4):1781-1790.
71. Smolinska A, Blanchet L, Buydens LM, Wijmenga 
SS. NMR and pattern recognition methods in me-
tabolomics: from data acquisition to biomarker 
discovery: a review. Analytica chimica acta. Oct 
31 2012;750:82-97.
72. van den Berg RA, Hoefsloot HC, Westerhuis JA, 
Smilde AK, van der Werf MJ. Centering, scaling, 
and transformations: improving the biological 
information content of metabolomics data. BMC 
genomics. 2006;7:142.
73. Heijmans BT, Beekman M, Houwing-Duistermaat 
JJ, et al. Lipoprotein particle profiles mark famil-
ial and sporadic human longevity. PLoS medicine. 
Dec 2006;3(12):e495.
74. Schunkert H, Konig IR, Kathiresan S, et al. Large-
scale association analysis identifies 13 new sus-
ceptibility loci for coronary artery disease. Nature 
genetics. Apr 2011;43(4):333-338.
75. International Consortium for Blood Pressure Ge-
nome-Wide Association S, Ehret GB, Munroe PB, 
et al. Genetic variants in novel pathways influence 
blood pressure and cardiovascular disease risk. 
Nature. Oct 6 2011;478(7367):103-109.
76. Mozaffarian D. Fish and n-3 fatty acids for the 
prevention of fatal coronary heart disease and 
sudden cardiac death. The American journal of 
clinical nutrition. Jun 2008;87(6):1991S-1996S.
77. Harris WS, Mozaffarian D, Rimm E, et al. Omega-6 
fatty acids and risk for cardiovascular disease: a 
science advisory from the American Heart Asso-
ciation Nutrition Subcommittee of the Council 
on Nutrition, Physical Activity, and Metabolism; 
Council on Cardiovascular Nursing; and Council 
on Epidemiology and Prevention. Circulation. Feb 
17 2009;119(6):902-907.
78. De Caterina R. n-3 fatty acids in cardiovascular dis-
ease. The New England journal of medicine. Jun 
23 2011;364(25):2439-2450.
79. Raatz SK, Bibus D, Thomas W, Kris-Etherton P. 
Total fat intake modifies plasma fatty acid com-
position in humans. The Journal of nutrition. Feb 
2001;131(2):231-234.
80. Cho HP, Nakamura M, Clarke SD. Cloning, expres-
sion, and fatty acid regulation of the human del-
ta-5 desaturase. The Journal of biological chemis-
try. Dec 24 1999;274(52):37335-37339.
81. Cho HP, Nakamura MT, Clarke SD. Cloning, expres-
sion, and nutritional regulation of the mammali-
an Delta-6 desaturase. The Journal of biological 
chemistry. Jan 1 1999;274(1):471-477.
20
21







A metabolomics profile is associated with 
the risk of incident coronary heart disease
Anika A.M. Vaarhorst1*, Aswin Verhoeven2*, Claudia M. Weller3*, Stefan Böhringer4, 
Sibel Göraler2, Axel Meissner2, André M. Deelder2, Peter Henneman3, Anton P.M. Gorgels5, 
Piet A. van den Brandt6,7, Leo J. Schouten7, Marleen M. van Greevenbroek8, 
Audrey H.H. Merry6, W.M. Monique Verschuren9, Arn M.J.M. van den Maagdenberg3,10, 
Ko Willems van Dijk3,11, Aaron Isaacs12, Dorret Boomsma13, Ben A. Oostra12, 
Cornelia M. van Duijn12, J. Wouter Jukema14,15,16, Jolanda M.A. Boer9, Edith Feskens17, 
Bastiaan T. Heijmans1, P. Eline Slagboom1,18
*These authors contributed equally to this work
From the departments of 1) Molecular Epidemiology, 2) Center for Proteomics and Metabolomics, 3) Human 
Genetics, 4) Medical Statistics, 10) Neurology, 11) Endocrinology, 14) Cardiology, Leiden University Medical 
Center, Leiden, the Netherlands From the departments of 5) Cardiology, 8) Internal Medicine (CARIM School for 
Cardiovascular diseases), Maastricht University Medical Centre, Maastricht, the Netherlands From the departments 
of 6) Epidemiology (CAPHRI School for Public Health and Primary Care), 7) Epidemiology (GROW School of 
Oncology and Developmental Biology), Maastricht University, Maastricht, the Netherlands; 9) National Institute for 
Public Health and the Environment, Bilthoven, the Netherlands; 12) Department of Epidemiology, Erasmus Medical 
Center, Rotterdam, the Netherlands; 13) Biological Psychology, VU University, Amsterdam, the Netherlands; 15) The 
Durrer Center for Cardiogenetic Research, Amsterdam, the Netherlands; 16) Interuniversity Cardiology Institute of 
the Netherlands (ICIN), Utrecht, the Netherlands; 17) Division of Human Nutrition, Wageningen University and 
Research Center, Wageningen, the Netherlands; 18) Netherlands Consortium for Healthy Ageing




Background Metabolomics, defined as the comprehensive identification and quantification 
of low-molecular-weight metabolites to be found in a biological sample, has been put 
forward as a potential tool for classifying individuals according to their risk of coronary 
heart disease (CHD). Here, we investigated whether a single-point blood measurement of 
the metabolome is associated with and predictive for the risk of CHD.
Methods & Results We obtained proton nuclear magnetic resonance (1H-NMR) spectra in 79 
cases who developed CHD during follow-up (median 8.1 years) and in 565 randomly selected 
individuals. In these spectra 100 signals representing 36 metabolites were identified. 
Applying LASSO regression, we defined a weighted metabolite score consisting of 13 1H-NMR 
signals that optimally predicted CHD. This metabolite score, including signals representing 
a lipid fraction, glucose, valine, ornithine, glutamate, creatinine,  glycoproteins, citrate and 
1.5-anhydrosorbitol, was associated with the incidence of CHD independent of traditional 
risk factors (TRFs) (HR=1.50; 95%CI=1.12-2.01). Predictive performance of this metabolite 
score on its own was moderate (C-index=0.75; 95%CI=0.70-0.80) but after adding age and 
sex the C-index was only modestly lower than that of TRFs (C-index=0.81; 95%CI=0.77-0.85 
and C-index=0.82; 95%CI=0.78-0.87, respectively). The metabolite score was also associated 
with prevalent CHD independent of TRFs (OR=1.59; 95%CI=1.19-2.13). 
Conclusion A metabolite score derived from a single-point metabolome measurement is 
associated with CHD and metabolomics may be a promising tool for refining and improving 
the prediction of CHD. 
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Over the last 50 years, risk factors that are robustly and independently associated with 
coronary heart disease (CHD), including lipid levels, blood pressure, lifestyle factors, family 
history, sex and age, were identified.1,2 Based on these traditional risk factors (TRFs), scores 
have been developed to predict CHD risk for an individual.1,2 The discriminatory capabilities 
for these scores, as assessed by the C-index, ranges from 0.71 to 0.84.1
Metabolomics refers to the identification and quantification of low-molecular-weight 
metabolites in a biological sample.3 Recent technological developments made it possible 
to generate metabolomics profiles of blood samples consisting of 10s to 100s metabolites 
in a single measurement.4 These profiles are considered to be promising tools to efficiently 
capture the predictive information of TRFs and may potentially contribute to further 
improvement of primary CHD risk prediction.3
Several studies have attempted to use a metabolomics approach to diagnose prevalent 
CHD5,6 or to predict incident CHD events in individuals free from cardiovascular disease7-9 or 
diagnosed with CHD10-13 or diabetes.14 According to some studies, a metabolomics approach 
might improve CHD risk prediction.8-13 For example, in one study, 1H-NMR spectroscopy 
improves the prediction of subclinical atherosclerosis in comparison to conventional 
lipid testing.8 Other studies found that a baseline metabolomics profile based on mass-
spectroscopy was associated with incident cardiovascular events in patients diagnosed with 
CHD11 or in patients with suspected CHD.10,12,13 However, none of these studies investigated 
if a metabolite profile based on low-molecular-weight molecules identified by proton 
nuclear magnetic resonance (1H-NMR) spectroscopy could predict incident CHD, defined as 
an acute myocardial infarction (MI), unstable angina pectoris (UAP) or dead because of CHD, 
in individuals free from cardiovascular disease. Therefore, we studied the association of 
an 1H-NMR based metabolite profile with incident CHD in a prospective case-cohort study. 
Subsequently, a second study was performed in an independent population to test if the 
selected metabolites were also relevant to classify prevalent CHD.
Material and Methods
Study populations
Primary study: We conducted a prospective case-cohort study within the Monitoring 
project on chronic disease risk factors (MORGEN-Project) 1993-1997,15 one of the two 
monitoring studies that were included in the Cardiovascular Registry Maastricht study.16 
In total 6459 men and women, between 20-59 years old at the moment of inclusion, had 
given informed consent to retrieve information from the municipal registries and from the 
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general practitioner and specialist. The study complied with the Declaration of Helsinki and 
was approved by the Medical Ethics Committee of TNO (Dutch Organization for Applied 
Scientific Research). We excluded participants who were younger than 30 years at baseline 
(n=1301), who had had an acute MI, UAP, a coronary artery bypass graft or a percutaneous 
transluminal coronary angioplasty before baseline (n=69), or were lost to follow-up (n=15), 
resulting in an eligible cohort of 5074 participants.
Sub-cohort selection: From the eligible cohort, a sub-cohort of 738 participants was randomly 
drawn. This took place before cardiologic follow-up. EDTA plasma was unavailable for 92 
participants and 1H-NMR analysis failed in 19 participants. For 62 participants information 
on TRFs (i.e. total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], systolic 
blood pressure [SBP], current smoking, body mass index [BMI], current diabetes status and 
a parental history of MI) was incomplete, resulting in a sub-cohort of 565 participants.
Cardiologic follow-up: The cardiologic follow-up has been described in detail earlier16 
and ended on 31 December 2003 with a median follow-up of 8.1 years (range=0.2-10.9 
years). During follow-up 125 participants developed CHD (acute MI n=55, UAP n=51, dead 
due to CHD n=19, [ICD-9 410-414 and ICD-10 I20-I25]). For 31 patients EDTA plasma for 
1H-NMR analysis was unavailable and in one patient 1H-NMR analysis failed. For 14 patients 
information on TRFs was incomplete, resulting in 79 patients.
Determination of TRFs: At baseline, participants filled in a questionnaire on medical history 
(including self-reported diabetes), parental history of MI (defined as no parents with MI, one 
parent with MI or both parents with MI), and lifestyle factors (including smoking). During 
a medical examination, information on SBP and BMI was collected and non-fasting EDTA 
blood samples were taken.17,18 The blood was centrifuged for 10 minutes at 1000 rpm at 4˚C 
and EDTA plasma aliquots were stored at -80°C in tubes of 0.5 mL for future analysis, or at 
-20°C for cholesterol determinations. HDL-C and TC levels were determined in the plasma 
samples stored at -20°C using a CHOD-PAP method.19
Secondary study: The Erasmus Rucphen Family study is a population-based study in a 
genetically isolated community in the Southwest of the Netherlands and includes 3465 
individuals, who are living descendants of 22 couples that had at least six children baptized 
in the community church between 1850 and 1900. Details are described elsewhere.20 The 
study was approved by the Medical Ethical Committee of the Erasmus Medical Center in 
Rotterdam and all participants gave written informed consent.
Determination of TRFs: All participants filled in questionnaires about lifestyle, personal 
and family medical history. During personal interviews performed by study physicians, 
information on lifestyle factors, medication use, personal and family medical history was 
collected. Physical examinations were performed, including measurements of SBP and BMI.21 
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In addition, fasted blood samples were taken. An electrocardiogram (ECG) was performed 
and scored by an experienced cardiologist. Plasma concentrations of HDL-C and TC were 
determined according to standard procedures.22 Diabetes was defined as the use of blood 
glucose-lowering medication and/or fasting glucose levels of ≥7 mmol/L.
Diagnosis of CHD in the secondary study: Participants were classified as CHD cases if they 
indicated during the interview or in the questionnaire that they had experienced a MI or 
underwent a coronary revascularization procedure, they reported angina symptoms in the 
interview, and/or showed signs of MI on ECG.
From 2919 participants fasting serum samples were available. Good quality 1H-NMR spectra 
from 2415 participants were obtained. For 2327 of these participants data on CHD diagnosis 
was available and 170 were classified as having CHD.
1H-NMR metabolite profiling
The stored EDTA plasma and serum samples were thawed at 4°C and were mixed by 
inverting the tubes 10 times. Next, samples (300 µL) were mixed with 300 µL TSP buffer (see 
Supplement I, supplementary Material & methods) and transferred into 5mm NMR tubes 
and kept at 6°C while queued for acquisition. Two-dimensional J-resolved and Carr-Purcell-
Meiboom-Gill spectra were acquired on a 600 MHz Bruker Avance II spectrometer (Bruker 
BioSpin, Karlsruhe, Germany), operating at a sample temperature of 310 K. For details on 
acquisition, processing, quality control, scaling and calibration of the 1H-NMR spectra see 
Supplement I, supplementary material & methods.
Using the procedure described in the Supplement I, supplementary Material & methods, 
100 signals were detected and quantified in the 1H-NMR spectra of every individual in the 
primary study. For 76 signals metabolites were assigned (see Supplement I, table S1 for 
all 1H-NMR signals and their assigned metabolites). These signals represented 36 different 
compounds (i.e. after subtracting the signals representing free EDTA). Signals representing 
calcium-EDTA and magnesium-EDTA complexes may give an indication of the levels of 
calcium and magnesium ions, respectively. Using the same procedure, 68 out of 100 signals 
detected in the primary study were detected in the secondary study. For 54 out of these 68 
signals metabolites could be assigned, representing 28 different compounds.
Statistical analysis 
In the primary study, Cox regression, adjusted for delayed entry, and according to the 
method of Prentice to adjust for the case-cohort design was performed to see whether 
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baseline characteristics were associated with incident CHD.23 Age in years was used as the 
time-scale variable.
Prior to analysis, the 1H-NMR signals were transformed to Z-scores. We selected a subset of 
the most informative signals for CHD prediction, using least absolute shrinkage and selection 
operator (LASSO) regression,24 and performed 10-fold cross-validation to determine the 
tuning parameter.24,25 This set was further reduced to signals that could be detected in both 
studies. The linear predictor of the Cox-model was used as a weighted metabolite score 
(sum of regression coefficients multiplied by the corresponding covariate values).
Cox regression, according to the method of Prentice to adjust for the case-cohort design, 
was used to calculate whether this metabolite score was associated with incident CHD 
before and after adjusting for TRFs.23
To investigate whether the metabolite score improved risk discrimination, Harrell’s 
concordance index (C-index),26 the net reclassification index (NRI) and the integrative 
discrimination index (IDI) were  calculated.27 For the NRI the following risk categories were 
applied: 0-<5%, 5-<10%, 10-<20%, ≥20%. Next, using ANOVA, we investigated to what extent 
TRFs can explain the variance in the metabolite score in the sub-cohort. Stata/SE version 
11.2 was used to calculate the C-index. R-package PredictABEL version 1.2-1 was used to 
calculate the IDI. For all other analyses, R version 2.14.1 was used.
In the secondary study, raw 1H-NMR signal  data were adjusted for kinship by linear regression 
in GenABEL.28 The residuals for all signals were transformed into Z-scores. Logistic regression 
was performed to assess the association of TRFs with prevalent CHD.  To assess whether the 
metabolite signals selected by LASSO regression in the primary study were also relevant for 
the identification of prevalent CHD cases, we put these signals into one logistic regression 
model to determine their individual regression coefficients. Next, we used logistic regression 
analysis to test the association of this metabolite score, thus with weights based on the 
secondary study, with prevalent CHD. Finally, we tested to what extent TRFs can explain the 
variance in the metabolite score using ANOVA. For these analyses, PASW statistics version 
18 (SPSS-IBM, New York, US) was used.
Results
Primary study: The TRFs were associated with incident CHD. When all TRFs were entered 
into one Cox proportional hazards model with age in years as the time-scale variable, HDL-C, 
SBP, sex and current smoking remained independently associated with incident CHD (table 
1). See supplement I, table S2 for the baseline characteristics before excluding individuals 
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with missing data. For the association of the individual 1H-NMR signals with incident CHD 
see supplement I, table S1.
Table 1 | TRFs and their association with incident CHD in the primary study.
Cases Sub-cohort HR HR
(n=79) (n=565)* (95%CI)† (95%CI)‡
Age (years) 51.9±6.1 44.8±8.3 - -
Total cholesterol (mmol/L) 5.9±1.0 5.3±1.0 1.30 (1.03-1.64) 1.21 (0.93-1.58)
HDL cholesterol (mmol/L) 1.1±0.3 1.3±0.4 0.12 (0.05-0.30) 0.34 (0.12-0.94)
SBP (mmHg) 134.5±16.8 121.5±15.1 1.04 (1.02-1.05) 1.03 (1.01-1.05)
BMI (kg/m2) 27.6±4.6 25.4±3.8 1.10 (1.03-1.17) 1.03 (0.95-1.11)
Men 79.6% (63) 44.6% (252) 4.95 (2.72-9.02) 3.30 (1.65-6.57)
Current smoking 51.9% (41) 38.8% (219) 2.16 (1.29-3.62) 1.84 (1.02-3.32)
Diabetes 3.8% (3) 0.5% (3) 3.99 (0.70-22.84) 3.34 (0.41-27.43)
Parental history of MI 50.6% (40) 40.2% (227) 1.32 (0.88-1.98) 1.24 (0.78-1.98)
Data are expressed as mean±SD or %(n). HR, hazard ratio; HDL, high-density lipoprotein; MI, myocardial infarction; 
SBP, systolic blood pressure; BMI, body mass index
*Including 10 cases
†Univariate HR were calculated per unit increase for age, total cholesterol, HDL cholesterol, SBP, BMI, and for the 
categorical traits. Age in years was used as the time-scale variable. 
‡All variables were added into one multivariable Cox proportional hazards model, except for age, which was used 
as the time-scale variable.
We determined 16 1H-NMR signals as the best prediction subset using LASSO regression, 
of which, 13 were available in the secondary study (see figure 1). These 16 1H-NMR signals 
represent creatinine, serine, glucose, 1,5-anhydrosorbitol, trimethylamine N-oxide (TMAO), 
ornithine, citrate, glutamate, glycoproteins, an unsaturated lipid structure, valine and five 
non-annotated signals located at 3.924, 3.145, 2.412, 1.391 and 0.988 ppm. From the 
13 signals present in both the primary and secondary study a weighted metabolite score 
was constructed using the corresponding coefficients (figure 1). This metabolite score 
was normally distributed in cases and sub-cohort members (supplement I, figure S1), and 
associated with incident CHD (hazard ratio per standard deviation [HR/SD]=1.91, 95% 
confidence interval [95%CI]=1.50-2.44). After adjusting for TRFs, this metabolite score 
remained associated with incident CHD (HR/SD=1.50, 95%CI=1.12-2.01). For the results of 
the metabolite score based on the 16 signals see supplement I, table S3.
The metabolite score had a C-index of 0.75, (95%CI=0.70-0.80). Adding age and sex to 
the metabolite score, resulted in a C-index of 0.81 (95%CI=0.77-0.85), which is similar to 
a C-index when only TRFs are included (C-index=0.82, 95%CI=0.78-0.87, p=0.327). When 
the metabolite score was added to a model containing all TRFs, the C-index increased 
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from 0.82 to 0.84, which was non-significant (p=0.107). Both the improvement in the NRI 
(NRItotal=0.038; p=0.209) and the IDI (0.012; p=0.091) were non-significant (supplement I, 
table S4 and S5). Inspecting C-indices for individual TRFs and evaluating improvement of 
adding the metabolite score indicated that the metabolite score improved the C-indices of 
all individual TRFs (supplement I, table S6a/b).
Figure 1 | The subset of signals selected using 10-fold cross-validated LASSO regression and their coefficients in the 
primary study (left panel) and the secondary study (right panel).
We tested to what extent TRFs explain the variance in the metabolite score in the sub-
cohort of the primary study. HDL-C, sex, BMI, TC, SBP, age and diabetes explained respective 
16.4%, 11.7%, 10.0%, 7.9%, 5.6%, 4.1% and 2.3% of the variance in the metabolite score. 
Current smoking and parental history of MI all explained less than 1% of the variance in 
the metabolite score (figure 2). When all TRFs were combined, 32.6% of the variance in the 
metabolite score was explained.
Secondary study: To test if the 13 metabolite signals selected in the primary study were 
relevant for the identification of prevalent CHD cases, we investigated 170 CHD cases and 
2157 controls for which equivalent metabolomics profiles were obtained. In this non-
prospective cohort, combining all TRFs in one logistic regression model resulted in only age, 
sex, and parental history of MI to be independently associated with prevalent CHD (table 
2). See supplement I, table S7 for the baseline characteristics before excluding individuals 
with missing data. 
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Table 2 | TRFs and their association with prevalent CHD in the secondary study.
Cases Controls OR OR
(n=170) (n=2157) (95%CI)* (95%CI)†
Age (years) 60.9±11.7 47.7±14.0 1.08 (1.07-1.10) 1.08 (1.05-1.10)
Total cholesterol (mmol/L) 5.0±1.1 5.6±1.1 0.57 (0.49-0.67) 0.47 (0.37-0.59)
HDL cholesterol (mmol/L) 1.2±0.3 1.3±0.4 0.30 (0.18-0.49) 1.25 (0.60-2.61)
SBP (mmHg) 148.2±22.9 139.1±19.7 1.02 (1.02-1.03) 1.00 (0.99-1.01)
BMI (kg/m2) 28.1±4.4 26.8±4.6 1.06 (1.03-1.09) 1.01 (0.96-1.07)
Men 61.2% (104) 42.5% (917) 2.40 (1.79-3.22) 1,93 (1.18-3.14)
Current smoking 36.5% (62) 39.1% (844) 0.90 (0.66-1.24) 1.18 (0.75-1.88)
Diabetes 12.9% (22) 4.3% (93) 3.44 (2.15-5.49) 1.25 (0.56-2.79)
Parental history of MI 31.2% (53) 19.9% (430) 2.03 (1.53-2.71) 1.60 (1.16-2.21)
Data are expressed as mean±SD or %(n). OR, odds ratio; HDL, high-density lipoprotein; MI, myocardial infarction; 
SBP, systolic blood pressure
*Univariate OR were calculated per unit increase for age, total cholesterol, HDL cholesterol, SBP, BMI, and for the 
categorical traits.
†All the variables were added into one multivariable logistic regression model.
The metabolite score, based on the 13 best predicting signals in the case-cohort study, but 
with weights based on the secondary study (figure 2), was associated with prevalent CHD 
before (OR=2.72, p<0.001) and after adjusting for TRFs (odds ratio [OR]=1.59, p=0.002). 
After excluding statin users (n=299), similar results were obtained (supplement I, table S8).
The proportion of variance in the metabolite score explained by age, SBP and diabetes was 
higher for the secondary study than for primary study, whereas the variables TC, HDL-C and 
BMI explained a lower proportion of the variance (figure 2). The proportion of variance 
explained by sex, current smoking and parental history of MI was comparable for both 
studies. With all TRFs combined, 32.1% of the variance of the metabolite score could be 
explained, which is comparable to that of the primary study.
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Figure 2 | The proportion of variance in the metabolite score explained by TRFs in the primary study (upper panel) 
and the secondary study (lower panel). 
Discussion
A metabolite score, based on 1H-NMR spectroscopy, is significantly associated with incident 
CHD independent of TRFs. When combined with age and sex, this score was as predictive 
for incident CHD as all TRFs combined. A score based on the same 1H-NMR signals was also 
associated with prevalent CHD, independent of TRFs.
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The observation that the metabolite score could not improve CHD risk prediction beyond TRFs 
in individuals free from CHD is in line with a previous study published by El Harchaoui et al..7 
However, Würtz et al. found that metabolites measured by 1H-NMR spectroscopy improved 
risk stratification for subclinical atherosclerosis in comparison to conventional lipids.8 In this 
study both 1H-NMR determined lipoproteins and low-molecular weight metabolites were 
included.8 We only included information on low-molecular weight metabolites, whereas in 
the study by El Harchaoui et al. only information on lipoproteins was included.7 Perhaps 
the combination of both lipoproteins and low-molecular-weight metabolites results in the 
optimal prediction of CHD.
The metabolite score represents the metabolites valine, ornithine, glucose, 1.5-anhydro-
sorbitol, creatinine, an unsaturated lipid structure, glutamate and, glycoproteins, citrate, 
and TMAO, of which TMAO was not available in the secondary study. Most of these 
metabolites have been associated with CHD or CHD risk factors before.11,13,29-31 Valine has 
been associated with metabolic risk factors,30 insulin resistance,32 incident type 2 diabetes,31 
and future cardiovascular events.11 Ornithine, is produced by splitting of urea from arginine, 
resulting in a lower bioavailability of arginine. Arginine is necessary to produce nitric oxide, 
which is essential for a normal endothelial function.29 This pathway has been linked to CHD10 
and CHD mortality.29 The presence of glucose and 1,5-anhydrosorbitol, a short-term marker 
for glycemic control,33 could indicate that our metabolite score marks individuals at higher 
risk of developing diabetes or insulin resistance and thereby CHD. Low creatinine levels are 
a marker for high HDL-C and low LDL cholesterol levels.34 Thus the presence of creatinine 
and an unsaturated lipid structure could indicate that our metabolite risk score is a marker 
for an unfavorable lipid profile. This is confirmed by the proportion of variance explained 
by HDL-C and TC levels, 7.9% and 16.4%. In the secondary study these explained variances 
are only 0.9% and 4.6%, but this discrepancy might be caused by statin treatment, resulting 
in lower cholesterol levels for the cases compared to controls. A secondary explanation for 
the incorporation of creatinine in the metabolite score is that elevated creatinine levels may 
indicate kidney dysfunction, which is associated with cardiovascular disease.35 Increased 
TMAO levels have been associated with cardiovascular risk before.13,36 Thus it seems that 
the LASSO procedure selected relevant metabolites that have been associated with CHD and 
CHD risk factors before.
Several issues have to be resolved before it can be concluded if a metabolomics approach is 
useful for CHD risk prediction. First, the known, quantifiable serum metabolome consists of 
4229 metabolites,37 of which only 36 (0.9%) were included in this study. Other studies that 
use 1H-NMR spectroscopy also incorporated lipoproteins.11,12 Therefore we hope that we 
can achieve better in follow-up studies when incorporating H-NMR determined lipoproteins 
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in addition to low-molecular-weight metabolites in our analysis. Moreover, other 
metabolomics platforms should be also be included.37 Second, the 16 signals provided by 
our study should be measured in large prospective cohorts for replication and to determine 
universally applicable weights. The current study is too small for that purpose. Third, we 
had non-fasting samples in the primary study and fasted samples in the secondary study. 
However, we still found that the 1H-NMR signals selected in the primary non-fasted study 
were also associated with prevalent CHD in the fasted secondary study. This indicates that 
we have selected 1H-NMR signals that are robust whether fasted or non-fasted samples 
are used. Fourth, constructing robust prediction models constitutes a statistical challenge, 
especially in a high-dimensional setting. In our case, model selection by LASSO regression 
resulted in predictor selection that eliminated high correlations among predictors. This can 
lead to reduced transferability of prediction models as correlation structures of predictors 
can vary between studies. A wide variety of penalized regression models are available 
(e.g. elastic net, ridge regression) and further research is needed to select the appropriate 
methods for the application at hand. 
Conclusion
A metabolite score derived from a single point metabolome measurement is associated 
with the risk of CHD independent of TRFs, but thus not improve risk prediction beyond 
TRFs On the other hand, LASSO regression resulted in the selection of relevant metabolites, 
suggesting that more comprehensive metabolomics methods may be promising tools to 
further improve upon CHD disease understanding and risk stratification.
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Two commonly used methods for extracting information from proton nuclear magnetic 
resonance (1H-NMR) spectra are a targeted approach, which involves determining the surface 
area of all resolvable signals in the 1H-NMR spectrum, and an untargeted approach, by 
portioning the 1H-NMR spectrum into discrete sections. Here we compare both approaches 
for predicting coronary heart disease (CHD).  Using 1H-NMR spectroscopy, two-dimensional 
J-resolved (JRES) projection spectra were obtained in plasma samples from 79 incident CHD 
cases (median follow-up 8.1 years) and 565 randomly selected individuals from the same 
cohort (N=5074). Prior to analysis the data was autoscaled and pareto scaled, respectively. 
For the targeted approach, LASSO regression on  autoscaled data resulted in the selection of 
11 signals from a total of 96. A score based on these 11 signals was associated with incident 
CHD independent of traditional CHD risk factors (TRFs) (HR = 1.46; 95%CI = 1.09-1.98). Pareto 
scaled data resulted in the selection of 6 signals. A score based on these signals was not 
associated with CHD independent of TRFs (HR = 1.16; 95%CI = 0.83-1.62). For the untargeted 
approach, LASSO regression on autoscaled data resulted in the selection of 21 bins from a 
total of 400. Eight bins were located in a part of the 1H-NMR spectra were no peaks were 
observed, which could indicate overfitting. A score based on these bins was associated with 
incident CHD independent of TRFs (HR = 2.25; 95%CI = 1.54-3.29). After pareto scaling, 6 
bins were selected. None of the bins were located in the part of the 1H-NMR spectra were 
no peaks were observed. A score based on these 6 bins was not associated with incident 
CHD independent of TRFs (HR = 1.17; 95%C = 0.81-1.69). We conclude that the untargeted 
approach might be more prone to overfitting compared to the targeted approach. However 
to test this presumption, it is necessary to validate the metabolite scores in independent 
prospective cohorts.
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It is expected that acquiring information about metabolite concentrations in body fluids 
is useful in diagnosing, understanding and predicting disease.1 Acquiring information 
about metabolites in a systematic and non-biased way is the main concern of the field 
of metabolomics. Proton nuclear magnetic resonance (1H-NMR) spectroscopy and mass 
spectrometry (MS) are two commonly used methods to gain information about a person’s 
metabolites at a large scale.2 However, for large population based studies, 1H-NMR 
spectroscopy might be preferred due to faster processing times and being more robust 
compared to MS based methods.2
Two distinct approaches can be used to extract information from the 1H-NMR spectrum: 
the targeted approach, by determining the surface area of all resolvable signals in the 
1H-NMR spectrum3 and the untargeted approach, which involves partitioning the 1H-NMR 
spectrum into discrete sections, and determine the sum of the spectral intensity in each 
section (“equidistant binning”).4 Conceptually, both techniques have their advantages and 
disadvantages. For example, the targeted approach treats each signal (and therefore, in 
principle, each metabolite) separately, as long as they can be properly deconvoluted.5 Any 
underlying uninformative background signal, can be included in the deconvolution process, 
removing its intensity from the final result.5 However, not every metabolite has signals 
that can easily be separated from the other signals, or reach the detection level in every 
individual. Therefore, the targeted approach may not only remove unwanted background 
signal, but also real information. Another disadvantage is that signal selection is partly a 
manual process which is time-consuming and prone to human error and bias.6,7 In contrast, 
the untargeted or binning approach includes all the spectral intensities in the analysis, also 
of as yet unidentified signals, which may occur as a result of low concentration or spectral 
crowding. The obvious disadvantage of this approach is that each bin can potentially contain 
overlapping signals or that signals are obscured by background variation in the same bin.5 
This can complicate the interpretation of the result, or could mask the effect of a low intensity 
metabolite that happen to be situated in the same bin as a very high intensity metabolite.5 
Also, variations of the baseline intensity that is uninformative will be included in the bins.5 
This could potentially result in overfitting of the model. Overfitting occurs when variables 
show a difference between cases and non-cases, which are actually based on chance and 
are therefore not reproducible in independent cohorts.8 This problem increases with the 
inclusion of too many noise variables.8
When applying multivariate techniques to find 1H-NMR signals or bins associated with 
incident CHD, 1H-NMR signals or bins with high intensities can obscure the 1H-NMR signals 
or bins with low intensities.9 Two commonly used methods to overcome this problem are 
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autoscaling and pareto scaling.10 With autoscaling or standardizing, the standard deviation 
is used as the scaling factor, and as a result differences in the variation amplitude of the 
peaks or bins are eliminated and can no longer influence the variable selection.9,10 With 
pareto scaling the square root of the standard deviation is used as the scaling factor.9,10 With 
this method, the influence of the peaks or bins with high intensities and strong variation is 
reduced but not completely eliminated.9,10
In order to decide if the targeted approach is more suitable than the untargeted approach 
for predicting coronary heart disease (CHD), both approaches in combination with both 
scaling methods were applied to 1H-NMR spectra obtained from EDTA plasma samples from 
study persons who participated  in a prospective cohort study. For efficiency, a case-cohort 
design was used.11 Data from both approaches were used to generate models to predict 
CHD using LASSO regression.12,13
Material and Methods
study population
We conducted a prospective case-cohort study within the Monitoring project on chronic 
disease risk factors (MORGEN-Project) 1993-1997,14 one of the two monitoring studies that 
were included in the Cardiovascular Registry Maastricht study.15 For detailed information 
of the study population, including information on inclusion and exclusion criteria and 
obtaining information on traditional risk factors (TRFs, i.e. total cholesterol [TC], high-density 
lipoprotein cholesterol [HDL-C], systolic blood pressure [SBP], current smoking, body mass 
index [BMI], current diabetes status and a parental history of MI) see chapter 2 of this thesis.
Sub-cohort selection: As shown in figure 1 the cohort consisted of 5074 eligible cohort 
members. From this eligible cohort, a sub-cohort of 738 participants was randomly drawn. 
This took place before cardiologic follow-up. EDTA plasma was unavailable for 92 participants 
and 1H-NMR analysis failed in 19 participants. For 62 participants information on TRFs was 
incomplete, resulting in a sub-cohort of 565 participants.
Cardiologic follow-up: The cardiologic follow-up has been described in detail earlier15 
and ended on 31 December 2003 with a median follow-up of 8.1 years (range=0.2-10.9 
years). During follow-up 125 participants developed CHD (acute MI n=55, UAP n=51, dead 
due to CHD n=19, [ICD-9 410-414 and ICD-10 I20-I25]). For 31 patients EDTA plasma for 
1H-NMR analysis was unavailable and in one patient 1H-NMR analysis failed. For 14 patients 
information on TRFs was incomplete, resulting in 79 patients.
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Fig 1 | Schematic representation of the case-cohort design and the 
inclusion criteria for the study participants
1H-NMR metabolite profiling 
For detailed information on obtaining the 1H-NMR spectra in the EDTA plasma samples see 
Material & methods from chapter 2 of this thesis.
Targeted approach - Using the procedure described in chapter 2 of this thesis, 100 signals 
were detected and quantified in the 1H-NMR spectra of every individual. For 76 signals 
metabolites were assigned (see Supplement I, table S1 for all 1H-NMR signals and their 
assigned metabolites). These signals represented 36 different compounds (i.e. after 
subtracting the two signals representing free EDTA). Signals representing calcium-EDTA 
and magnesium-EDTA complexes were not removed from analysis since they may give an 
indication of the levels of calcium and magnesium ions, respectively. In total we had 98 
signals available for analysis.
The untargeted approach - For the untargeted approach, the projected JRES 1H-NMR spectra 
were partitioned into discrete sections of 0.02 ppm, using the sum of the spectral intensity 
in each section (“equidistant binning”).4
Data pretreatment
Principal component analysis (PCA) showed that three individuals had abnormal values 
for the signal located at 1.174 ppm representing ethanol (Supplement II, figure S1). This 
signal and another signal located at 3.649 ppm also representing ethanol were left out from 
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further analysis in all participants. We also found six individuals with high values for signals 
representing glucose (Supplement II, figure S1). Since these participants also had high 
glucose levels when measured using a conventional technique, both the participants and 
glucose signals were not removed from further analysis. Thus in total 96 signals representing 
35 different metabolites were included in the analysis.
For the untargeted approach, after removing the water signal (from bin 4.41 to 5.09 ppm) 
and the two EDTA signals (from bin 3.15 to 3.25 ppm and from bin 3.53 to 3.67 ppm), the 
1H-NMR spectra were divided into 401 bins of 0.02 ppm. The PCA scores plot showed that 
the bin located at 1.17 ppm, containing an ethanol peak, was abnormal in the same three 
individuals (Supplement II, figure S1). This bin was removed from further analysis. The bin 
containing the other ethanol peak at 3.66 ppm, was left in because it was lower and located 
in a more crowded region of the spectrum. In total there were 400 bins available for further 
analysis. 
Next the data were autoscaled and pareto scaled. Both scaling methods were combined with 
mean centering. Thus we now have four different datasets with information on the 1H-NMR 
spectra. One for the targeted approach combined with autoscaling, one for the targeted 
approach combined with pareto scaling, one for the untargeted approach combined with 
autoscaling and one for the untargeted approach combined with pareto scaling. The effects 
of autoscaling and pareto scaling are visualized in figure 2.
Fig  2 | The upper panel shows 
the 1H-NMR spectra of a 36-year 
old women after partitioning the 
1H-NMR spectra into discrete 
sections of 0.02 ppm. The resulting 
bins are visualized by vertical bars. 
The height of the bars corresponds 
to the intensities of the bins before 
any scaling method was applied. 
The middle panel shows the effects 
of autoscaling combined with mean 
centering on the intensities of the 
bins. The lower panel shows the 
effects of pareto scaling combined 
with mean centering on the 
intensities of the bins.
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The first step in the data analysis was to select a subset of the most informative 1H-NMR 
signals or bins for CHD risk prediction, both for the targeted and the untargeted approach. 
To perform this first step, we used least absolute shrinkage and selection operator (LASSO) 
regression.12,13 Twenty-fold cross-validation was used to determine tuning parameters.12,13 
Next, to construct weighted metabolite scores based on the results from LASSO regression, 
the selected metabolites by LASSO regression were multiplied by their corresponding 
coefficients and the resulting values were summed in each individual. Cox regression 
according to the method of Prentice to adjust for the case-cohort design was used to see 
if these metabolite score was associated with incident CHD before and after adjusting for 
TRFs.11 The hazard ratios were expressed per standard deviation increase in the metabolite 
scores. Age in years was used as the timescale variable.
The predictive value of both the targeted and the untargeted approach was evaluated using 
Harrell’s concordance index (C-index)16 using Stata/SE version 11.2. For all other statistical 
calculations, R version 2.14.1 was used. For LASSO regression R-package glmnet (version 1.9-
5) was used that was modified to perform an analysis adapted to the case-cohort design.17 
Results
Targeted approach
Using LASSO regression on the autoscaled and mean-centered data, 11 signals were 
selected as the best prediction set (Fig. 3). These included 7 signals representing 5 individual 
compounds (glutamate, ornithine, 1,5-anhydrosorbitol, glucose and creatinine), as well as 
signals for unsaturated lipids (CH2CH=CH) and glycoproteins. For 4 signals, no metabolite 
Fig 3 | The 11 signals and their corresponding coefficients 
selected by LASSO regression using the targeted approach 
in combination with autoscaling. 
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could be assigned.  As shown in table 1, the metabolite score based on these signals and 
their corresponding coefficients (range = -2.22-5.53)  was associated with incident CHD 
before (HR = 1.86; 95 CI = 1.46-2.37) and after adjusting for TRFs (HR = 1.46; 95% CI = 1.09-
1.98). This metabolite score had a C-index of 0.74 (95% CI = 0.68-0.79) (see table 2).
The analysis was repeated with pareto scaled data. This resulted in the selection of 6 
signals. These 6 signals represented different 3 compounds (glutamate, Trimethylamine 
N-oxide [TMAO] and glucose), two signals representing lipid structures (CH3 and CH2) and 
glycoproteins. A metabolite score based on these metabolites and corresponding weights 
(range = -2.19-4.51) was associated with incident CHD before (HR = 1.68; 95% CI = 1.32-2.14) 
but not after adjusting for traditional CHD risk factors (HR = 1.16; 95% CI = 0.83-1.62). As 
shown in table 2, this metabolite score had a C-index of 0.72, (95% CI = 0.66-0.77).
Table 1 | Metabolite scores based on variables selected by LASSO regression and elastic net using the targeted and 




N predictors Univariate Adjusteda
HR (95% CI) P-value HR (95% CI) P-value
Targeted approach
Auto 11 1.86 (1.46-2.37) <0.001 1.46 (1.09-1.98) 0.011
Pareto 6 1.68 (1.32-2.14) <0.001 1.16 (0.83-1.62) 0.388
Untargeted approach
Auto 21 2.65 (1.94-3.64) <0.001 2.25 (1.54-3.29) <0.001
Pareto 6 1.85 (1.43-2.41) <0.001 1.17 (0.81-1.96) 0.394
HR, hazard ratio; CI, confidence interval; CHD, coronary heart disease; TRFs, traditional risk factors
aAdjusted for sex, total cholesterol, HDL cholesterol, systolic blood pressure, body mass index, current smoking, 
self-reported diabetes and parental history of MI. Age in years was used as the time scale variable.
Untargeted approach
Using LASSO regression on the autoscaled and mean-centered data, 21 bins were selected 
as the best prediction set (Fig. 4). As shown in figure 5, eight of the 21 selected bins were 
located in a part of the 1H-NMR spectra were no peaks were observed.  A metabolite score 
constructed from these bins and their corresponding coefficients was associated with 
incident CHD before (HR = 2.65; 95% CI = 1.94-3.64) and after adjusting for TRFs (HR = 2.25; 
95% CI = 1.54-3.29) (Table 1). This metabolite score had a C-index of 0.81, (95% CI = 0.78-
0.85), resulting in a significantly better (p<0.001) discrimination than the metabolite score 
based on the targeted approach (Table 2).
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Fig 4 | The 21 bins and their corresponding coefficients 
selected by LASSO regression using the untargeted 
approach in combination with autoscaling.
When applying LASSO regression after pareto scaling 6 bins were selected as the best 
prediction set. A metabolite score constructed from these bins and their corresponding 
coefficients was associated with incident CHD before (HR = 1.85; 95% CI = 1.43-2.41), but not 
after adjusting for TRFs (HR = 1.17; 95% CI = 0.81-1.69). As shown in table 2, this metabolite 
score had a C-index of 0.73, (95% CI = 0.68-0.78), which is comparable to the C-index of the 
metabolite score obtained by the targeted approach after pareto scaling (C-index = 0.72; 
95%CI = 0.66-0.77).
Table 2 | Discrimination of the models generated using the targeted and the untargeted approach.
Targeted approach Untargeted approach
Scaling Method C-index 95% CI C-index 95% CI P-valuea
Auto 0.74 0.68-0.79 0.81 0.78-0.85 <0.001
Pareto 0.72 0.66-0.77 0.73 0.68-0.78 0.176
aThe p-value obtained after comparing the models from the two approaches (targeted versus untargeted)
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Fig. 5 | Both panels shown the 
same 1H-NMR spectrum of a 36-
year old women. In the upper 
panel, the red vertical lines 
indicate the location of the peaks 
selected by LASSO regression 
using the targeted approach in 
combination with autoscaling. In 
the lower panel, the blue vertical 
lines indicate the locations of the 
bins selected by LASSO regression 
using the untargeted approach in 
combination with autoscaling.
Discussion
Two approaches for extracting data from 1H-NMR spectra obtained in EDTA plasma samples 
from individuals participating in a prospective case-cohort study for finding CHD risk markers 
were compared. A targeted approach, which involves identifying and quantifying individual 
signals in the 1H-NMR spectra and an untargeted approach, for which we used data obtained 
by equidistant binning. For both approaches we also evaluated the use of auto scaling and 
paretoscaling.
When comparing the targeted versus the untargeted approach after autoscaling, we 
found that the metabolite scores based on both approaches were significantly associated 
with incident CHD before and after adjusting for TRFs. The metabolite score based on the 
untargeted approach showed a stronger association with incident CHD than the metabolite 
based on the targeted approach. Also the metabolites score based on the untargeted 
approach resulted in better discrimination than the metabolite score based on targeted 
approach. However, we observed that when using the untargeted approach, LASSO 
regression resulted in the selection of bins that were located in a part of the 1H-NMR spectra 
were no peaks were observed. Possible these bins represent only noise. When comparing 
the targeted versus the untargeted approach after pareto scaling, we found that the 
metabolite scores based on both approaches were associated with incident CHD, but not 
after adjusting for TRFs. In the univariate analysis, the association between the metabolite 
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score and incident CHD was slightly stronger then when the untargeted approach was used. 
The discriminatory capabilities for both metabolite scores were comparable.
At first sight the metabolite score based on untargeted approach combined with autoscaling 
as data pretreatment seems the best approach for predicting CHD. However, in a study 
conducted by Weljie et al. it was observed that the targeted approach resulted in more 
stable PCA clustering than when using the untargeted approach.3 The main reason for 
this observation is that very small and random fluctuations within the noise of a 1H-NMR 
spectrum can lead to large and irrelevant variations in the PCA clustering, which was also 
observed by Halouska et al.18 In a study by Rubtsov et al. it was found that a targeted 
approach led to better results in a metabolomics study of liver toxicity response to 
acute phenobarbital exposure.5 They reasoned that the targeted approach gives a better 
resolution and sensitivity compared to equidistant binning because one bin can contain 
two or more separate peaks, thus reducing the resolution of those signals.5 We cannot 
confirm their findings since we found that after autoscaling the metabolite score based on 
the untargeted approach resulted in a better discrimination for incident CHD. After pareto 
scaling no differences between both approaches were observed.
A possible explanation for our observation that the untargeted approach in combination 
with autoscaling resulted in a better discrimination of incident CHD than the targeted 
approach could be that the inclusion of noise variables resulted in overfitting.  Normally 
bins representing only noise have very low intensities. However autoscaling makes all bins, 
including the ones representing only noise, equally important.10 In contrast pareto scaling 
stays closer to the original measurement, thus giving less weight to the bins representing 
only noise.10 This could explain that after pareto scaling, the two approaches resulted in 
metabolite scores with comparable discriminatory capabilities. To answer the question 
if the good discriminatory capability of the metabolite score based on the untargeted 
approach combined with autoscaling is caused by overfitting, it is necessary to replicated 
this metabolite score in an independent prospective cohort and compare its performance 
with the metabolite scores based on the targeted approach. Another possibility is to split 
our dataset in a discovery cohort and a validation cohort.8 The discovery cohort can be 
used to construct the metabolite score, which is then tested in the validation cohort.8 The 
disadvantage of this method is that our study group might be too small for that.8
We conclude that for data reduction in metabolomics data the untargeted approach is 
possible more prone to false positives results than the targeted approach. Therefore we 
hypothesize that it is better to use the targeted approach in combination with autoscaling. 
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Mechanisms underlying the variation in human life expectancy are largely unknown, but 
lipid metabolism and especially lipoprotein size was suggested to play an important role 
in longevity. We have performed comprehensive lipid phenotyping in the Leiden Longevity 
Study (LLS). By applying multiple logistic regression analysis we tested for the first time the 
effects of parameters in lipid metabolism (i.e., classical serum lipids, lipoprotein particle 
sizes, and apolipoprotein E levels) on longevity independent of each other. Parameters in 
lipid metabolism were measured in offspring of nonagenarian siblings from 421 families 
of the LLS (n=1,664; mean age, 59 years) and in the partners of the offspring as population 
controls (n=711; mean age, 60 years). In the initial model, where lipoprotein particles 
sizes, classical serum lipids and apolipoprotein E were included, offspring had larger low-
density lipoprotein (LDL) particle sizes (p=0.017), and lower triglyceride levels (p=0.026), 
indicating that they displayed a more beneficial lipid profile. After backwards regression 
only LDL size (p=0.014) and triglyceride levels (p=0.05) were associated with offspring from 
long-lived families. Sex-specific backwards regression analysis revealed that LDL particle 
sizes were associated with male longevity (increase in log odds ratio (OR) per unit=0.21; 
p=0.023). Triglyceride levels (decrease OR per unit=0.22; p=0.01), but not LDL particle size, 
were associated with female longevity. Due to the analysis of a comprehensive lipid profile, 
we confirmed an important role of lipid metabolism in human longevity, with LDL size and 
triglyceride levels as major predicting factors.
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Over the last century, life expectancy has dramatically increased in western societies;1 
nevertheless, inter-individual differences in life expectancy remain. For example, family 
members of nonagenarian siblings and centenarians have a 30% survival benefit for three 
generations compared with their birth cohort.2,3 Offspring of nonagenarians siblings and 
centenarians are characterized by a lower prevalence of several major diseases, including 
diabetes, hypertension, coronary artery disease (CAD),4,5 and strokes,6 implying that these 
differences in life expectancy are associated with a familial, possible genetic factor that 
influences the risk of metabolic diseases.
The mechanisms underlying the variation in human life expectancy are still largely unknown 
but various studies suggest involvement of lipid metabolism. Specifically, low plasma apoE 
levels in elderly apolipoprotein E gene (APOE) ε3/ε3 carriers are associated with a decreased 
mortality risk7 and in comparison with same-aged controls, offspring of centenarians or 
nonagenarian siblings had a tendency for higher plasma levels of high-density lipoprotein 
cholesterol (HDL-C), lower levels of low-density lipoprotein cholesterol (LDL-C),8 and 
larger lipoprotein particle sizes.9,10 Studies into longevity performed so far, often analysed 
a subset of blood lipid parameters only and were relatively small. Their findings thus 
require confirmation in larger studies, particularly because they could not account for the 
correlation between the various lipid parameters. The importance of the latter is illustrated 
by the disappearance of the association of HDL particle size with coronary artery disease 
and familial longevity after adjustment for triglyceride and/or apolipoprotein B levels.9-11 
To improve the understanding of the association between lipid metabolism and human 
longevity, we performed multiple analyses of classical blood lipid parameters, lipoprotein 
particle sizes and apoE levels in long-lived families from the Leiden Longevity Study. We 
compared 1,664 offspring of nonagenarian sibships, who were shown to have a life-long 
survival advantage3 and a decreased incidence of metabolic and cardiovascular disease,5 
with 711 similarly aged partners as controls. Since men and women differ in lipid metabolism 




Study design and subjects
The Leiden Longevity Study (Fig. 1) included 421 Caucasian families consisting of long-lived 
siblings together with their offspring and the spouses of the offspring.3 Long-lived families 
were recruited if at least two long-lived siblings were alive and willing to participate. Males 
were considered long-lived if 89 years or older and females 91 years or older. The mean age 
of the long-lived siblings was 93.4±2.6 years. In 2001, less than 0.5% of the Dutch population 
fulfilled these criteria. The Medical Ethical Committee of the Leiden University Medical 
Centre approved the study and informed consent was obtained from all subjects.
Figure 1 | Schematic representation of the Leiden Longevity 
Study. The Leiden longevity study consists of 982 long-lived 
siblings (males >89 years; females >91 years), their offspring 
(n=1,671), and the partners of the offspring (n=745)
Previously, lipoprotein particle sizes have been analysed in 165 families from the Leiden 
Longevity Study using a 400-MHz proton NMR analyser at LipoScience.10 Between June 
2007 and September 2007, lipoprotein particle sizes were measured in the remaining 
255 families using the same method as described in Heijmans et al. 2006.10 In short this 
technique takes advantage of the natural proton NMR spectroscopy “signatures” emitted 
by lipoprotein particles of different sizes. This information can be used to calculate the 
concentration of each lipoprotein particle subclass. Next, mean particle sizes (diameter in 
nanometers) were determined by weighting the relative mass percentage of each subclass 
according to its diameter.13 Together with the previous study, lipoprotein particle sizes were 
available for 2,416 individuals consisting of the offspring (n=1,671) of long-lived siblings and 
the partners of the offspring as controls (n=745). Between November 2006 and May 2008, 
additional information on self-reported bodily measures was collected for the offspring 
and the controls, and in addition information on medication use was requested from the 
participants’ pharmacist.5
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In all subjects non-fasting venous blood samples were taken. Lipid levels (triglycerides, total 
cholesterol, and HDL-C) were determined in serum samples using fully automated equipment 
(the Hitachi Modular or the Cobas Integra 800 both from Roche, Almere, the Netherlands).14 
LDL-C levels were calculated using the Friedewald formula (LDL-C= total cholesterol - HDL-C 
- (triglcyerides/2.2); unit mmol/L) and set to missing if plasma triglyceride levels exceeded 
4.52 mmol/L.10 ApoE was determined in serum samples using a human apoE-specific 
sandwich ELISA.7,15
APOEε2/ε3/ε4 genotyping
DNA was isolated using standard techniques (QIAamp bloodmaxi kit,QIAGEN, (Venlo, the 
Netherlands) high salt extraction). For determining APOEε2/ε3/ε4 genotypes, two SNPs in 
the APOEε2/ε3/ε4 gene were genotyped using two Taqman SNP genotyping assays with 
the following assayIDs: C_904973_10 (rs7412) and C_3084793_20 (rs429358) (APPLIED 
BIOSYSTEMS, Foster City, USA). The assay was run on a 7900HT (APPLIED BIOSYSTEMS) 
according to manufacturer’s specification and genotypes were called using the Sequence 
Detection Software version 2.2 (APPLIED BIOSYSTEMS). The genotype call rate for the 
APOEε2/ε3/ε4 polymorphism was 98.7%.
Statistical analysis
Continuous variables were tested for normality; if appropriate, they were logarithmically 
transformed to obtain a normal distribution. Differences in lipid parameters between 
offspring and their controls were assessed using logistic regression, adjusted for age, sex, and 
the interaction between them. Robust standard errors were used to adjust for dependencies 
within families. To determine the effects of lipid parameters in more detail and independent 
of each other, multiple logistic regression was used. The lipid variables LDL particle size, HDL 
particle size, LDL-C, HDL-C, triglyceride levels, and ApoE levels were included in the initial 
starting model together with the covariates age, sex, and the interaction between them. 
Using a backward regression procedure, the lipid parameter with the highest p-value was 
removed each round until a model only including lipid variables independently associating 
with familial longevity was obtained. We also stratified for sex. Differences between offspring 
and controls for genotype distributions of rs5882 and the APOEε2/ε3/ε4 polymorphism 
were evaluated using the chi-square test. Only subjects with complete measurements for all 
the biochemical variables were included in the analysis. STATA/SE version 8.0 for Windows 




To test the association of blood lipid parameters with human longevity, we studied 
individuals for whom complete measurements were available (total cholesterol, HDL-C, 
LDL-C, triglycerides levels, ApoE, mean HDL, and LDL particle sizes). Compared with controls 
(n=711), offspring of long-lived siblings (n=1,664) had lower triglyceride levels (1.67 vs. 
1.75 mmol/L; p=0.001), larger mean HDL particle sizes (9.05 vs. 9.03 nm; p=0.01), larger 
mean LDL particle sizes (21.32 vs. 21.22 nm; p<10−3), and a smaller total cholesterol/
HDL-C ratio (4.08 vs. 4.20; p=0.004). These observations were independent of age, sex, and 
the interaction between them (Table 1). Further adjustment for self-reported body mass 
index (BMI), which was available in 619 controls and 1,399 offspring, did not affect these 
associations (triglyceride levels, p=0.01; HDL particle size, p=0.03; LDL particle size, p<10−3; 
total cholesterol/HDL-C ratio, p=0.03). As shown in Table 1, no differences were observed 
for apoE levels for the complete group, even when the analysis was restricted to APOE ε3/
ε3 carriers only. We observed that the genotype distribution for the APOE polymorphism 
differs between offspring and controls (ε2/ε2=0.4, ε2/ε3=10.2, ε2/ε3=3.2, ε3/ε3=62.3, ε3/
ε4=21.3 and ε4/ε4=2.5; ε2/ε2=1.0, ε2/ε3=13.3, ε2/ε3=2.3, ε3/ε3=60.8, ε3/ε4=21.2, and ε4/
ε4=1.2, respectively, p=0.019).
Sex-specific analysis revealed that female offspring had lower triglyceride levels (1.51 
mmol/L vs. 1.62 mmol/L, p=0.001), a lower cholesterol/HDL-C ratio (3.75 vs. 3.88, p=0.018), 
larger LDL particle sizes (21.60 nm vs. 21.49 nm, p=0.01), and larger HDL particle sizes (9.25 
nm vs. 9.21 nm, p=0.031) compared with controls. After adjusting for BMI, HDL particle 
size and the cholesterol/HDL-C ratio were no longer significant different between offspring 
and controls (data not shown). In males however, offspring only had larger LDL sizes (20.99 
nm vs. 20.86 nm, p=0.023) compared to offspring and for the cholesterol/HDL-C ratio a 
trend was observed were offspring had a lower ratio compared to controls (4.47 vs. 4.64, 
p=0.080). Adjustment for BMI did not affect these results (data not shown).
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Table 1 | Baseline characteristics of the Leiden Longevity Study population
Leiden Longevity Study Controls Mean (SD)
Offspring
 Mean (SD) P value
Number of individuals 711 1664 -
  Females N (%) 409 (57.5) 898 (54.0)
Lipid lowering medication N (%)a 68 (9.56) 109 (6.55) 0.011
  Males 32 (10.60) 60 (7.83) 0.172
  Females 36 (8.80) 49 (5.46) 0.032
Age (yr) 58.87 ± 7.45 59.40 ± 6.53 0.046
  Males 61.55 ± 7.33 59.26 ± 6.50 <10-3
  Females 56.88 ± 6.91 59.52 ± 6.56 <10-3
Body Mass Indexc 25.56 ± 3.67 25.28 ± 3.46 0.055d
  Males 25.84 ± 3.27 25.64 ± 2.86 0.486e
  Females 25.34 ± 3.94 24.97 ± 3.86 0.060e
Triglyceride (mmol/L)b 1.75 ± 0.86 1.67 ± 0.82 0.001d
  Males 1.93 ± 0.89 1.86 ± 0.85 0.311e
  Females 1.62 ± 0.81 1.51 ± 0.76 0.001e
HDL-cholesterol (mmol/L) 1.43 ± 0.46 1.46 ± 0.44 0.053d
  Males 1.25 ± 0.36 1.29 ± 0.37 0.104e
  Females 1.57 ±0.48 1.60 ± 0.45 0.240e
LDL-cholesterol (mmol/L) 3.33 ± 0.92 3.34 ± 0.99 0.750d
  Males 3.27 ± 0.94 3.30 ± 0.94 0.997e
  Females 3.37 ± 0.94 3.37 ± 1.03 0.701e
Total cholesterol/HDL ratiob 4.20 ± 1.39 4.08 ± 1.28 0.004d
  Males 4.64 ± 1.49 4.47 ± 1.29 0.080e
  Females 3.88± 1.21 3.75± 1.17 0.018e
HDL particle size (nm) 9.03 ± 0.51 9.05 ± 0.50 0.010d
  Males 8.79 ± 0.43 8.83 ± 0.44 0.172e
  Females 9.21± 0.50 9.25± 0.46 0.031e
LDL particle size (nm) 21.22 ± 0.83 21.32 ± 0.81 <10-3d
  Males 20.86 ± 0.76 20.99 ± 0.78 0.023e
  Females 21.49 0.78 21.60 ± 0.73 0.010e
ApoE (mg/dL)b 2.81 ± 0.98 2.82 ± 0.99 0.967d
  Males 2.72 ± 0.92 2.76 ± 0.97 0.424e
  Females 2.87 ± 1.02 2.87 ± 1.01 0.481e
APOEε3/ε3 carriers 441 (62.03) 989 (59.44) -
  Males 198 (65.56) 443 (57.83) -
  Females 243 (59.41) 546 (60.80) -
ApoE (mg/dL) in APOEε3/ε3 carriers 2.71 ± 0.73 2.68 ± 0.79 0.356
  Males 2.66 ± 0.72 2.61 ± 0.81 0.495
  Females 2.80 ± 0.74 2.73 ± 0.77 0.104
aLipid lowering medication includes  3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors 
(statin), fibrates, niacin, bile acid sequestrants, and Niemann-Pick C1-like 1 protein inhibitors
b Logarithmically transformed to obtain a normal distribution
c Body Mass Index was calculated based on self-reported height and weight in 1867 participants of the LLS, 
consisting of 822 males and 1045 females.
d Adjusted for medication use, age, sex and the interaction between age and sex
e Adjusted for age
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Table 2 | Pearson correlation coefficientsa between the lipid parameters in the Leiden Longevity Study.
HDL size TG CHOL HDL-C LDL-C Chol/HDL ApoE
LDL size Total population 0.793 -0.470 0.067 0.624 -0.016** -0.606 -0.074
Men 0.778 -0.489 -0.027** 0.633 -0.077* -0.621 -0.141
Women 0.734 -0.375 0.015 0.518 -0.076 -0.527 -0.077
HDL size Total population - -0.550 -0.005** 0.742 -0.143 -0.754 -0.065
Men - -0.519 -0.092 0.736 -0.150 -0.741 -0.169
Women - -0.525 -0.075 0.683 -0.194 -0.741 -0.051**
TG Total population - - 0.327 -0.372 0.191 0.614 0.233
Men - - 0.378 -0.393 0.150 0.616 0.306
Women - - 0.390 -0.290 0.244 0.587 0.209
CHOL Total population - - - 0.364 0.924 0.317 0.188
Men - - - 0.255 0.922 0.389 0.169
Women - - - 0.364 0.924 0.360 0.198
HDL-C Total population - - - - 0.129 -0.743 0.021**
Men - - - - 0.119* -0.765 -0.087*
Women - - - - 0.126 -0.715 0.053**
LDL-C Total population - - - - - 0.486 0.115
Men - - - - - 0.508 0.078*
Women - - - - - 0.559 0.103
CHOL/HDL Total population - - - - - - 0.129
Men - - - - - - 0.195
Women - - - - - - 0.116
aSignificant at  <0.01 (2-tailed), unless otherwise indicated: *0.01<p<0.05, **p>0.05
LDL size, mean LDL lipoprotein particle size; HDL size mean, HDL lipoprotein particle size; TG, triglycerides; CHOL, 
cholesterol; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; CHOL/HDL, ratio between total cholesterol and HDL-
cholesterol; ApoE, apolipoprotein E
These univariate analyses do not account for the strong correlations that exist between 
the various lipid parameters. For example, the Pearson’s correlation coefficient between 
LDL particle size and triglyceride levels is −0.470, and the correlation between HDL-C and 
LDL particle size is 0.624 (Table 2). To assess the association between longevity and the 
lipid parameters in more detail and independent of each other, we used multiple logistic 
regression where the starting model included the all the available lipid parameters, except 
for total cholesterol and the ratio LDL-C/HDL-C which were not included because they are 
highly correlated with LDL-C and HDL-C, respectively, which introduces multicollinearity. In 
this initial model (Table 3), the lipid parameters LDL size (increase in log OR per unit=0.21; 
p=0.017) and triglyceride levels (decrease in log OR per unit=0.26; p=0.026) were significantly 
different between offspring and controls independent from the other lipid variables. After 
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backwards regression, were age, sex, and the interaction between age and sex were not 
removed to account for the study design, the final model included LDL particle size (increase 
in log OR per unit=0.16; p=0.014) and triglyceride levels (decrease in log OR per unit=0.21; 
p=0.05). 
Table 3 | Multiple variate logistic regression analysis with all measured lipid variables included. 
Total population (N=2375) Males (N=1068) Females (N=1307)
betaa SE p-value betaa SE p-value betaa SE p-value
Age (yr) 0.062 0.010 <10-3 -0.050 0.012 <10-3 0.066 0.010 <10-3
Sex 6.901 1.066 <10-3 - - - - - -
Sex*Age -0.112 0.018 <10-3 - - - - - -
LDL size (nm) 0.207 0.087 0.017 0.268 0.140 0.055 0.178 0.117 0.127
HDL size (nm) -0.124 0.201 0.537 -0.283 0.333 0.395 -0.064 0.259 0.805
LDL-C (mmol/L) -0.001 0.053 0.992 -0.031 0.080 0.697 0.024 0.074 0.741
HDL-C (mmol/L) 0.010 0.177 0.953 0.235 0.322 0.466 -0.080 0.219 0.713
Triglycerides (mmol/L)b -0.257 0.115 0.026 -0.039 0.171 0.821 -0.417 0.164 0.011
ApoE  (mmol/L)b 0.117 0.163 0.473 0.240 0.226 0.287 0.000 0.203 1.000
Constant -6.210 1.784 0.000 0.425 2.898 0.883 -6.092 2.391 0.011
People using lipid lowering medication were excluded from analysis. Robust standard errors were used to account 
for dependencies within families in all analysis
SE, standard error; LDL size, mean LDL lipoprotein particle size; HDL size, mean HDL lipoprotein particle size; HDL-C, 
HDL-cholesterol; LDL-C, LDL-cholesterol; CHOL/HDL, ratio between total cholesterol and HDL-cholesterol; ApoE, 
apolipoprotein E
a Change in log OR per unit
b Logarithmically transformed to obtain a normal distribution
Sex-specific multiple regression indicated differences between men and women. In the 
initial multivariate logistic regression model, none of the lipid parameters was significantly 
different in male offspring compared with controls, but for LDL size a trend was observed 
(p=0.055) (Table 3). After backwards regression, male offspring had a larger LDL particle 
size than controls (increase in log OR per unit=0.21; p=0.023), whereas no differences in 
triglyceride levels were observed. For female offspring, in the initial starting model, only 
triglyceride levels were lower among female offspring (decrease in log OR per unit=0.42; 
p=0.011) (Table 3). After backwards regression, no difference in LDL size were observed in 
female offspring as compared with controls, whereas triglyceride levels were significantly 
lower among female offspring (decrease in log OR per unit=0.22; p=0.01).
The valine allele of rs5882 in the cholesterol ester transfer protein gene was previously 
found to be associated with larger LDL and HDL particle sizes.9 The association of the valine 
allele with larger LDL size was replicated in a linear regression analysis in controls and 
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offspring combined (p=0.008; adjusted for age, sex, and triglyceride levels), but this allele 
was not associated with HDL size (p=0.200). The polymorphism, however, did not explain 
the difference in LDL size between controls and offspring (increase in log OR per unit= 0.16; 
p=0.009 after accounting for rs5882, as compared with increase in log OR per unit=0.17; 
p=0.014 without rs5882). Nor was the valine allele associated with the offspring group 
(p=0.131). Similar results were obtained for man and women separately.
Discussion
We investigated the association of classical serum lipid levels, apoE levels and lipoprotein 
particle sizes with human longevity, in a study that was sufficiently large to account for 
correlations among lipid parameters and to test for differences between sexes. Our main 
finding is that both LDL particle size and triglyceride levels are associated with human 
longevity independent of other lipid parameters. Further analysis indicated that LDL particle 
size is particularly associated with male, whereas triglyceride levels are associated with 
female longevity.
Our study (N=2,375) confirms the association of LDL particle size previously observed in a 
smaller study (N=474).9 The differences in the final end model were comparable with the 
findings from Barzilai for males (0.21 nm increase), but not for females (in the final model only 
triglyceride levels were significantly different between offspring and controls). Remarkable, 
an association of triglyceride levels with longevity was not reported before. In one study, only 
a trend was observed10 and in another study triglycerides were not mentioned in relation to 
longevity.9 In a very small study where fasting samples were used, no association between 
longevity and triglyceride levels were found.8 Since we used non-fasting samples and had a 
large study population, this could explain why we did found an association with triglyceride 
levels and longevity. Our results did not confirm the previously reported association of LDL 
and HDL cholesterol levels8 and HDL particle size.9 For HDL particle size we did observe an 
association in a univariate analysis, but a multiple analysis that accounted for the correlation 
between lipid parameters showed that this result depended on other blood lipid parameters 
in particular triglyceride levels.10
Because the APOE genotype was previously found to confound the association between 
ApoE level and all-cause mortality in elderly subjects,7 it was necessary to stratify the data 
according to APOE genotype. Still we did not find an association of apoE level with longevity. 
However, we did find that the beneficial APOEε2 allele was more common in the offspring 
compared with controls, which might explain why offspring have a more beneficial lipid 
profile compared with controls.7
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Since offspring of nonagenarian siblings from the Leiden Longevity Study have a lower 
prevalence of late-onset metabolic diseases,5 it could be hypothesized that low triglyceride 
levels and a larger mean LDL particle size are protective against diseases like type II diabetes 
and CAD. High triglyceride levels are a component of the metabolic syndrome, which is 
associated with a higher risk for cardiovascular diseases (CVD) and type II diabetes.16 
Triglyceride levels itself are also independently associated with a higher risk for CVD.17 
Elevated triglyceride levels are associated with increased levels of remnants lipoproteins, 
which might initiate and promote the development of atherosclerotic plaques.18 Mean 
LDL particle size is determined by summing the size-weighted relative contribution made 
by each subspecies (i.e., small, medium and large LDL particles) to the total concentration 
of LDL particles.19 Thus, people with a small mean LDL particle size have relatively more 
small LDL particles as compared with people with a large mean LDL particle sizes. Small 
LDL particle sizes are associated with type II diabetes,20 metabolic syndrome,21,22 insulin 
resistance,23,24 incident CVD,25 and future CAD.26 Possible atherosclerosis could be induced 
by those small LDL particles, as indicated in a study of two knockout mice strains with 
similar cholesterol levels, were the Ldr−/−Apob100/100 mice had a larger number of smaller 
lipoprotein proteins and more atherosclerosis than the Apoe−/−Apob100/100 mice.27 Thus 
from literature it is clear that LDL particle size and triglyceride levels have been contributing 
to cardiovascular diseases.
LDL particle size seems to be particularly associated with male longevity whereas triglyceride 
levels are associated with female longevity, indicating that the role of lipid metabolism in 
longevity may be different in men and women. In women it was found that LDL particle size 
associated with incident CVD, however in that study LDL particle size was comparable but 
not superior to standard lipid levels in predicting CVD.25 This could support our finding that 
triglyceride levels eliminated the association between LDL size and longevity in women. 
Moreover, in a meta-analysis of population based prospective studies it was concluded that 
high triglyceride levels are a larger risk factor for cardiovascular disease in women than in 
men.28 But in a more recent meta-analysis, it was found that the effect of triglyceride levels 
on cardiovascular disease did not differ between men and women.17 On the other hand, 
men are characterized by smaller and denser LDL particles and higher triglyceride levels 
than women,12,29 which is also the case in our study. In addition, men have higher hepatic 
lipase activity compared with women, resulting in a smaller mean LDL particle size.30,31 Thus 
different plasma concentrations of enzymes involved in intravascular lipid remodelling 
between men and women31 may explain our observed sex differences regarding LDL particle 
size and familial longevity. But further research on lipid enzymes difference between men 
and women in relation to longevity is needed to confirm this hypothesis.
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This study has several strong points. Firstly, due to the large sample size it was possible to 
adjust for the correlations among the lipid parameters and to stratify for gender. Secondly, 
since controls are the partners of the offspring of long-lived siblings, they did not differ 
on any major indicators of lifestyle, including current smoking, self-reported BMI, and 
level of education.5 A weak point is that the NMR spectroscopy-based lipid parameters 
were not determined in a single measurement which introduced batch effects, for which 
it was necessary to adjust during analysis. We choose not to correct for the treatment of 
high cholesterol levels with lipid lowering medication, which mostly consist of 3-hydroxy-
3-methylglutaryl-coenzyme-A reductase inhibitor (statin) treatment (93.8%), because per 
individual it is unknown if statin treatment reduces moderate to severe hypercholesterolemia 
to above or below population average lipid levels. Since the offspring group is using lesser 
lipid lowering medication than the controls, this might bias our results in such a way that 
we underestimate the effect of lipid metabolism on longevity. Also, the use of non-fasting 
samples introduced noise in our dataset, which may lead to an underestimation of the 
effects found our study.
Our study confirms the link between lipid metabolism and human longevity and identifies 
LDL particle size and triglyceride levels as the key lipid parameters. To gain more insight 
into why there are differences between males and females, it is necessary to include 
information on lipid enzymes, genetic and expression data of genes known to be involved in 
lipid metabolism in future studies investigating the relation between lipid metabolism and 
longevity in humans.
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Background  Genome-wide association studies (GWAS) have identified many single 
nucleotide polymorphisms (SNPs) associated with coronary heart disease (CHD) or CHD risk 
factors (RF). Using a case-cohort study within the prospective CAREMA cohort, we tested if 
genetic risk scores (GRS) based on GWAS identified SNPs are associated with and predictive 
for future CHD.
Methods and Results  742 incident cases, i.e. participants who developed CHD during a 
median follow up of 12.1 years (range 0.0-16.9 years) were compared with a randomly 
selected sub-cohort of 2221 participants selected from the total cohort (n=21,148). We 
genotyped 179 SNPs previously associated with CHD or CHD RF in GWAS as published up 
to May 2, 2011. The allele-count GRSs, composed of all SNPs, the 153 RF SNPs or the 29 
CHD SNPs, were not associated with CHD independent of CHD RF. The weighted 29 CHD 
SNP GRS, with weights obtained from GWAS for every SNP, was associated with CHD 
independent of CHD RF (HR=1.12 per weighted risk allele; 95%-CI=1.04-1.21) and improved 
risk reclassification with 2.8% (p=0.031). As an exploratory approach to achieve weighting, 
we performed LASSO regression analysis on all SNPs and the CHD SNPs. The CHD LASSO 
GRS performed equal to the weighted CHD GRS, whereas the Overall LASSO GRS performed 
slightly better that the weighted CHD GRS.
Conclusions  A GRS composed of CHD SNPs improves risk prediction, when adjusted for 
the effect sizes of the SNPs. Alternatively LASSO regression analysis may be used to achieve 
weighting; however validation in independent populations is required.
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Coronary heart disease (CHD) is a complex disease influenced by both lifestyle and genetic 
factors. During past years, genome-wide association studies (GWAS) have identified multiple 
common single nucleotide polymorphisms (SNPs) that are robustly associated with the risk 
of CHD1-5 or CHD risk factors including blood pressure6,7 and plasma lipid levels.8,9 It was 
hoped that GWAS would identify SNPs that were useful in predicting CHD risk.  Individually, 
however, these SNPs have a relatively small effect size. Greater effect sizes may be expected 
for genetic risk scores (GRSs) that comprise the cumulative effect of individual SNPs.10,11
Two previous prospective studies investigated the association of a GRS with incident CHD.12,13 
Paynter et al.12 found that an allele-count GRS based on 101 published GWAS SNPs known 
to be associated with cardiovascular disease and its intermediate risk factors was associated 
with a cardiovascular disease in US women, but not independent from risk factors used in 
the ATP III or Reynolds risk score. The association was somewhat stronger for an allele-count 
GRS based on a subset of 12 SNPs selected for their association with clinical cardiovascular 
end points.12 In a recent Finnish cohort a weighted GRS based on 13 GWAS-identified, CHD-
associated SNPs was independently associated with 10-year incidence of CHD.13
In our study, we composed three allele-count GRS on the basis of 179 SNPs that were 
associated with CHD or CHD risk factors in GWAS published up to May 2, 2011; that is an 
Overall GRS based on all 179 SNPs, a Risk Factor GRS based on 153 SNPs associated with CHD 
risk factors and an allele-count CHD GRS based on 29 SNPs associated with CHD. In addition 
a weighted CHD GRS, with the weights obtained from 2 published GWAS, was constructed. 
As an exploratory analysis we constructed a least absolute shrinkage and selection operator 
(LASSO) GRS based on all 179 SNPs and on the 29 CHD SNPs. We investigated their predictive 
value for CHD during a median follow-up of 12.1 years in a population-based setting.
Methods
Study population
The Cardiovascular Registry Maastricht (CAREMA) study population has been described 
before.14 In short, the study participants, living in the Maastricht region, were selected from 
two large monitoring projects in the Netherlands: the monitoring project on cardiovascular 
disease risk factors (PPHVZ) 1987-1991 and the monitoring project on chronic disease risk 
factors (MORGEN Project) 1993-1997, including the transition year (1992) between these 
two projects. Each year, a random sample of people aged between 20 and 59 years were 
selected from municipal registries of Maastricht and surrounding communities. In total 
21,662 men and women, born between 1927 and 1997, were included in this study and 
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21,148 participants (97.6%) had given informed consent to retrieve information from the 
municipal population registries and from their general practitioner and specialist.
Cardiologic follow-up
The cardiologic follow-up has been described earlier.14 In short by linking the cohort to 
the hospital information system of the University Hospital Maastricht (UHM), 97.6% of 
the cohort members could be found (n=20,632). Next, these subjects were linked to the 
cardiology information system of the department of cardiology. For participants who died, 
the cause of death was obtained from Statistics Netherlands. In addition, the CAREMA 
cohort was linked to the hospital discharge registry of the UHM to enlarge the completeness 
of the cardiologic follow-up.
All participants, who were younger than 30 years of age at baseline (n=3505), who had an 
acute myocardial infarction (MI), unstable angina pectoris, a coronary artery bypass graft 
or a percutaneous transluminal coronary angioplasty before baseline (n=187), were lost to 
follow-up (n=17), or were included in the transition year 1992 (n=2203), were excluded from 
further analysis.
Case-cohort design
During the follow-up period (median, 12.1 yrs; range, 0.0-16.9 yrs), which ended on 31 
December 2003, 742 participants developed incident CHD, consisting of 368 patients with 
incident MI, 294 patients with unstable angina pectoris and 80 patients who have died 
because of CHD. No blood for DNA extraction was available for 59 patients, and in 15 cases 
DNA extraction was unsuccessful. Twenty-two cases were excluded because no complete 
information on traditional risk factors (TRFs, i.e. total cholesterol, high density lipoprotein 
[HDL] cholesterol, systolic blood pressure, current smoking, body mass index [BMI], self-
reported diabetes and parental history of MI) was available. Thus the available case group 
consists of 646 patients. 
From the full eligible CAREMA cohort, randomly a sub-cohort of 2221 participants was 
drawn. No blood was available for 188 participants, DNA extraction was unsuccessful in 49 
participants and no complete information on TRF was available for 71 participants. Thus the 
available sub-cohort group consisted of 1913 participants.
Determination of risk factors
At baseline, all participants filled in a questionnaire on medical history, parental history of 
MI, and lifestyle factors. During a medical examination at baseline, information was collected 
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on blood pressure, height and weight. In addition, non-fasting blood samples were collected 
using EDTA tubes. The blood was centrifuged for 10 minutes at 1000 rpm, fractioned into 
blood plasma, white blood cells fractions (buffy coats) and erythrocytes and subsequently 
stored at -20°C. Within three weeks, the blood plasma samples were transported to the 
Lipid Reference Laboratory of the University Hospital Dijkzigt (LRL) in Rotterdam where total 
and HDL-cholesterol levels were determined using a CHOD-PAP method.15 
SNP selection
Using the GWAS Catalog16 (www.genome.gov/gwastudies; accessed at May 2, 2011), 248 
SNPs were identified that showed an association with CHD or its intermediate risk factors 
(i.e. blood pressure, anthropomorphic traits [BMI, waist circumference and waist to hip 
ratio], blood lipid levels and type 2 diabetes) in at least two GWAS or in a meta-analysis 
at a genome-wide significance levels (p<5*10-8). For the SNPs that were in perfect linkage 
disequilibrium (LD) (D’=1; R2=1) with each other, one of them was excluded (n=22). For 29 
SNPs it was impossible to design primers or they did not fit in the assay designs, leaving 197 
SNPs for genotyping (supplement III, table S1).
DNA extraction & genotyping
DNA was extracted from the buffy coats, using a standard procedure.17 The resulting DNA 
pellet was dissolved in TE buffer and DNA concentrations were determined using the 
Nanodrop ND1000 Spectrophotometer. SNPs were genotyped using the iPLEX Gold chemistry 
of Sequenom’s MassARRAY platform (San Diego, CA, USA). Sequenom’s MassARRAY® 
Assay Design 3.1 Software was used for assay designs, and Sequenom’s SpectroTyper 4.0 
software was used to call genotypes automatically, followed by manual review. Nine SNPs 
failed genotyping (e.g. no PCR product or an abnormal cluster plot), 2 SNPs were removed 
due to a success rate <90%, and 7 SNPs were removed because they were out of Hardy 
Weinberg equilibrium (p<0.001) calculated in the sub-cohort, leaving 179 SNPs for analysis 
(supplement III, table S2). Individuals were removed when their success rate was <80%, 
leaving 642 cases and 1905 sub-cohort members. The overall call-rate for the remaining 
SNPs and individuals was 98.24%. For success rate per SNP see supplement III, table S2)
Statistical analysis 
To impute missing genotypes (1.76%) a multiple imputation method was used (R packages mi 
v0.08-08). Missing genotypes were imputed, where the chance of being a major homozygote, 
heterozygote or minor homozygote depends on the distribution of the particular SNPs. This 
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process was repeated 20 times; thus, 20 new datasets with nonmissing data were created. 
Next, all imputed datasets were analyzed as described below and the results from every 
imputed dataset were combined using the R package mitools (version 2.0). For results on 
the non-imputed dataset, see supplement III, table S3)
We constructed three allele-count GRSs and one weighted GRS. The first GRS compromised 
all 179 SNPs associated with CHD and its intermediate risk factors (Overall GRS). The 
rationale behind this GRS was to combine the information of all known SNPs associated 
with CHD or its intermediate risk factors and test its predictive value in a prospective cohort 
study. The second one consisted of the 153 SNPs associated with intermediate risk factors 
for CHD (Risk Factor GRS). This GRS was included to evaluate to what extent such SNPs could 
replace TRF. The third GRS consisted of SNPs previously associated with CHD (CHD GRS). 
The reason for including this GRS (not diluted by SNPs with only a small effect on TRF) was 
to test if this GRS would associate with incident CHD and possibly improving risk prediction 
in addition to TRFs. A similar approach was used by Paynter et al,12 although fewer SNPs 
associated with CHD or its intermediate risk factors were identified at that time. The fourth 
GRS contained the same 29 CHD SNPs, but every SNP was weighted according to their effect 
size (weighted CHD GRS) to allow the prediction to be based mainly on the most informative 
SNPs. For estimating the weights of the individual SNPs, the effect sizes were obtained from 
two large GWAS on CHD (see supplement III, table S4 ).4,18 A similar approach was used by 
Ripatti et al.13 
We tested whether the four GRSs were associated with future CHD, using Cox-proportional 
hazards models with robust variance estimation to adjust for the case-cohort design 
according to the method of Prentice.19 These models were used to estimate the 10-year risk 
of CHD using a base model with and without each GRS. The base model consists of these 
TRFs; sex, current smoking, self-reported diabetes, parental history of MI, HDL cholesterol, 
total cholesterol, systolic blood pressure and BMI. Age in years was used as the time-scale 
variable, and we adjusted for delayed entry. The same analyses were also done for every 
SNP separately.
Because of a change in scaling (the allele-count CHD GRS theoretically ranges from 0 to 58, 
whereas the weighted CHD GRS ranges from 0 to 22.14), the hazard ratio of a weighted GRS 
cannot be directly compared with an allele-count GRS. Thus, for comparing the effects of 
the different GRS, we calculated the z-scores for all GRS in all individuals and performed the 
above analysis on these standardized GRS. 
To test if adding a GRS to the base model improved risk prediction, c-statistics, according 
the non-parametric method of DeLong et.al.20 and the net reclassification improvement 
(NRI) as described by Pencina et al.21 were used. The NRI was not directly applicable to our 
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study because of non-cases (n=550) who were censored (e.g. due to mortality from causes 
other than CHD during the 10-year follow up period) and cases (n=208) that got an event 
after 10 years of follow-up.22 Therefore, cases who developed an event after 10 years of 
follow-up were treated as controls that left the study at 10 years of follow-up (n=208), which 
resulted in 434 cases and 2012 non-cases. Next, we calculated a Kaplan-Meier curve for the 
sub-cohort. Based on this Kaplan-Meier curve, weights were assigned to every individual. 
Weights of zero were assigned to non-cases who left the study before 10 years of follow-
up (n=550). Using the 10-year risk estimates, subjects were divided in the following risk 
categories: 0-<5%, 5-<10%, 10-<20%, ≥20%, as previously applied.12, 13 For all analyses we 
used the software R (version 2.10.1, www.r-project.org) in combination with the package 
survival (version 2.35-8) for the Cox-proportional hazards models according to Prentice and 
the Kaplan-Meier curve. For estimating the c-statistics and corresponding p-values, we used 
the R package pROC (version 1.4.1).
GRS based on LASSO regression 
Not all GWAS-identified SNPs may contribute to the risk of future CHD in our population-
based prospective study.23 Therefore, as an exploratory analysis, we selected a subset of 
the most informative SNPs using LASSO regression,24 in combination with 10-fold cross-
validation to address the issue of internal validation.24-26 Using the LASSO approach a subset 
of informative SNPs was extracted from the 29 CHD SNPs (CHD LASSO GRS) and the complete 
SNPs set (Overall LASSO GRS). Both GRS were subject to the same statistical analysis as for 
the previous four GRS. For the LASSO regression analysis the R package penalized (version 






The TRFs are associated with future CHD in the CAREMA study population (see table 1). 
When all TRFs were entered in one Cox proportional hazards model, with age as the time-
scale variable, BMI was no longer significantly associated with future CHD.







Age, y 50.2 ± 7.1 45.2 ± 8.4 1.08 (1.07-1.09)§ -
Tot Chol, mmol/L 6.3 ± 1.2 5.6 ± 1.1 1.47 (1.35-1.61) 1.33 (1.20-1.48)
HDL-C, mmol/L 1.0 ± 0.3 1.3 ±  0.3 0.05 (0.03-0.07) 0.14 (0.08-0.22)
SBP, mm Hg 128.9 ± 17.1 120.2 ± 15.2 1.02 (1.02-1.03) 1.02 (1.01-1.03)
BMI, kg/m2 26.6 ± 4.0 25.0 ± 3.7 1.08 (1.05-1.10) 1.02 (0.99-1.05)
Men 483 (74.8%) 870 (45.5%) 1.41 (3.31-50.3) 2.52 (1.93-3.29)
Current smoking|| 373 (57.7%) 790 (41.3%) 2.03 (1.68-2.46) 1.95 (1.54-2.46)
Type 2 diabetes 24 (3.7%) 17 (0.9%) 3.60 (1.83-7.08) 3.03 (1.46-6.26)
Parental history of MI 270 (41.8%) 670 (35.0%) 1.31 (1.12-1.54) 1.41 (1.16-1.72)
CAREMA indicates Cardiovascular Registry Maastricht; HR, hazard ratio; 95% CI, 95% confidence interval; Tot Chol, 
total cholesterol; HDL-C, high density lipoprotein cholesterol; SBP, systolic blood pressure; BMI, body mass index; 
MI, myocardial infarction
Results are presented as means ± SD or N (%)
*Includes 101 cases
†Univariate analysis; age in years was used as the time-scale variable
‡All the variables were added into one multivariable Cox proportional hazards models model and age was used as 
the time scale-variable. 
§Follow-up time in years was used as the time-scale variable
||Current smokers compared to non-current smokers 
Genetic Risk Scores
An Overall GRS was constructed of all the 179 SNPs, of which a detailed overview including 
their association with incident CHD before and after adjustment for TRF is presented 
in supplement III, table S5. The Overall GRS had a mean value (SD) of 182.9 (9.2) for all 
participants, with a range from 142 to 217 risk alleles. As shown in table 2, this Overall GRS 
was associated with CHD with a hazard ratio (HR) of 1.02 per risk allele (95% confidence 
interval [CI], 1.01-1.03); after adjustment for TRFs the effect size further attenuated (HR/risk 
allele, 1.01; 95% CI, 1.00-1.02).
As shown in Table 2, the Risk Factor GRS constructed from the 153 SNPs selected for their 
previous association with CHD risk factors (blood pressure, anthropomorphic traits, blood 
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lipid levels and type 2 diabetes) was associated with future CHD (HR/risk allele, 1.02; 95% 
CI, 1.01-1.03), but not after adjustment for TRFs (HR/risk allele, 1.00; 95% CI, 0.99-1.02).










HR (95% CI) HR Std†  (95% CI) P
Overall GRS
179 184.1 ±  8.8 182.5 ±  9.2
1.02 (1.01-1.03) 1.20 (1.09-1.32) <0.001
Adjusted for TRFs* 1.01 (1.00-1.02) 1.07 (0.99-1.16) 0.084
Risk Factor GRS
153 156.5 ± 8.3 155.3 ± 8.5
1.02 (1.01-1.03) 1.16 (1.06-1.27) 0.002
Adjusted for TRFs* 1.00 (0.99-1.02) 1.03 (0.95-1.12) 0.452
CHD GRS
29 31.2 ±  3.3 30.7 ±  3.5
1.04 (1.01-1.07) 1.16 (1.04-1.26) 0.004
Adjusted for TRFs* 1.03 (0.95-1.12) 1.12 (0.85-1.49) 0.413
Weighted CHD GRS 
29 11.9 ± 1.3 11.6 ± 1.4
1.15 (1.07-1.23) 1.21 (1.10-1.33) <0.001
Adjusted for TRFs* 1.12 (1.04-1.21) 1.17 (1.06-1.30) 0.001
LASSO CHD GRS
3 1.82 ± 0.74 1.66 ± 0.75
1.38 (1.21-1.57) 1.27 (1.16-1.40) <0.001
Adjusted for TRFs* 1.36 (1.21-1.52) 1.26 (1.16-1.37) <0.001
LASSO GRS
14 4.0 ± 1.0 3.7 ± 1.0
1.48 (1.31-1.67) 1.49 (1.31-1.69) <0.001
Adjusted for TRFs* 1.39 (1.26-1.53) 1.40 (1.27-1.53) <0.001
GRS indicates genetic risk scores; CHD, coronary heart disease; SNPs, single-nucleotide polymorphisms; HR, hazard 
ratio; Std, standardized; TRF, traditional risk factors; LASSO, least absolute shrinkage and selection operator
*sex, current smoking (yes/no), systolic blood pressure, total cholesterol, HDL cholesterol, self-reported diabetes 
(yes/no), body mass index and parental history of myocardial infarction (MI) (no MI, one parent with MI, both 
parents with MI). Age was used as the time scale variable 
†Increase in hazard ratio per standard deviation
Next, the CHD GRS constructed from the 29 SNPs selected for their previous association with 
CHD was investigated. The allele-count CHD GRS was associated with future CHD with a HR 
of 1.04 per risk allele (95% CI, 1.01-1.07). After adjustment for TRFs this GRS was no longer 
associated (HR, 1.03; 95% CI, 0.95-1.12). The CHD GRS that was weighted for previously 
reported effect sizes of the included SNPs, however, was associated with future CHD both 
before (HR, 1.15; 95% CI, 1.07-1.23) and after the adjustment for TRFs (HR, 1.12; 95% CI, 
1.04-1.21). 
C-indexes
The discriminatory capabilities of the 4 GRS without including other variables were low 
(C-index = 0.547 for the Overall GRS, 0.538 for the Risk Factor GRS, 0.527 for the CHD GRS, 
0.550 for the weighted CHD GRS), but all statistically significant (see Table 3). As shown in 
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the Figure and table 3, when using a prediction model based on all TRFs (C-index=0.816), 
adding any of the four GRS did not improve risk discrimination.
Figure | Receiver-operator 
characteristic curves for 
coronary heart disease (CHD). 
Curves were based on the 
traditional risk factors (age, 
sex, total cholesterol, HDL-
cholesterol, systolic blood 
pressure, current smoking, 
self-reported diabetes and 
parental history of MI) with 
and without each genetic risk 
score (GRS). The following 
GRS were included: A, Overall 
GRS; B, Risk factor GRS; C, 
CHD GRS; D, weighted CHD 
GRS; E, CHD LASSO GRS; and F, 
the LASSO GRS. AUC indicates 
area under the curve.
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Table 3 | Improvement in discrimination, as assessed with c-statistics, when the different GRSs were added to the 
base model (composed age, sex, current smoking plus TRF*).
Model C-index P value
Overall GRS 0.547 <0.001
Risk Factor GRS 0.538 0.002
CHD GRS 0.527 0.021
Weighted CHD GRS 0.550 <0.001
CHD LASSO GRS 0.559 <0.001
LASSO GRS 0.599 <0.001
Base model  composed of TRF* 0.816
Base model and overall GRS 0.816 0.966
Base model and risk factor GRS 0.816 0.858
Base model and CHD GRS 0.817 0.417
Base model and weighted CHD GRS 0.818 0.134
Base model van CHD LASSO GRS 0.820 0.048
Base model and LASSO GRS 0.824 0.011
GRS indicates genetic risk scores; TRFs, traditional risk factors; CHD, coronary heart disease; LASSO, least absolute 
shrinkage and selection operator.
*Sex, current smoking, systolic blood pressure, total cholesterol, high density lipoprotein cholesterol, self-reported 
diabetes, body mass index and parental history of myocardial infarction. Age was used as the time scale variable 
Net reclassification improvement
We found no improvement in reclassification when the Overall GRS, the Risk Factor GRS 
or the allele-count CHD GRS were added to the base model (Table 4, for more details 
see supplement III, table S6, A through C). When we used the weighted CHD GRS, 8.1% 
of the participants were classified into a more appropriate risk category, but for 5.3% of 
the population the reclassification got worse; thus, the NRI improved with 2.8% (p=0.031), 
which could be attributed to an improvement in reclassification for events (i.e. individuals 
who did have a CHD event; NRI=2.5%, p=0.040, see supplement III, table S6d). 
GRS based on LASSO regression
As an exploratory analysis, we performed LASSO regression analysis on the 29 SNPs previously 
associated with CHD, extracting 3 SNPs with corresponding weights. These SNPs and their 
weights were used to compose a weighted GRS (see supplemental results and supplement 
III, table S7 for the included SNPs and their corresponding weights). This CHD LASSO GRS 
was associated with incident CHD (HR, 1.38; 95% CI, 1.21-1.57) and remained significantly 
associated after adjusting for TRFs (HR, 1.36; 95% CI, 1.21-1.52). The standardized HR of 
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this CHD LASSO GRS (HR/sd increase, 1.27; 95% CI, 1.16-1.40) is comparable to that of the 
weighted CHD GRS (HR/sd increase, 1.21; 95% CI, 1.10-1.33). Next, we performed LASSO 
regression analysis on all SNPs; resulting in the extraction 14 SNPs with corresponding 
weights (see supplement III, results and table S7 for the included SNPs and their weights). 
The LASSO Overall GRS based on these 14 SNPs and their weights was associated with 
incident CHD (HR, 1.48; 95% CI, 1.31-1.29) and remained significantly associated when 
adjusted for TRFs (HR, 1.39; 95% CI, 1.26-1.53). As shown in Table 2, the standardized HR of 
the LASSO GRS was higher than that of the weighted CHD GRS.
Table 4 | Improvement in reclassification of future CHD when using a model with different GRSs in addition to TRF* 
compared to a model with only TRF.
Genetic risk score Reclassification
P Up P Down NRI Z-score P-value
Overall GRS Event         0.013 0.011 0.002 0.256 0.399
Non-event 0.006 0.009 0.003 1.020 0.154
Total          … … 0.005 0.604 0.273
Risk Factor GRS Event 0.009 0.004 0.005 0.919 0.179
Non-event 0.003 0.001 -0.001 -0.976 0.836
Total … … 0.003 0.633 0.263
CHD GRS Event 0.039 0.027 0.012 0.997 0.159
Non-event 0.011 0.014 0.003 0.983 0.163
Total … … 0.015 1.237 0.108
Weighted CHD GRS Event 0.062 0.037 0.025 1.755 0.040
Non-event 0.016 0.019 0.003 0.676 0.249
Total … … 0.028 1.873 0.031
LASSO CHD GRS Event 0.077 0.059 0.018 1.068 0.143
Non-event 0.019 0.026 0.007 1.472 0.071
Total … … 0.025 1.422 0.077
LASSO GRS Event 0.142 0.083 0.059 2.721 0.003
Non-event 0.029 0.039 0.010 1.691 0.045
Total … … 0.068 3.062 0.001
CHD indicates coronary heart disease; GRS, genetic risk score; TRFs, traditional risk factors; P, proportion; NRI, net 
reclassification index; and LASSO, least absolute shrinkage and selection operator. 
*Traditional risk factors include sex, age, total cholesterol, HDL cholesterol, systolic blood pressure, body mass 
index, current smoking, diabetes and a parental history of myocardial infarction.
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Over the past 5 years, the pace of identification of genetic variants underlying susceptibility to 
CHD has rapidly increased, leading to an interest in investigating if and how this information 
may be used in improving CHD risk prediction. Therefore, we evaluated the predictive 
“potential” of various GRS constructed on the basis of 179 SNPs associated with CHD and/or 
intermediate CHD risk factors in published GWAS. The weighted CHD GRS, constructed from 
29 SNPs previously associated with CHD using information on effect sizes from two large 
GWAS on CHD,4,18 was associated with incident CHD, the effect being independent from 
age, sex, current smoking, self-reported diabetes, parental history of MI, HDL cholesterol, 
total cholesterol, systolic blood pressure and BMI. This weighted CHD GRS also improved 
risk reclassification, but not discrimination above a model using only TRFs. The three allele-
count GRS (i.e. the Overall GRS, the Risk factors GRS and the CHD GRS) were associated with 
incident CHD, but not independently of TRFs; neither did they improve risk prediction above 
a model using only TRFs.
The lack of improvement in risk prediction may be related to the fact that most GWAS-
identified SNPs have a very low effect size and only a few SNPs have a higher effect size and 
as a result an allele-count GRS may be diluted. We observed that weighting SNPs according 
to their effect sizes may overcome this problem. However, it may not always be possible to 
provide weights to novel identified SNPs. To overcome this limitation and as an exploratory 
analysis, we used LASSO regression, which can be used to achieve data selection and 
shrinkage at the same time. With this approach we extracted a subset of 3 SNPs from the 29 
SNPs previously associated to CHD. This GRS performed equally compared to the weighted 
CHD GRS composed of all 29 CHD SNPs. Because it is impossible to apply weighting on the 
SNPs associated with intermediate CHD risk factors based on previously published studies, 
LASSO regression was used to select the set of best predicting SNPs from all 179 SNPs, 
resulting in a 14-SNP LASSO GRS. The association of this 14-SNP LASSO GRS with future CHD 
risk was stronger than the CHD LASSO GRS, and modestly but significantly improved both 
risk discrimination and reclassification. With cross-validation we have addressed the issue 
of internal validation.27 Cross-validated LASSO regression, however is exploratory and needs 
to be externally validated in independent prospective cohort studies.
Our findings for the allele-count Overall GRS based on all 179 SNPs are in line with a recently 
published large prospective cohort study.12 In this study, a GRS composed of 101 SNPs 
previously associated with cardiovascular disease (CVD) or an intermediate phenotype was 
not associated with CVD after adjustment for risk factors used in the ATP III or Reynolds risk 
score.1212 This GRS also did not improve risk discrimination or reclassification.12 The allele-
count CHD GRS was not associated with CHD after adjustment for TRFs in our population, 
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which confirms findings in a recently published large prospective cohort study of women, 
where a GRS composed of 12 CVD associated SNPs was associated with  CVD but not after 
adjusting for TRFs.12 A weighted GRS, composed of 13 SNPs associated with CHD and sharing 
8 genetic variants with our CHD GRS, was tested in a large Finnish cohort study.13 This GRS 
was associated with CVD after adjustment for TRFs, which confirms our finding for the 
weighted GRS. In a recently published meta-analysis of 14 case-control studies, a weighted 
GRS of 23 SNPs associated with CHD was constructed. This GRS was highly associated with 
CHD, although the outcome was not adjusted for TRFs. The currently tested weighted CHD 
GRS encompassing 29 SNPs was associated with incident CHD in our prospective case-cohort 
also after adjustment for TRFs.
From our study we can conclude the following. First, the 3 allele-count GRS composed 
of common SNPs previously associated with CHD and/or intermediate CHD risk factors, 
currently has no value in predicting incident CHD compared to measuring classical 
biochemical parameters and systolic blood pressure measurement at one single point in 
time. Second, it might be important to account for the different effect sizes of SNPs in a GRS, 
given the fact that the weighted CHD GRS was still associated with CHD after adjustment for 
TRFs and the allele-count CHD GRS was not. These results are in line with a study by Davies 
et al,23 in which they show that a weighted GRS outperforms allele counting. Third, when 
using the weighted CHD GRS in addition to TRFs and when accounting for the fact that using 
a new predictor also can deteriorate reclassification, 2.8% of the participants were placed in 
a more appropriate risk category. Fourth, 10-fold cross-validated LASSO regression possible 
could be used for extracting a subset of SNPs from a larger set of SNPs, although this method 
must be externally validated in independent prospective cohort studies.
The SNPs that we used for constructing the GRS were detected in GWAS with large sample 
sizes. Our study has lower power to detect the small effect sizes, which will have contributed 
to our observation that most of SNPs were not significantly associated with CHD when 
analyzed individually. We did remove SNPs in complete LD, but not the ones in high LD, 
which could bias the results of the Overall GRS and the Risk factor GRS, depending on the 
regions that were over represented. For the allele-count and the weighted CHD GRS this is 
not an issue, since none of the included SNPs in the CHD GRS were in very high LD with each 
other. Also, for constructing the LASSO GRS, highly correlated SNPs were not a problem, 
since penalized logistic regression methods, such as LASSO regression, only select 1 SNP 
from many correlated SNPs.28 We have not externally validated the LASSO analysis method 
in an independent population and therefore we cannot say that this exploratory method 
applies to other populations.
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In conclusion, the weighted CHD GRS, in contrast to the allele-count CHD GRS, was associated 
with future CHD independent of TRFs and improves risk reclassification. We conclude that it 
is important to adjust for the effect sizes of the different SNPs. If information on effect sizes 
is not available, LASSO regression analysis may be used to estimate these effect sizes. This 
method must be externally validated in independent prospective cohort studies.
Clinical perspective
Genome-wide association studies (GWAS) have identified many single-nucleotide 
polymorphisms (SNPs) associated with coronary heart disease (CHD) or its risk factors. 
We tested the combined effect of those SNPs on incident CHD in a Dutch population. By 
summing the number of risk alleles, three genetic risk scores (GRS) were constructed (i.e. a 
GRS based on all 179 SNPs, one based on 153 risk factor–associated SNPs and one based on 
29 CHD-associated SNPs). These GRS were associated with future CHD but not independent 
from traditional risk factors (i.e. age, sex, smoking, self-reported diabetes, parental history 
of myocardial infarction, blood lipids, blood pressure, and body mass index). Next, a 
weighted CHD GRS was constructed by summing the number of CHD-associated risk alleles 
multiplied by their effect sizes obtained from 2 GWAS. This GRS was associated with CHD 
independent of traditional risk factors and improved risk reclassification. Effect sizes are 
sometimes difficult to obtain; therefore, as an exploratory analysis, least absolute shrinkage 
and selection operator (LASSO) regression analysis was used to obtain weighting. Using this 
method on the 29 CHD SNPs, 3 SNPs and corresponding weights were selected for a GRS. This 
GRS performed equally to the weighted CHD GRS. When applied on all 179 SNPs, 14 SNPs 
and corresponding weights were selected for a GRS, which performed slightly better than 
the weighted CHD GRS. Thus, weighting is important, and, when weights are not available, 
LASSO regression might be used to construct a weighted GRS; however, this method must 
be tested in independent populations.
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Background  Intakes of n-3 polyunsaturated fatty acids (PUFAs), especially EPA (C20:5n-3) 
and DHA (C22:6n-3), are known to prevent fatal coronary heart disease (CHD). The effects 
of n-6 PUFAs including arachidonic acid (C20:4n-6), however, remain unclear. δ-5 and 
δ-6 desaturases are rate-limiting enzymes for synthesizing long-chain n-3 and n-6 PUFAs. 
C20:4n-6 to C20:3n-6 and C18:3n-6 to C18:2n-6 ratios are markers of endogenous δ-5 
and δ-6 desaturase activities, but have never been studied in relation to incident CHD. 
Therefore, the aim of this study was to investigate the relation between these ratios as well 
as genotypes of FADS1 rs174547 and CHD incidence.
Methods  We applied a case-cohort design within the CAREMA cohort, a large prospective 
study among the general Dutch population followed up for a median of 12.1 years. Fatty 
acid profile in plasma cholesteryl esters and FADS1 genotype at baseline were measured in a 
random subcohort (n=1323) and incident CHD cases (n=537). Main outcome measures were 
hazard ratios (HRs) of incident CHD adjusted for major CHD risk factors.
Results  The AA genotype of rs174547 was associated with increased plasma levels of 
C20:4n-6, C20:5n-3 and C22:6n-3 and increased δ-5 and δ-6 desaturase activities, but not 
with CHD risk. In multivariable adjusted models, high baseline δ-5 desaturase activity was 
associated with reduced CHD risk (P for trend=0.02), especially among those carrying the 
high desaturase activity genotype (AA): HR (95% CI)=0.35 (0.15–0.81) for comparing the 
extreme quintiles. High plasma DHA levels were also associated with reduced CHD risk.
Conclusion  In this prospective cohort study, we observed a reduced CHD risk with an 
increased C20:4n-6 to C20:3n-6 ratio, suggesting that δ-5 desaturase activity plays a role in 
CHD etiology. This should be investigated further in other independent studies.
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Polyunsaturated fatty acids (PUFAs) are generally believed to reduce coronary heart disease 
(CHD) risk.1-4 Intakes of n- 3 PUFAs, especially eicosapentaenoic acid (EPA, C20:5n-3) and 
docosahexaenoic acid (DHA, C22:6n-3) present in fish oil, are confirmed to prevent fatal 
CHD and sudden cardiac death in both observational studies and large-scale randomized 
controlled trials (RCTs).1,3 However, direct evidence for the preventive effect of n-3 PUFAs 
on non-fatal CHD was only recently observed in some, but not all, large-scale RCTs.5-7 The 
replacement of saturated fatty acids by n-6 PUFAs protected against incident CHD in a recent 
meta-analysis including 8 RCTs.8 As some of these RCTs also included n-3 PUFAs in addition 
to n-6 PUFAs,2,8 the effects specific to n-6 PUFAs, however, remain unclear.
The fatty acid profile of various biological tissues is often used as a biomarker of dietary fatty 
acid intake. Adipose tissue reflects the intake of past months to years, while erythrocyte 
membranes, and plasma or serum phospholipids or cholesteryl esters reflect the intake 
of several weeks.9-11 However, the PUFA profile in biological tissues does not only reflect 
dietary intake, but is also strongly dependent on the endogenous metabolism of PUFAs.10,12 
Therefore, PUFA biomarkers in biological tissues mirror the internal PUFA exposure that 
may be biologically more relevant. Several PUFAs can be endogenously synthesized by a 
series of alternate desaturation and elongation processes.12,13 The δ-5 desaturase and δ-6 
desaturase are rate-limiting enzymes for synthesizing long-chain n-3 and n-6 PUFAs (Figure 
1).12,14-16 They are encoded by the FADS1 and FADS2 genes on chromosome 11 (11q12–13.1), 
respectively.12,17 Potential functional genetic variants in these genes have been identified 
including rs174547,18 and confirmed in recent genome-wide association studies.19-21 They 
have an impact on FADS1 mRNA abundance,22-26 and, as a result, on desaturase activity, 
plasma PUFA levels, and endogenous PUFA pools.18-21,26-29 Since it is impractical to directly 
assay the enzyme activities of δ-5 and δ-6 desaturase in humans,12,14,15,29 especially in large-
scale epidemiological studies, their activities have traditionally been estimated by using 
PUFA product-to-precursor ratios.11,21,27,28
Although few prospective cohort studies have investigated PUFA biomarkers in relation 
to the incidence of CHD,30 the relation with PUFA product-to-precursor ratios as markers 
of desaturase activities has, to the best of our knowledge, never been evaluated. In this 
prospective cohort study, we therefore aim to investigate whether C20:4n-6 to C20:3n-6 






We conducted a case-cohort study within the Monitoring Project on Cardiovascular Disease 
Risk Factors 1987–1991,31 one of the two monitoring studies that were included in the 
Cardiovascular Registry Maastricht (CAREMA) study. The CAREMA study was described in 
detail before.32,33 In total, 12,486 men and women, born between 1927 and 1967 and living 
in the Maastricht area, participated in the Monitoring Project on Cardiovascular Disease 
Risk Factors and had given informed consent to retrieve information from the municipal 
population registries and from the general practitioner and specialist. The Medical Ethics 
Committee of the Netherlands Organization for Applied Scientific Research (TNO) approved 
the study protocol and all participants signed an informed consent form.
Cardiologic follow-up
The cardiologic follow-up has been described before.32 In brief, 97.6% of the CAREMA 
members could be found by linking the cohort to the hospital information system of 
University Hospital Maastricht (UHM). They were linked to the cardiology information 
system of the Department of Cardiology to obtain information about the occurrence of 
myocardial infarction (MI), unstable angina pectoris (UAP), coronary artery bypass grafting 
(CABG), or percutanous transluminal coronary angioplasty surgery (PTCA). For participants 
who died, the cause of death was obtained from Statistics Netherlands. In addition, the 
CAREMA cohort was linked to the hospital discharge registry of the UHM to increase the 
completeness of the cardiologic follow-up. Follow-up ended on 31 December 2003 with a 
median follow-up of 12.1 yrs (range: 0.0-16.9 yrs).
Subcohort and incident CHD selection for case-cohort design
For the present study, participants who were younger than 30 years at baseline (n=2204), 
had a history of MI, UAP, CABG, or PTCA before baseline (n=118), or were lost to follow-
up (n=2) were excluded. Thus, the eligible cohort consisted of 10,164 participants. All 620 
participants who developed incident CHD during follow-up (315 MIs, 244 UAPs and 61 CHD 
deaths) were included in the case-cohort study. From the eligible cohort, 1483 participants 
were randomly drawn as a subcohort.34 By randomly selecting a subcohort and using the 
specific statistics for this type of research design, the results are expected to be extrapolated 
to the entire cohort without the need of biomarker measurements in the entire cohort.11,34-36
85
Markers of endogenous desaturase activity and risk of 






Risk factor determination 
At baseline, all participants filled in a questionnaire on life-style characteristics, medical 
history, and parental history of MI. During a medical examination, information was collected 
on blood pressure, height, and weight. In addition, non-fasting blood samples were collected 
using EDTA tubes. The blood was centrifuged for 10 minutes at 1000 rpm and fractioned into 
blood plasma, white blood cells and erythrocytes and subsequently stored at -20˚C. Within 
three weeks, the plasma samples were transported to the Lipid Reference Laboratory of 
the University Hospital Dijkzigt (LRL) in Rotterdam where the total and HDL-cholesterol 
levels were determined using a CHOD-PAP method.37 The LRL in Rotterdam is a permanent 
member of the International Cholesterol Reference Method Laboratory Network.
Fatty acid determination
Fatty acids from plasma cholesteryl esters were quantified by gas-liquid chromatography 
between 2010 and 2011 at the Department of Human Nutrition of Wageningen University. 
The case and non-case samples were evenly distributed among the different batches and 
the assay sequence within each batch was random. The solid-phase extraction method 
was used to separate the cholesteryl ester fraction from total plasma lipid extracts. Fatty 
acid methyl esters were prepared by incubating isolated cholesteryl esters with acidified 
methanol. Peak retention times and area percentages of total fatty acids were identified by 
using known cholesteryl ester standards (mixture of FAME components from Sigma (MO) and 
NuChek (MN)) and analyzed with the Agilent Technologies ChemStation software (Agilent, 
Amstelveen, The Netherlands). For certain fatty acids, the values were too low to be reliably 
detected in some subjects, and ‘‘0’’ was assigned to their values. Interassay coefficients 
of variance in fatty acids in plasma cholesteryl esters were 1.68% for C16:0, 1.01% for 
C18:2n-6, 1.88% for C20:4n-6, and 5.02% for C22:6n-3, respectively. Fatty acid product-to-
precursor ratios were calculated, i.e. C20:4n-6 to C20:3n-6 to reflect δ-5 desaturase activity, 
and C18:3n-6 to C18:2n-6 to reflect δ-6 desaturase activity (Figure 1). The 20 subjects with a 
‘‘0’’ value for C20:3n-6 were not included in the analyses for the C20:4n-6 to C20:3n-6 ratio, 
reflecting δ-5 desaturase activity. Information on plasma fatty acids was available on 1323 
subcohort members and 537 CHD cases.
DNA extraction and genotyping 
DNA was extracted from the white blood cell fraction (buffy coats), using a standard 
procedure.38 The resulting DNA pellet was dissolved in TE buffer and DNA concentrations 
were determined using the Nanodrop ND1000 Spectrophotometer. The single nucleotide 
polymorphism (SNP) of rs174547 in the FADS1 gene was selected based on its association 
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with blood cholesterol and triglyceride levels in a genome-wide association study.23 This 
SNP is in high linkage disequilibrium (D’=1 and r2=0.8) with several other SNPs around the 
FADS1 and FADS2 gene region, which have an impact on mRNA abundance of FADS1,22-25 
desaturase activity, plasma PUFA levels, and endogenous PUFA pools.18-21,26-29 Rs174547 was 
genotyped entirely independent of case and non-case status using the iPLEX Gold chemistry 
of Sequenom’s MassARRAY platform (San Diego, CA) at the Leiden University Medical 
Center. Sequenom’s MassARRAYH Assay Design 3.1 Software was used for SNP assay design, 
and Sequenom’s SpectroTyper 4.0 software was used to call genotypes automatically, 
followed by manual review. The total genotyping success rate was 93%. Among the subjects 
who were measured for plasma fatty acid levels, information on rs174547 genotype was 
available for 1246 subcohort members and 492 CHD cases. The genotype distribution was 
consistent with Hardy-Weinberg equilibrium expectations.
Statistical Analysis 
Generalized linear models adjusted for age and sex were used to study the relations of 
rs174547 genotypes with PUFAs and PUFA ratios. Cox proportional hazards models adapted 
for the case-cohort design according to the Prentice’s method35 were used to calculate hazard 
ratios (HRs) as measures for relative risk.36 All the major predictors satisfied the proportional 
hazard assumption (data not shown). We estimated hazard ratios for quintiles of fatty 
acids (expressed as the percentage of total fatty acids present in the chromatogram) and 
ratios of C20:4n-6 to C20:3n-6 and C18:3n-6 to C18:2n-6 based on subcohort distributions, 
and the respective lowest quintile was used as reference. The base models included age 
and sex. Additional models were further adjusted for covariates from the Third Report of 
the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults (ATP III) risk score based on the Framingham 
cohort (current smoking, systolic blood pressure, hypertensive medication use, total and 
HDL cholesterol levels) with the addition of a history of diabetes.39 The models were also 
further adjusted for the total percentage of n-3 PUFAs or n-6 PUFAs in plasma cholesteryl 
esters where necessary. Additional covariates studied were parental history of MI, alcohol 
use and physical activity. The significance of a linear trend across quintiles of fatty acids 
and ratios of C20:4n-6 to C20:3n-6 and C18:3n-6 to C18:2n-6 was examined by including 
the exposure as a continuous variable in the model. Potential interactions between 
continuous ratios of C20:4n-6 to C20:3n-6 and C18:3n-6 to C18:2n-6 and dichotomized 
rs174547 genotype (homozygous major allele carriers vs. minor allele carriers) were tested 
by including interaction terms into the model. Statistical significance was considered to be 
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met with a P value < 0.05 and all testing was 2-sided. All statistical analyses were performed 
with SAS version 9.1 software (SAS Institute, Cary, NC).
Results
The general characteristics of the study population by subcohort-case status are shown in 
Table 1. As expected, cases were older, more frequently male, had higher blood pressure 
and total cholesterol levels, lower HDL cholesterol levels, smoked more often, and more 
often reported to have diabetes and a parental history of MI. 










Age (y) 45.2 ± 8.5 49.7 ± 7.3 1.07 (1.06-1.09) 1.05 (1.04-1.07)
Male sex 608 (46.0%) 392 (73.0%) 3.34 (2.69-4.15) 2.22 (1.66-2.99)
Total cholesterol (mmol/L) 5.7 ± 1.1 6.4 ± 1.2 1.71 (1.56-1.87) 1.42 (1.26-1.60)
HDL cholesterol (mmol/L) 1.2 ± 0.3 1.0 ± 0.2 0.04 (0.03-0.06) 0.09 (0.05-0.16)
Systolic blood pressure (mmHG) 119.2 ± 14.9 128.0 ± 16.9 1.03 (1.02-1.04) 1.02 (1.01-1.03)
Hypertensive medication use 67 (5.1%) 58 (10.8%) 2.34 (1.63-3.35) 1.27 (0.79-2.05)
Diabetes mellitus 13 (1.0%) 20 (3.7%) 5.33 (2.74-10.36) 2.83 (1.39-5.78)
Current smoking 551 (41.8%) 304 (56.7%) 1.81 (1.49-2.21) 1.72 (1.33-2.22)
Parental history of MI 452 (34.3%) 228 (42.5%) 1.40 (1.14-1.71) 1.51 (1.16-1.95)
1Data are expressed as mean ± SD or n (%) unless otherwise indicated. HDL: high-density lipoprotein; MI: myocardial 
infarction; and HR (95% CI): hazard ratio and 95% confidence interval. 
2Including 84 cases. 
3Hazard ratios were calculated per unit increase in total cholesterol, HDL cholesterol, and systolic blood pressure, 
and for the presence of the categorical traits. 
4All variables were added into one multivariable Cox proportional hazards model.
Carrying the minor G allele of rs174547 was associated with higher levels of substrates 
for desaturases (C18:2n-6, C20:3n-6 and C18:3n-3) and lower levels of products from 
desaturases (C18:3n-6, C20:4n-6, C20:5n-3 and C22:6n-3) in the plasma cholesteryl esters. 
Consequently, lower C20:4n-6 to C20:3n-6 and C18:3n-6 to C18:2n-6 ratios, as markers of 
δ-5 and δ-6 desaturase activity, respectively, were observed in carriers of the G allele as 
compared to those with the AA genotype (Table 2 and Figure 1). A high baseline C20:4n-6 
to C20:3n-6 ratio was associated with reduced CHD risk (Table 3). A 30% reduction in CHD 
risk was observed among the participants in the second, third, fourth and fifth quintile of 
C20:4n-6 to C20:3n-6 ratio compared with those in the first quintile after adjustment for 
age, sex, systolic blood pressure, hypertensive medication use, current smoking, diabetes, 
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total cholesterol and high-density lipoprotein cholesterol (P for trend = 0.02). Although the 
statistical interaction between rs174547 and δ-5 desaturase activity was not significant (P = 
0.56), the protective effect of high δ-5 desaturase activity was mainly confined to subjects 
with the AA genotype (Supplement IV, Table S1). In this group, the effect was stronger with a 
65% risk reduction for the subjects in the fifth quintile compared with the first quintile (P for 
trend = 0.02). Rs174547 itself was not associated with CHD risk, the age- and sex-adjusted 
HR per G-allele being 0.99 (95% CI 0.84–1.16, Supplement IV, Table S2).
Figure 1 | Effect of genotypes of rs174547 on synthesis of PUFAs in the n-3 and n-6 pathways. Measurements of n-3 
and n-6 polyunsaturated fatty acid (PUFA) levels in plasma cholesteryl esters in the sub-cohort of CAREMA study 
(n = 1246, Table 2). The three bars in each of the smaller plots represent levels of fatty acids (%) in individuals who 
carry AA, AG and GG genotypes of rs174547, respectively.
No association was observed between δ-6 desaturase activity and CHD risk (Table 3), also 
not after stratification by rs174547 genotype (data not shown). 
The results for the four n-6 PUFAs that determine δ-5 and δ-6 desaturase activity are shown 
in Supplement IV, Table S3. No associations with CHD were observed for the C20 precursor 
(C20:3n-6) and product (C20:4n-6, arachidonic acid) of δ-5 desaturase (Figure 1), or for the 
C18 precursor (C18:2n-6, linoleic acid) and product (C18:3n-6) of δ-6 desaturase (Figure 1) 
after adjustment for age, sex, systolic blood pressure, hypertensive medication use, current 
smoking, diabetes, total cholesterol, and high-density lipoprotein cholesterol (P for trend > 
0.16). 
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Regarding the n-3 PUFAs affected by desaturases, a significant inverse association was 
observed between C22:6n-3 (DHA) and CHD risk. This association became stronger after 
adjustment for plasma total and HDL cholesterol levels, and the percentages of n- 6 PUFA in 
plasma cholesteryl esters (P for trend = 0.027, supplement IV, table S4). The proportion of 
plasma C20:5n-3 (EPA) was not associated with incident CHD (P for trend = 0.724, supplement 
IV, table S4). No association was observed between C18:3n-3 (α-linolenic acid) and CHD 
risk (data not shown). To explore whether there is any independent effect of C20:4n-6 to 
C20:3n-6 ratio on CHD beyond DHA, we additionally adjusted the models in Table 3 for 
percentages of DHA. The association between C20:4n-6 to C20:3n-6 ratio and CHD risk 
attenuated, but remained highly significant, especially among the AA carriers of rs174547 
(HR = 0.44; 95% CI = 0.44:0.19–1.04 for comparing the extreme quintiles, supplement IV, 
table S1). 
Additional adjustment for parental history of MI, alcohol use or physical activity did not 
materially change any of the aforementioned associations (data not shown).
Table 2 | Association of rs174547 in FADS1 with baseline PUFAs in plasma cholesteryl esters and desaturase 
activities in the sub-cohort (n=1246).1
PUFA
RS174547 P-value2
AA (545) AG (569) GG (132)
n-6 PUFA C18:2n-6 (%) 44.30±0.272 4.88±0.26 46.60±0.54 7.48x10-4
C18:3n-6 (%) 0.60±0.009 0.48±0.009 0.40±0.019 6.87x10-28
C20:3n-6 (%) 0.42±0.005 0.43±0.005 0.44±0.010 0.051
C20:4n-6 (%) 4.29±0.05 3.56±0.05 2.89±0.09 3.92x10-46
n-3 PUFA C18:3n-3 (%) 0.40±0.005 0.41±0.005 0.45±0.010 3.28x10-4
C18:4n-3 (%)3 0.18±0.007 0.18±0.007 0.17±0.014 0.708
C20:5n-3 (%) 0.56±0.01 0.46±0.01 0.40±0.03 8.71x10-8
C22:6n-3 (%) 0.34±0.006 0.31±0.006 0.30±0.013 0.005
Desaturase activity δ-54 10.65±0.09 8.59±0.09 6.86±0.19 6.40x10-85
δ-64 0.014±0.0002 0.011±0.0002 0.009±0.0005 2.51x10-27
177 subjects in the subcohort had missing values for rs174547. PUFAs: polyunsaturated fatty acids. 
2General linear models were used, and all values are mean 6 SEM, adjusted for age and sex. 
3Only few subjects were successfully measured (AA=161, AG=185, and GG=42). 
4d-5 and d-6 desaturase activities were assessed by the ratio of C20:4n-6 to C20:3n-6 and C18:3n-6 to C18:2n-6 in 
plasma cholesteryl esters, respectively.
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Table 3 | Association between baseline δ-5 and δ-6 desaturase activity and incident coronary heart disease (CHD).
Quintile of δ-5 desaturase activity1
P for 
trend2First (6.45) Second (7.93) Third (9.07) Fourth (10.32) Fifth (12.52)
Incident 
CHD, n
155 117 94 93 67
Model 13 1 0.70 (0.51–0.97) 0.60 (0.42-0.83) 0.60 (0.43-0.83) 0.49 (0.34-0.70) <0.0001
Model 24 1 0.75 (0.54–1.06) 0.66 (0.46-0.94) 0.57 (0.39-0.82) 0.51 (0.35-0.75) <0.0001
Model 35 1 0.68 (0.47–0.98) 0.66 (0.45-0.96) 0.69 (0.46-1.01) 0.68 (0.45-1.02) 0.0249
Model 46 1 0.71 (0.49–1.03) 0.70 (0.48-1.04) 0.74 (0.50-1.09) 0.77 (0.50-1.18) 0.1114















92 99 93 122 131
Model 13 1 0.99 (0.69–1.42) 0.87 (0.60–1.25) 1.09 (0.76–1.55) 1.03 (0.73–1.45) 0.606
Model 24 1 1.03 (0.70–1.51) 0.89 (0.61–1.31) 1.07 (0.73–1.58) 0.93 (0.63–1.36) 0.627
Model 35 1 1.07 (0.71–1.63) 0.86 (0.55–1.33) 1.11 (0.73–1.69) 0.96 (0.63–1.47) 0.867
1 δ-5 and δ-6 desaturase activity were assessed by the ratio of C20:4n-6 to C20:3n-6 and the ratio of C18:3n-6 to 
C18:2n-6 in plasma cholesteryl esters, respectively and median ratios in each quintile are listed between brackets. 
2From models with desaturase activity included as a continuous variable. 
3Model 1 was adjusted for age and sex. 
4Model 2 was adjusted for age, sex, systolic blood pressure, hypertensive medication use, current smoking, and 
diabetes. 
5Model 3 was adjusted for all covariates in model 2, total cholesterol, and high-density lipoprotein cholesterol. 
6Model 4 was adjusted for all covariates in model 3 and percentages of C22:6n-3 (DHA) in plasma cholesteryl esters.
Discussion
In this prospective cohort study, we observed an inverse association between C20:4n-6 
to C20:3n-6 ratio, as the marker of δ-5 desaturase activity, and incident CHD risk, but 
no association with C18:3n-6 to C18:2n-6 ratio, as the marker of δ-6 desaturase activity. 
This association was partly mediated by DHA. Furthermore we confirmed associations of 
rs174547 in the FADS1 gene with plasma PUFA levels and C20:4n-6 to C20:3n-6 ratio.18-21,27,28 
Consistent with the established cardiovascular protective effects of n-3 PUFAs,1,3 and 
especially tissue DHA,4,30 high DHA in plasma cholesteryl esters was associated with a 
reduced CHD risk. However, no association was observed between arachidonic acid or other 
n-6 PUFAs related to δ-5 or δ-6 desaturase activity in plasma cholesteryl esters and CHD risk. 
Common genetic variants (including rs174547) in the FADS gene region have been associated 
with plasma lipid levels (total, LDL and HDL cholesterol, triglycerides, phospholipids and 
sphingolipids),19,21,23,40,41 glycemic traits (fasting glucose and beta-cell function),26 and resting 
heart rate42 in recent genome-wide association studies. However, none of them have been 
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associated with CHD risk directly.40,43 This was also the case in our relatively large prospective 
study. In contrast, when using the estimated δ-5 desaturase activity based on the fatty acid 
proportion in plasma cholesteryl esters, we found a significant inverse association with 
incident CHD. This seems contradictory, as a strong association between rs174547 genotypes 
and estimated δ-5 desaturase activities was observed. However, the reduced risk was already 
observed with relatively low δ-5 desaturase activities (the second quintile) and remained 
constant over the following quintiles. Therefore, the majority of the participants with the 
GG genotype of rs174547 might have sufficient δ-5 desaturase activity to protect them from 
CHD. This might explain why no association between rs174547 genotypes and CHD risk was 
found. Both rs174547 genotypes and C20:4n-6 to C20:3n-6 ratio reflect endogenous δ-5 
desaturase activity, but from two different perspectives. The former can be regarded as the 
desaturase effect conferred by a single common genetic variant in the FADS1 gene,20,26-29 and 
the latter as an approximate estimation of full desaturase activity.21,27,28 Their combination 
might provide the most accurate estimate of δ-5 desaturase activity. This might explain the 
stronger CHD risk reduction with high δ-5 desaturase activity in the subjects who inherited 
the AA genotype. 
The exact biological mechanisms that link δ-5 desaturase activity with CHD risk are still not 
well understood. Arachidonic acid, EPA, and DHA are currently considered to be potentially 
involved directly in the pathogenesis of CHD through thrombotic, inflammatory, arrhythmic 
and/or lipid regulatory pathways.1,3,12,13,44-46 δ-5 Desaturase is the key enzyme synthesizing 
these PUFAs, while δ-6 desaturase is important at the beginning of the n-3 and n-6 PUFA 
synthetic pathways.14,15 Therefore, it is biologically plausible that CHD risk could be influenced 
by δ-5 desaturase activity, but not by δ-6 desaturase activity12,13 as was shown in our data. 
The non-significance of δ-6 desaturase activity on CHD risk is perhaps, also compatible with 
the reported normal viability and life span of δ-6 desaturase knockout mice.47 Increased 
δ-5 desaturase activity might contribute to the intracellular increase of EPA and especially 
arachidonic acid levels.16 In non-fish eating populations, arachidonic acid is the predominant 
tissue very-long-chain PUFA, reaching 80% of the total very-long-chain PUFA.30,44 Despite the 
potential pro-coagulant and pro-inflammatory effects of increased exposures to arachidonic 
acid and its derived eicosanoid metabolites,2,13,44-46,48,49 there is no evidence of increased 
CHD risk with ≈ 5–7 times habitual arachidonic acid intake based on short-term small-scale 
controlled feeding studies.2,50-54 Tissue arachidonic acid levels are generally not associated 
with CHD risk.30 This was supported by our finding based on the fatty acid profile in plasma 
cholesteryl esters, which suggests that arachidonic acid does not mediate the observed 
association between C20:4n-6 to C20:3n-6 ratio, as the marker of δ-5 desaturase activity, 
and CHD risk. 
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Increased δ-5 desaturase activity (C20:4n-6 to C20:3n-6 ratio) was associated with increased 
plasma levels of EPA and DHA. Our results showed that a possible protective effect of 
increased δ-5 desaturase activity on CHD may partly be mediated by increased endogenous 
exposure to DHA. The observation that increased DHA levels associated with increased δ-5 
desaturase activity protect against CHD is consistent with the established cardiovascular 
protective effect of increased n-3 PUFA exposure (EPA and/or DHA).1,3 Accumulating evidence 
from observational studies suggests that DHA might be more protective for CHD than EPA,4,30 
which is consistent with our findings. However, EPA and DHA are usually correlated with 
each other in tissues, and their potential effects cannot be easily discerned. More research 
on this issue is therefore warranted. In addition to blood triglyceride lowering and HDL 
cholesterol increasing effects of EPA and DHA, n-3 PUFAs have long been observed to have 
anti- thrombotic, anti-inflammatory, anti-arrhythmic, and blood pressure-lowering effects 
in humans even though the underlying mechanisms for these effects are incompletely 
understood.1,3,12,13,46 Interestingly, the protective effects on fatal CHD and sudden cardiac 
death have been shown to level off with a modest intake of EPA and/or DHA (250 mg/day), 
and little additional benefit was observed with higher intakes.1 This is also consistent with our 
results for C20:4n-6 to C20:3n-6 ratio as the marker of δ-5 desaturase activity. Nevertheless, 
there might be other unidentified pleiotropic cardiovascular protective effects of increased 
δ-5 desaturase activity. For example, these desaturases are also significantly expressed in 
immune cells55,56 that play important roles in atherosclerotic CHD progression. 
Our results should be interpreted in the context of several limitations. First, our analyses 
were based on a single baseline measurement of fatty acid levels in plasma cholesteryl esters 
that may not accurately reflect long-term fatty acid exposures. However, we did detect the 
established protective effect of DHA against CHD.1,3,4,12,13,30 Second, we estimated δ-5 and δ-6 
desaturase activities based on n-6 PUFAs, while δ-5 and δ-6 desaturases are not only involved 
in n-6 PUFA conversion, but also in n-3 PUFA conversion. However, in comparison to n-6 
PUFA conversion, the amount of n-3 PUFA conversion is relatively small,16 which should not 
have affected our results. Third, other potential unmeasured environmental or physiological 
factors could have confounded the observed associations. However, the relatively large 
magnitude of the protective effect of increased δ-5 desaturase activity relative to the effect 
of other risk factors for CHD makes confounding with either unknown risk factors unlikely. 
Finally, our models that included total and HDL cholesterol may have been over-adjusted, as 
these are probably intermediates in the metabolic pathway between desaturase and CHD 
risk (supplement IV, note S1).
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In conclusion, in this prospective cohort study, we observed a reduced CHD risk with 
increased C20:4n-6 to C20:3n-6 ratio that was partly mediated by DHA. These results suggest 
that δ-5 desaturase activity plays a role protecting us from CHD.
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Chapter 7
The prediction of incident coronary heart disease (CHD) in individuals free from 
cardiovascular disease (CVD) is currently based on traditional risk factors (TRFs) such as age, 
gender, self-reported diabetes, total cholesterol, HDL cholesterol, systolic blood pressure, 
current smoking, body mass index and a parental history of myocardial infarction (MI).1,2 
In this thesis we investigated whether CHD risk prediction can potentially be improved 
by applying a metabolomics approach and by including information on common genetic 
variation previously reported to be associated with CVD or risk factors associated with 
CVD. We tested if metabolic profiles generated by 1H-NMR spectroscopy could mark 
individuals at high risk for CHD using the Cardiovascular Registry Maastricht (CAREMA) 
cohort and the Erasmus Rucphen Family (ERF) study. In addition we compared two different 
approaches for analysing 1H-NMR spectroscopy data. Next, using the CAREMA cohort, it was 
investigated if single nucleotide polymorphisms (SNPs) associated with CHD and/or CHD 
risk factors identified by genome-wide-association studies (GWAS) could improve CHD risk 
prediction. In the Leiden Longevity Study (LLS), we examined comprehensive lipid profiles 
for their ability to mark metabolic health in middle-aged individuals. Finally we focused on 
combining genetic information of the FADS1 locus with a comprehensive fatty acid profile 
for understanding and predicting CHD using the CAREMA cohort.
Main findings
In chapter 2 we explored the potential use of metabolomics technology for estimating CHD 
risk. In a case-cohort study design within the CAREMA cohort, it was investigated whether 
a single-point blood measurement of the metabolome, using 1H-NMR spectroscopy, can be 
instrumental to predict CHD risk in individuals free from CVD. By applying a targeted approach 
we identified and quantified 100 signals in the obtained 1H-NMR spectra representing 36 
different low-molecular-weight metabolites. To select the 1H-NMR signals associated with 
incident CHD, Least Absolute Shrinkage and Selection Operator (LASSO) regression was 
applied.3,4 This method performs variable selection and shrinkage at the same time, which is 
useful when aiming at finding prediction rules in high-dimensional data.3,4 Using this method 
we found that a combination of 16 signals out of the 100 was the best subset for CHD risk 
prediction. These signals represent valine, various lipid fractions, glycoproteins, glutamate, 
citrate, ornithine, trimethylamine N-oxide (TMAO), 1,5-anhydrosorbitol, glucose, serine 
and creatine. A metabolite score based on these 16 signals was associated with incident 
CHD with a hazard ratio (HR) of 1.91 per standard deviation (SD). Indicating that someone 
with 1 SD increase in the metabolite score had a 1.91 increased chance of developing CHD. 
After adjusting for the traditional CHD risk factors the HR decreased from 1.91 to 1.50 but 
remained significant, indicating that the metabolite score also captured information that 
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is not reflected by TRFs. Next, it was tested if this metabolite score improved CHD risk 
prediction beyond TRFs using Harrell’s C-index. This index assesses the ability of a marker 
to discriminate between events and non-events, by ranking participants who develop an 
event during follow-up higher than the ones who stay free from an event.5 For scores based 
on traditional CHD risk factors, like the Framingham risk score, the C-index ranges between 
0.71 to 0.84.6 The metabolite score, when combined with age and sex, had a C-index of 
0.81, which is comparable to a score based on TRFs (C-index = 0.82). Using the ERF study, 
an independent study population, it was found that the same 1H-NMR signals were also 
relevant for distinguishing between prevalent CHD cases and CHD-free controls.
In chapter 3 we compared our own targeted approach for data reduction (see chapter 2) 
to a more commonly applied method which involves partitioning the 1H-NMR spectra into 
discrete sections, and uses the sum of the spectral intensity in each section.7 This process is 
also known as equidistant binning.7 The reason for this comparison is that different methods 
for data reduction may have a different impact on subsequent data analysis and biomarker 
discovery.8 The 1H-NMR spectra were partitioned in sections of 0.02 parts per million (ppm), 
resulting in 401 bins. As mentioned in chapter 2, the targeted approach resulted in 100 
1H-NMR signals representing 36 metabolites. In addition we also evaluated the impact of 
two different scaling methods (autoscaling versus pareto scaling) on data analysis. LASSO 
regression in combination with autoscaling was performed to select the most important 
bins (when using the untargeted approach) or signals (when using the targeted approach) 
for CHD risk prediction. The selected bins or signals and their corresponding coefficients 
were used to construct a metabolite score. When using autoscaling, the metabolite scores 
based on both approaches were associated with incident CHD, independent of TRFs. 
The metabolite score based on the untargeted showed better discrimination as assessed 
by the C-index than the metabolite score based on the targeted approach. However the 
untargeted approach might be more prone to overfitting than the targeted approach. To test 
this presumption, the metabolite scores need to be validated in independent prospective 
cohorts. To avoid the selection on bins located in the noise region of the 1H-NMR spectrum, 
pareto scaling can be used as a data pre-treatment step. When using pareto scaling as data 
pretreatment, both the targeted and the untargeted metabolite score had comparable 
discriminatory capabilities. However, these metabolites scores had a lower discriminatory 
capability when compared to the metabolite score based on the targeted approach using 
autoscaling as a data pre-treatment step. 
In chapter 4, using the LLS, we investigated whether a comprehensive lipid profile obtained 
by 1H-NMR spectroscopy,9 can classify middle-aged individuals according to their metabolic 
health. Information on classical lipids was also available. The LLS consists of long-lived 
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siblings, their offspring and the partners of the offspring (see figure 1 for a visualization of the 
study design). As a group, the middle-aged offspring of long-lived individuals show a survival 
advantage, and a lower prevalence of CHD, hypertension and type 2 diabetes than their 
spouses, who act as controls.10 The offspring therefore represent individuals with a better 
metabolic health as compared with controls of comparable age, sex and BMI representing 
the general population.10 We investigated whether lipoprotein particle sizes obtained by 
1H-NMR spectroscopy represented improved markers of familial longevity compared to 
traditional lipids. We found that indeed for males, metabolic health was best characterized 
by larger mean low-density lipoprotein (LDL) particle sizes, whereas in females metabolic 
health was characterised by lower triglyceride levels. 
Figure 1 | Schematic representation of the Leiden Longevity 
Study.
In chapter 5, using the CAREMA case-cohort study, it was investigated if genetic risk scores 
(GRSs) based on SNPs associated with CHD or CHD risk factors according to previously 
published GWAS could improve CHD risk prediction beyond TRFs. Several approaches to 
construct a GRS were explored. The first approach was based on counting the number of 
risk alleles in every individual. These counted GRSs were not associated with CHD, nor did 
these GRS improve risk reclassification or discrimination. Second, to account for different 
effect sizes, every risk allele was multiplied by its corresponding weight. These weights were 
based on two published meta-GWAS.11,12 For practical reasons only the 29 SNPs associated 
with CHD were used to construct a weighted GRS. This weighted CHD GRS was associated 
with CHD before and after adjusting for TRFs and improved risk reclassification with 2.8%, 
but not risk discrimination. From these results it can be concluded that it is important to 
account for the different effect sizes of the SNPs. A GRS composed of 14 SNPs selected by 
LASSO regression improved risk discrimination and reclassification. This LASSO regression 
based GRS needs to be validated in independent populations.
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In chapter 6 we investigated if the product C20:4n-6 to precursor C20:3n-6 and the product 
C18:2n-6 to precursor C18:3n-6 ratios, as markers of δ-5 and δ-6 desaturase activity, 
influence CHD risk (see for more information on the synthesis of these polyunsaturated 
fatty acids figure 1 in chapter 6 and for more information on the nomenclature of fatty acids 
see box 1). We found that an increased C20:4n-6 to C20:3n-6 ratio marking  an increased 
δ-5 desaturase activity,13,14 was associated with a reduced CHD risk. This suggests that a 
high δ-5 desaturase activity is protective against the development of CHD, whereas no 
effect was found for δ-6 desaturase. δ-5 desaturase is encoded by FADS1. The minor G allele 
of a common genetic variant located in the FADS1 gene (rs174547) has been associated 
with a lower C20:4n-6 to C20:3n-6 and C18:3n-6 to C18:2n-6 ratio,15 increased plasma lipid 
levels,16-19 and resting heart rate,20 but never with CHD. In the study described in this thesis 
it was also observed that carriers of the minor G allele of that SNP had lower C20:4n-6 
to C20:3n-6 and C18:3n-6 to C18:2n-6 ratios, but not an increased CHD risk. This seems 
counterintuitive, however we did find  that the protective effect of a high δ-5 desaturase 
activity was mainly observed in AA carriers of the FADS1 genotype, which could be indicative 
for a gene-environment interaction. 
Box 1 | The nomenclature of the fatty acids
A fatty acid consists of a carboxylic acid (the -COOH group) with a long aliphatic tail and can be saturated or 
unsaturated.21 Saturated fatty acids have no double-bounds.21 Mono unsaturated fatty acids (MUFAs) have 
one double bound and polyunsaturated fatty acids (PUFAs) are characterized by multiple double bounds.21
In this thesis the fatty acids are named by their common or trivial names, but also the lipid numbers and 
the ω-x nomenclature are used to identify the fatty acids in a more systematic way. The lipid numbers take 
the form C:D, were C is the number of carbon atoms and D in the number of double bounds.21 For example 
as shown in the figure the fatty acid arachidonic acid consists of 20 carbon atoms and has 4 double bounds, 
thus its lipid number is C20:4. The ω-x nomenclature indicates were the first double bound is located, 
counted from the CH3 end of the fatty acid.21 The first double bound of Arachidonic acid starts at the 6th 
carbon atom (ω-6).
Figure | The chemical structure of arachidonic acid (C20:4ω -6). This fatty acids 
consists of a carboxylic acid with a long aliphatic tail. There are 20 carbon atoms 
present and 4 double bounds (C20:4). The first double bound is located at the sixth 
carbon from the CH3 end of the fatty acid (ω-6).
Metabolomics and CHD risk prediction 
Based on chapter 2 of this thesis, it can be concluded that a subset of 16 signals from a total 
of 100 1H-NMR signals, when combined into a weighted score was predictive for incident 
CHD. When this metabolite score was combined with age and sex, its predictability was 
comparable to a score based on traditional CHD risk factors. This metabolite score however 
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could not improve risk prediction beyond traditional CHD risk factors. However the 100 
1H-NMR signals represent only 36 metabolites and the human serum metabolome consists 
of at least 4229 confirmed metabolites.22 
Several other studies have  investigated if a metabolomics approach using either 1H-NMR 
based or mass spectrometry (MS) based platforms could be useful to predict incident CHD.23-
26 Mora et al. found that information on lipoproteins obtained by 1H-NMR spectroscopy was 
comparable, but not superior to standard lipids when predicting incident CAD in women,23 
confirming the results described in this thesis. According to Würtz et al., when standard 
lipids were replaced by 1H-NMR determined LDL-cholesterol and medium HDL-cholesterol, 
docosahexaenoic acid, and tyrosine, the prediction of incident high intima media thickness 
improved in comparison to traditional lipids.24 Shah et al. showed that a MS based 
metabolite profile consisting of short-chain dicarboxylacylcarnitines was associated with 
subsequent incident cardiovascular events in CAD patients after adjusting for traditional 
CHD risk factors.25 Wang et al. showed that the metabolites choline, TMAO and betaine 
were associated with CVD risk independent of traditional cardiovascular risk factors and 
medication use.26 Thus it seems that there is potential for metabolomics approaches to 
improve CHD risk prediction. Thus for future research, metabolites from various platforms 
should be tested in independent prospective cohort studies by meta-analysis to evaluate 
their usefulness for CHD risk prediction in comparison to the traditional CHD risk factors.
When using the untargeted approach with autoscaling as a data pre-treatment step, LASSO 
regression resulted in the selection of bins located in noise region of the 1H-NMR spectra. 
Since other studies indicate that more reliable results are obtained with a targeted approach 
than binning approaches,27,28 this could indicate that the untargeted approach could result 
in overfitting. With the targeted approach, this part of 1H-NMR spectrum is eliminated. The 
metabolite score based on this approach was associated with incident CHD independent 
of TRFs. Moreover, when combined with age and sex this score had a comparable C-index 
to a score based on TRFs. Thus it seems that with a relative low number of metabolites 
measured by 1H-NMR spectroscopy it is possible to predict who will get an incident CHD 
event and that this score gives comparable results to a risk score based on TRFs. However, 
these results need to be confirmed in an independent population.
Novel risk makers tested in prospective studies indicate that it possible to improve CHD 
risk prediction.29 For example, a coronary artery calcium score, a family history of MI, 
ankle brachial index or high-sensitivity C-reactive protein improved risk discrimination and 
classification of incident CHD beyond the Framingham score.29 But the decision of using 
a novel risk marker should not only be based on improvement in risk discrimination and 
reclassification, but also on improvement in clinical outcome and cost-effectiveness.30 It took 
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information from 52 prospective studies that included 246,669 participants, to estimate 
that after initial screening with conventional CHD risk factors, the additional assessment of 
high sensitive C-reactive protein or fibrinogen in people at intermediate risk (i.e. between 
10 and 20% chance of developing a CVD event) could help prevent one additional CHD event 
over a period of 10 years for every 400 to 500 people.31 This illustrates how difficult it is to 
improve CHD risk prediction.
Genetics and CHD risk prediction 
As shown in chapter 5, adding a weighted GRS based on SNPs associated with CHD to a CHD 
risk score based on TRFs resulted in a slight improvement of CHD risk reclassification. Other 
studies also investigated if comparable GRSs can improve CHD risk prediction.32-38 In general, 
when using a GRS based on SNPs associated with CHD risk factors, no improvement in CHD 
risk prediction was observed,35-37 which is confirmed in the study described in this thesis. 
For GRSs based on SNPs associated with CHD the results are mixed. For example, Paynter et 
al. showed that a non-weighted CHD GRS failed to improve CHD risk prediction,36 whereas 
three other studies showed that a GRS based on CHD associated SNPs improved both risk 
discrimination and/or reclassification.32,34,37 Hughes et al. showed that a adding a weighted 
CHD GRS did not significantly improve risk discrimination beyond the Framingham score, but 
risk reclassification was significantly improved,34 which is in line with the results described 
in this thesis. Concluding so far, GRSs based on SNPs show a minor improvement in CHD risk 
prediction beyond conventional risk markers but this improvement is not clinically relevant. 
On the other hand, Ganna et al. showed that 318 people at intermediate risk (a 10-years 
risk of CHD between 10% and 20%) needed to be screened with a CHD based GRS to prevent 
1 additional CHD event.37 This is a better outcome than when C-reactive protein would be 
added to a score based on conventional risk markers, which would prevent 1 additional CHD 
event per 400-500 individuals at intermediate risk.31
One may argue that a family history of CHD can also be a marker of genetic risk, and with 
a family history you will also capture the lifestyle factors not included in scores based on 
TRFs like the Framingham score. As described in chapter 5 of this thesis, when adjusting 
for a parental history of MI, the weighted CHD GRS remained associated with incident CHD 
in our study. This indicates that a GRS captures some genetic information not available in a 
parental history of MI. The question if a family history of CHD is a marker of genetic risk was 
investigated in a study performed by Do et al.39 In this study it was found that a family history 
of CHD (only first degree relatives are included) resulted in a better risk discrimination than 
a GRS based on SNPs associated with CHD. This finding is also supported by a study from 
So et al., were it was found that 12 CHD associated SNPs combined could explain 25.15% of 
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the variance in heritability of coronary artery disease.40 This means that SNPs discovered in 
GWAS so far only explain a small proportion the heritability found in CHD.41 
Several hypotheses have been proposed to explain this missing heritability problem. 
According to the infinitisemal model many variants of small effect are responsible for the 
missing heritability.42 The rare allele model assumes that many rare alleles of large effect can 
explain the missing heritability and the broad sense heritability model assumes that non-
additive gene-gene and gene-environment interactions and epigenetic effects can explain 
the missing heritability.43 Recently studies have been published that favour the infinitisemal 
model.44-49 For example, common variants explain 61.8% of the variance in HDL-C and rare 
variants only explain 7.8% of the variance in HDL-C.44 Other studies also found that common 
SNPs explain a significant proportion of the heritability of traits like height,45,46 BMI,46 
rheumatoid arthritis,47 and other traits.48 These results might favour a polygene approach for 
disease risk prediction, which already has been proved to work for schizophrenia.49 To test 
this approach for CHD, Ganna and co-workers used a relative small data set (1972 cases and 
2891 controls) to select common SNPs with a very small effect size (i.e. SNPs with P-value 
lower than 0.2).37 These SNPs were combined into a weighted polygenic GRS.37 When tested 
in an independent population, this polygenic GRS performed worse than a GRS based on 
46 SNPs associated with CHD according to GWAS.37 Since Ganna and co-workers used a 
relative small study for SNP discovery, especially when compared to the large meta-analysis 
performed to date, it would be interesting to select SNPs with very small effect sizes using 
large meta-analysis studies. Next, these SNPs need to be tested in independent prospective 
cohorts to evaluate their usefulness in CHD risk prediction. 
Metabolic health 
In this thesis it is described that lower triglyceride levels characterize familial longevity in 
females and that familial longevity is characterized by larger LDL particle sizes in males. This 
indicates that females and males show a different metabolic pattern indicating metabolic 
health and familial longevity. This is confirmed in a study conducted by Gonzalez et al.50 
In this study a comprehensive lipid profile, consisting of 128 different lipid species, was 
obtained in the participants of the LLS.50 In males no differences between offspring from 
long-lived siblings and controls were found.50 However, female offspring were characterized 
by higher levels of ether phosphocholines and lower levels of phosphoethanolamine and 
long-chain triglyceride species, independent of classical triglyceride levels.50 This confirms 
our observation that a lipid profile indicating metabolic health and familial longevity is 
gender specific. 
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In the LLS it was further reported that healthy ageing and metabolic health are characterized 
by lower glucose levels,51 higher insulin sensitivity,51 lower free T3 levels,52 lower vitamin D 
levels,53 and a lower RPTOR gene expression in blood.54 Since offspring of long-lived siblings 
are characterized by a lower prevalence of MI and hypertension,10 it would be interesting to 
test if  markers for metabolic health and familial longevity can be included in scores for CHD 
risk prediction, especially the lipid profile.55 These markers for CHD risk prediction should be 
evaluated in males and females separately. 
Combining genetic and metabolomics data
In thesis it is shown that δ-5 desaturase activity is negatively associated with incident CHD, 
whereas no association between δ-6 desaturase activity and incident CHD was found. δ-5 
desaturase is encoded by FADS1. The minor G allele of a SNP  (rs174547) located in this gene 
has been associated with a lower desaturase activity before,19 but never with an increased 
CHD risk. Both observations have been confirmed in this thesis. Since the protective effect 
of a high δ-5 desaturase activity was mostly confined to the carriers of AA genotype, this 
could indicate that some metabolic markers may only be useful for CHD risk prediction in 
people with a specific genotype. This indicates that it is relevant to combine genetics and 
metabolomics data for improving CHD risk prediction. Another reason for combining genetics 
and metabolomics was shown in a study by Yu and co-workers.56 In this study it was found 
that novel SNPs for heart failure can be discovered when applying a GWAS on metabolites 
previously associated with heart failure.56 Individually these SNPs were not significantly 
associated with heart failure, but when combined into a risk score these SNPs predict heart 
failure.56 It will be interesting to test if the same approach leads to the discovery of SNPs that 
can improve risk prediction of CHD, since this approach would also lead to the inclusion of 
SNPs that are associated with CHD, but not at a genome-wide significance level. This may 
also be a better strategy than the polygenic approach used by Purcell and co-workers, were 
only a minority of the included SNPs are truly associated with the disease or phenotype of 
interest.49
In a study performed by Ganna et al. it was found that a CHD specific GRS based on 46 
SNPs associated with CHD according to a large meta-GWAS was not associated with the 
Framingham risk score.37 This could indicate that these SNPs represent other pathways than 
the conventional TRFs for increasing CHD risk. It would be interesting to test with which 
metabolites these SNPs are associated and if these metabolites combined predict CHD risk. 
Moreover, this approach can also be used to gain knowledge about the CHD pathogenesis.
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Conclusions and future research
The risk of CHD is influenced by genetic, environmental and lifestyle factors. The current 
scores for estimating CHD risk in individuals free from CVD do not incorporate metabolomics 
nor genetic information. Therefore we evaluated the usefulness of these types of data 
for CHD risk prediction. However, based on the results described in this thesis it remains 
inconclusive if a metabolomics profile based on 1H-NMR spectroscopy or a GRS based on 
SNPs associated with CHD can improve 10-year CHD risk prediction beyond the currently 
used risk scores based on TRFs only. Based on the results described in this thesis it can be 
argued that markers for healthy ageing such as a LDL particle size should also be evaluated 
for their usefulness in CHD risk prediction and that these markers should be evaluated in 
males and females separately.
Most scores developed to predict CHD or CVD risk are developed to estimate CHD or CVD 
risk in individuals at middle age free from CVD. These scores cannot be used to estimate CHD 
risk in elderly individuals. For example a high blood pressure is associated with less mortality 
and strokes in the healthy elderly.57,58 This means that the field of CVD risk prediction in the 
85+ part of the population is relatively unexplained. The metabolomics platforms described 
in this thesis could be used to discover if metabolites could indicate metabolic health, co-
morbidity and mortality in the oldest old. In this thesis it is described that metabolic health 
is characterized by different markers in males and females, therefore such analysis should 
done in females and males separately.
In a study conducted by Pencina et al. a cohort with individuals between 20 and 60 years 
old was followed for 30 years.59 It was found that an adverse risk profile leads to a high 30-
year CVD risk in an individual of 25 years.59 When using a follow-up time of 10 years, this 
individual would have been characterized as having a very low CVD risk.59 Especially within a 
young population health gains can be achieved by using intervention strategies. That is why 
we need large cohorts with a younger population and longer follow-up times than currently 
used for finding risk markers for CHD. Since genetic markers remain stable throughout 
live, it is possible to use genetic markers for CHD risk prediction much earlier in life than 
conventional CHD risk factors.37 This hypothesis can be investigated in the CAREMA cohort 
using a case-cohort study design.60 Cardiologic follow-up for this study was performed in 
December 2003 and only for the participants between 30 and 59 years of age at moment of 
inclusion. At that point the median follow-up time was 12.1 years. If cardiologic follow-up 
would be performed again in December 2013, including the participants between 20 and 
30 years of age at moment of inclusion, this would result in a study with a longer follow-up 
time (approximately 22.1 years). Moreover the study population would be younger. In this 
younger population with a longer follow-up time the hypothesis that genetic markers have 
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more value at a younger age for CHD risk prediction can be tested for relative low costs, 
because only additional samples need to be analysed.
It can be argued that to prevent CHD, instead of estimating CHD risk and treat high risk 
individuals, everybody of 55 years and older should be prescribed a polypill.61 This pill 
contains a statin to lower cholesterol levels, three blood pressure lowering drugs, folic acid 
and aspirin.61 It was estimated that such a pill would prevent 88% of heart attacks and 80% 
of strokes after two years of treatment.61 Several randomized clinical trials have investigated 
the efficacy of this polypill and were summarized in a meta-analysis.62 According to this 
meta-analysis, the use of the polypill reduced systolic blood pressure total cholesterol and 
LDL-cholesterol levels, but this reduction was less than previously estimated by Wald et 
al.62 This can be explained by the fact that the actual reduction in risk factors is dependent 
on the baseline levels of these risk factors.62 Thus it could be that the polypill is not as 
effective as expected in persons with a low cardiovascular risk. On the other hand, according 
to van Gils et al. the polypill strategy for primary prevention in the Netherlands is a cost 
effective strategy when given to participants of 40 years and older with a cardiovascular risk 
of more the 5%.63 Thus the combination of screening for cardiovascular risk with prescribing 
a polypill if this risk exceeds 5% might be an effective strategy.63
To get a better understanding of CHD pathology, it makes sense to integrate different omics 
datasets together with lifestyle and environmental factors. Moreover this type of data 
should be gathered in longitudinal cohorts in whom follow-up information on CHD or other 
metabolic disease is available or can be collected. Blood should not be only collected at 
baseline but also during follow-up (repeated measures design). This will make it possible to 
do a time-dependent analysis were it is possible to account for changes in risk factor levels 
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Een hartinfarct ontstaat door atherosclerose in de kransslagaders. Door de ophoping van 
vetachtige stoffen in de vaatwanden worden atherosclerotische plaques gevormd die leiden 
tot vernauwing van de kransslagaders. Deze atherosclerotische  plaques zijn kwetsbaar en 
kunnen openscheuren. Zodra dit gebeurt, vormt er zich een stolsel en wordt de kransslagader 
geblokkeerd. Hierdoor kan het achterliggende hartweefsel niet meer worden voorzien van 
zuurstof en voedingsstoffen. Dit leidt tot pijn op de borst die kan uitstralen naar de nek, de 
rug of de armen. Er is dan sprake van een acuut hartinfarct. Als deze blokkade tijdelijk is 
en niet leidt tot versterving van het hartweefsel dan is er sprake van een instabiele angina 
pectoris. Soms is het onderscheid tussen een acuut hartinfarct en een instabiele angina 
pectoris moeilijk te maken, beide aandoeningen worden daarom ingedeeld onder de 
noemer coronaire hartziekten.
De kans op het krijgen van coronaire hartziekten neemt toe met de leeftijd, het hebben 
van een hoge bloeddruk, een hoog cholesterol gehalte, het hebben van overgewicht 
en een familie geschiedenis van coronaire hartziekten. Daarnaast lopen ook rokers en 
mannen een groter risico op het krijgen van coronaire hartziekten. Op basis van deze 
zogenaamde “traditionele risicofactoren” is het mogelijk om mensen met een hoog risico 
op coronaire hartziekten te identificeren. Deze mensen krijgen een leefstijl advies, en/of 
worden behandeld met medicatie tegen een hoge bloeddruk of een te hoog cholesterol 
om zodoende coronaire hartziekten te voorkomen. Het doel van dit proefschrift is om na te 
gaan of deze risicoschatting verbeterd kan worden door het gebruik van nieuwe technieken 
waarmee patronen van veel metabolieten in het bloed kunnen worden gemeten. Daarnaast 
wordt er ook bekeken of genetische informatie bij de risicobepaling betrokken kan worden. 
Metabolieten zijn de tussen- en eindproducten die ontstaan nadat het menselijk lichaam een 
bepaalde stof heeft verwerkt. Voorbeelden zijn glucose, aminozuren, antioxidanten, vrije 
vetzuren. Samen geven deze metabolieten een idee van de metabole staat van het lichaam 
op dat moment. De term metabolomics duidt op het identificeren en het kwantificeren 
van veel metabolieten tegelijkertijd in lichaamsvloeistoffen hetgeen in dit proefschrift is 
gedaan door middel van één soort ‘metabolomics’ techniek. Om te kijken of informatie 
over erfelijke achtergrond de risicoschattingen kan verbeteren maken wij gebruik bekende 
veel voorkomende variaties tussen mensen in het DNA. We richten ons op de variaties 
van één enkele nucleotide (in het Engels: single nucleotide polymorphisms [SNPs]) die zijn 
geassocieerd met coronaire hartziekten en met risicofactoren voor deze ziekten. Daarnaast 
hebben wij ook bekeken of een uitgebreid lipiden profiel inzicht kan geven in factoren die 









Om te onderzoeken of metabolieten en genetische variaties bijdragen aan een betere 
voorspelling voor coronaire hartziekten is er gebruikt gemaakt van de Cardiovasculaire 
Registratie Maastricht (CAREMA) studie. Tussen 1987 en 1997 is er aan mensen, woonachtig 
in Maastricht en omstreken, gevraagd of ze wilden deelnemen aan deze studie. In totaal 
waren er 21.148 deelnemers die toestemming hadden gegeven om mee te werken. Van 
deze mensen waren er 14.720 geschikt voor deelname omdat ze tussen de 30 en 59 jaar oud 
waren en nog nooit eerder coronaire hartziekten hadden gehad. Deze mensen zijn tot en 
met 31 december 2003 gevolgd. Tijdens die periode waren er 742 personen die coronaire 
hartziekten ontwikkelden of hieraan zijn overleden. Dit zijn de “patiënten”. Vanuit het 
CAREMA cohort werd er een aselecte steekproef getrokken van 2221 deelnemers. Deze 
groep fungeerden als “controles”. Het belangrijkste voordeel van hiervan is dat de metingen 
alleen in de patiënten en de subcohort leden uitgevoerd moeten worden, en niet in alle 
14.720 deelnemers.
Om te kijken of metabolieten waren geassocieerd met bestaande gevallen van coronaire 
hartziekten is er gebruik gemaakt van de Erasmus Rucphen Family (ERF) studie. Deelnemers 
werden geclassificeerd als patiënt wanneer ze hadden vermeld ooit een acuut hartinfarct te 
hebben gehad, als ze ooit een bypass operatie hadden ondergaan, of als ze angina symptomen 
hadden gerapporteerd tijdens het interview met de arts. Van elke deelnemer werd ook een 
hartfilmpje gemaakt. Als hieruit bleek dat ze ooit een acuut myocard infarct hadden gehad 
werden ze ook ingedeeld bij de patiënten. In deze studie zaten 2415 deelnemers, waarvan 
170 patiënten, 2157 deelnemers werden als controles gebruikt. 
Om te beantwoorden welke factoren zijn geassocieerd met metabole gezondheid hebben 
wij gebruik gemaakt van de Leiden Langleven Studie. Aan deze studie doen 450  families 
mee, die door erfelijke en andere familiaire factoren beschermd zijn tegen coronaire 
hartziekten, hoge bloeddruk en diabetes type 2. Daarnaast leven deze families al enkele 
generaties langer dan andere mensen in de bevolking. De 450 langlevende families werden 
uit de Nederlandse bevolking geselecteerd als er in een familie minimaal twee broer/zusters 
van minimaal 90 jaar oud wilden meewerken met het onderzoek.  Omdat deze oude mensen 
niet meer vergeleken konden worden met hun inmiddels overleden generatiegenoten, 
werden ook de 1671 kinderen van deze langlevende mensen in de Leiden Langleven studie 
geïncludeerd. Deze kinderen, van middelbare leeftijd overigens,  werden vergeleken met 
hun leeftijdsgenoten en partners als controles (n=745). Leefstijl,  omgevingsfactoren en 
gewicht zijn in deze twee groepen gelijk. Al het voorgaande onderzoek heeft echter laten 
zien dat de intrinsieke metabole gezondheid bij de langlevende familieleden groter is dan 
bij de controles. Bij het onderzoek naar markers van metabole gezondheid op middelbare 
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leeftijd wordt steeds gekeken of het onderscheid tussen de twee groepen door een marker 
verbetert ten opzichte van traditionele variabelen. 
Metabolieten en het risico op coronaire hartziekten
Om te onderzoeken of metabolieten bruikbaar zijn voor de predictie van coronaire 
hartziekten hebben wij in een deel van de CAREMA studie (79 patiënten en 565 controles) 
metabolieten gemeten door middel van waterstof kernspin resonantie (in het Engels: proton 
nuclear magnetic resonance [1H-NMR]) spectroscopie. Deze techniek leverde 100 bruikbare 
signalen op en deze 100 signalen representeerden 36 verschillende metabolieten (sommige 
metabolieten geven meerdere signalen, en aan andere signalen kon geen metaboliet 
toegekend worden). Door middel van een statistische test (LASSO regressie) vonden wij 16 
verschillende signalen die, wanneer gecombineerd in één score konden voorspellen wie 
een verhoogd risico liep op coronaire hartziekten. Deze score in combinatie met leeftijd en 
geslacht presteerde ongeveer even goed als alle traditionele risicofactoren gecombineerd. 
Wanneer deze score werd toegevoegd aan een score bestaande uit alleen traditionele 
risicofactoren zagen wij geen verbetering in de risicopredictie. Door gebruik te maken van 
de ERF studie konden wij zien dat de geselecteerde pieken ook belangrijk waren voor het 
onderscheid tussen mensen met en zonder coronaire hartziekten.
Ook hebben wij bekeken wat de beste manier is om 1H-NMR data te analyseren. Om 
informatie uit een 1H-NMR spectrum te halen hebben wij twee verschillende methodes met 
elkaar vergeleken. Ten eerste een ongerichte aanpak waarbij het gehele 1H-NMR spectrum 
in kleine stukjes wordt opgedeeld. Deze stukjes worden bins genoemd. Ten tweede een 
gerichte aanpak, zoals beschreven in de paragraaf hierboven, waarbij we ons concentreren 
op de metabolieten die een duidelijk signaal in het 1H-NMR spectrum laten zien. Bij de 
gerichte aanpak vonden wij elf signalen die wanneer gecombineerd in één score waren 
geassocieerd met coronaire hartziekten, ook na correctie voor traditionele risicofactoren. 
Bij de ongerichte aanpak vonden wij 21 bins in het 1H-NMR spectrum, die wanneer 
gecombineerd in één score geassocieerd waren met coronaire hartziekten, ook na correctie 
voor traditionele risicofactoren. Deze score leek een beter onderscheidend vermogen te 
hebben dan de score die was gebaseerd op de gerichte aanpak. Maar het bleek dat een groot 
deel van de geselecteerde bins in een regio lagen waar alleen ruis aanwezig was. Dit kan 
duiden op overaanpassing, beter bekend als “overfitting” in de wetenschappelijk literatuur, 
van het model. Het gevolg hiervan is dat een score gebaseerd op data met veel ruis mogelijk 
weinig voorspellende waarde heeft in een onafhankelijke populatie. Om hiervan zeker te 








Op dit moment kan de risicopredictie van coronaire hartziekten niet verbeterd worden 
met de beperkte metabolomics meting die wij hebben verricht. Maar van de andere 
kant, een score gebaseerd op metabolieten (een gemakkelijk meting in bloed op één 
moment), gecombineerd met leeftijd en geslacht liet een even goede predictie zien als 
alle traditionele risicofactoren gecombineerd. Daarnaast is maar een klein deel van alle 
mogelijke metabolieten getest. Daarom is het erg interessant om in de toekomst te kijken 
of metabolieten gemeten met behulp van andere platformen kunnen bijdragen aan de 
risicopredictie van coronaire hartziekten. Hierbij zullen de resultaten gerepliceerd moeten 
worden in onafhankelijke studies.
Genetica en het risico op coronaire hartziekten
Om te onderzoeken of genetische informatie gebruikt kan worden bij de risicopredictie van 
coronaire hartziekten zijn er 179 SNPs gemeten in de CAREMA studie (642 patiënten en 1905 
controles). Deze 179 SNPs waren uitgekozen omdat ze volgens genoom-wijde associatie 
studies waren geassocieerd met coronaire hartziekten (29 SNPs) of met risicofactoren voor 
coronaire hartziekten (153 SNPs). Op basis van deze SNPs werden genetische risico scores 
(GRSs) samengesteld door het aantal risico allelen te tellen in elke persoon. Per SNP heb 
je maximaal twee risico allelen, dus voor een GRS bestaande uit 29 SNPs is de minimum 
score 0 en de maximum score 58. Dus hoe hoger de score van GRS, hoe groter de kans op 
ziekte. De GRSs (één gebaseerd op alle SNPs, één gebaseerd op de risicofactoren SNPs en 
één gebaseerd op de coronaire hartziekten SNPs) die op die manier werden samengesteld 
bleken te associëren met coronaire hartziekten, maar niet na correctie voor traditionele 
risicofactoren. Daarom hebben wij een GRS samengesteld op basis van de SNPs geassocieerd 
met coronaire hartziekten, maar aan een SNP met groter effect werd een groter gewicht 
toegekend. Deze gewogen GRS was geassocieerd met coronaire hartziekten, ook na correctie 
voor traditionele risicofactoren. Deze GRS zorgde ook voor een kleine verbetering in de 
risicopredictie. Als laatste probeerden wij een combinatie van SNPs te vinden die samen 
de beste risicopredictie laten zien, door gebruik te maken van een statische test waarmee 
de combinatie van de best voorspellende SNPs kan worden geselecteerd (LASSO regressie). 
Met deze test werden er 14 van de 179 SNPs geselecteerd. De GRS gebaseerd op deze SNPs 
was geassocieerd met coronaire hartziekten na correctie voor traditionele risicofactoren en 
liet een kleine verbetering in de risicopredictie zien. Om met zekerheid te kunnen zeggen 
of deze GRS de risicopredictie verbetert zal deze GRS nog getest moeten worden in een 
onafhankelijke populatie. 
Op basis van het hierboven beschreven onderzoek kan geconcludeerd worden dat een 
gewogen GRS gebaseerd op SNPs geassocieerd met coronaire hartziektes een heel kleine 
116
Chapter 8
verbetering laat zien in de risico predictie voor coronaire hartziektes. Maar waarschijnlijk is 
deze verbetering klinisch niet relevant. Dit wordt ook ondersteund door andere onafhankelijk 
gepubliceerde studies. 
Een gezonde stofwisseling en familiare langlevendheid 
Door middel van een uitgebreid lipiden profiel hebben wij bekeken of wij mensen kunnen 
classificeren op grond van hun metabole gezondheid. Hiervoor hebben wij gebruik gemaakt 
van de Leiden Langleven Studie. In deze studie zijn lipoproteïne deeltjes grootte gemeten 
met behulp van waterstof kernspin resonantie. Daarnaast hadden wij ook informatie 
over totaal cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceriden, apolipoproteine 
E, leeftijd, geslacht en body massa index beschikbaar. Uit onze analyses bleek dat de 
nakomelingen van langlevende mensen gemiddeld genomen grotere LDL en HDL deeltjes 
grootte hadden dan hun partners. Daarnaast hadden ze lagere triglyceriden waardes en 
een hogere totaal cholesterol/HDL-cholesterol ratio. Het bleek dat LDL deeltjes grootte bij 
mannen en triglyceriden niveaus bij vrouwen de meest informatieve markers waren voor 
familiare langlevendheid. 
Hieruit kan geconcludeerd worden dat een gezonde stofwisseling en familiare 
langlevendheid worden gekenmerkt door grotere LDL deeltjes in mannen en lagere 
triglyceriden niveaus in vrouwen. Het is zou interessant zijn om te kijken of deze markers 
voor een gezonde stofwisseling en familiaire langlevendheid ook gebruikt kunnen worden 
voor de risicopredictie van coronaire hartziekten. Omdat deze markers geslacht specifiek 
zijn zal dit apart in mannen en in vrouwen onderzocht moeten worden. 
Het combineren van metabolieten en genetische data 
In de CAREMA studie (in 537 patiënten en 1323 controles) is ook gekeken naar de invloed 
van de vrije vetzuren op het ontstaan van coronaire hartziekten. Hierbij lag de focus op 
linolzuur, gamma-linoleenzuur, dihomo-gammalinoleenzuur en arachidonzuur. Linolzuur 
wordt in het lichaam omgezet in gamma-linoleenzuur door het enzym delta-6 desaturase. 
Vervolgens wordt dit vetzuur omgezet in dihomo-gammalinoleenzuur door het enzym 
elongase. Daarna wordt dihomo-gammalinoleenzuur omgezet in arachidonzuur door het 
enzym delta-5 desaturase. De verhouding tussen gamma-linoleenzuur en linolzuur is een 
maat voor de activiteit van delta-6 desaturase. Hoe hoger dit getal, hoe actiever dit enzym. 
Zo geeft ook de verhouding tussen arachidonzuur en dihomo-gammalinoleenzuur de 
activiteit van delta-5 desaturase weer. Het bleek een hogere delta-5 desaturase activiteit 








was niet geassocieerd met coronaire hartziekten. Uit eerdere studies is bekend dat een SNP 
(rs174547) gelegen in het enzym FADS1 is geassocieerd met delta-5 desaturase activiteit, 
maar niet met coronaire hartziektes. In de CAREMA studie was deze SNP ook geassocieerd 
met een hogere delta-5 desaturase activiteit, maar niet met coronaire hartziektes. Het bleek 
wel dat het beschermende effect van een hoge delta-5 desaturase activiteit alleen werd 
gevonden in dragers van het AA genotype van FADS1. 
Hieruit kan geconcludeerd worden dat een hoge delta-5 desaturase activiteit beschermt 
tegen de ontwikkeling van coronaire hartziekten. Omdat het beschermende effect van 
een hoog delta-5 desaturase activiteit met name werd gevonden in dragers van het AA-
genotype van het FADS1 gen, zou kunnen zijn dat bepaalde markers alleen nuttig zijn voor 
risicopredictie in mensen met specifieke genotypen. Dit pleit voor het combineren van 
metabolieten met genetische data. 
Conclusie en toekomstig onderzoek
De huidige scores om het risico op coronaire hartziekten te voorspellen maken geen gebruik 
van metabolieten en genetische data. Daarom hebben wij de bruikbaarheid van dit soort 
data voor risicopredictie van coronaire hartziekten geëvalueerd. Op dit moment kunnen 
wij nog niet met zekerheid zeggen of metabolieten en/of genetische data de risicopredictie 
voor coronaire hartziekten kunnen verbeteren. Gebaseerd op de resultaten beschreven in 
dit proefschrift denken wij ook dat het belangrijk om te evalueren of markers voor gezond 
oud worden ook van nut kunnen zijn bij de predictie van coronaire hartziekten. Dit zal in 
mannen en vrouwen apart onderzocht moeten worden. Daarnaast is het ook belangrijk om 
genetische en metabolieten data met elkaar te combineren. 
De meeste scores zijn ontwikkeld om het risico op coronaire hartziekten te voorspellen op 
middelbare leeftijd en kunnen niet gebruikt worden voor oudere individuen (ouder dan 
85 jaar). Zo is bijvoorbeeld onder gezonde 85 plussers een wat verhoogde bloeddruk juist 
geassocieerd met een lagere mortaliteit. Dit houdt dat er nog veel onderzoek gedaan moet 
worden naar risicopredictie voor hart- en vaatziekten in de oudere bevolking. Het gebruik 
van metabolieten data kan hierbij een belangrijke rol spelen.
Bij een relatief jonge populatie leidt het gebruik van een 10-jarige risicoscore tot een 
onderschatting van het lange termijn risico op coronaire hartziekten. Juist bij een jonge 
populatie kan er veel gezondheidswinst worden behaald met preventieve strategieën. 
Daarom zijn cohorten nodig met jongere deelnemers en langere follow-up tijden dan 
gebruikelijk voor onderzoek naar coronaire hartziekten. Omdat genetische variatie stabiel is 
gedurende het hele leven, zouden juist deze markers geschikt kunnen zijn om het risico op 
coronaire hartziekten te voorspellen in een jongere populatie dan tot nu toe gebruikelijk. 
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Om een beter begrip te krijgen van coronaire hartziekten is het noodzakelijk om genetische 
markers en informatie over metabolieten met elkaar te combineren, samen met omgevings- 
en leefstijlfactoren. Deze informatie moet worden verzameld in grote longitudinale cohorten 
waarbij bloed wordt verzameld op het moment dat mensen deelnemen aan de studie, maar 
ook tijdens follow-up. Dit maakt het mogelijk om de effecten van bijvoorbeeld stoppen met 
roken te evalueren. Het is ook belangrijk om relatief jonge personen en oudere personen 
te includeren, omdat deze groepen ondervertegenwoordigd zijn in de meeste onderzoeken 





Supplementary material & methods
Acquisition and processing of 1H-NMR spectra
All proton nuclear magnetic resonance (1H-NMR) experiments were acquired on a 600 MHz 
Bruker Avance II spectrometer (Bruker BioSpin, Karlsruhe, Germany) equipped with a 5 mm 
TCI cryogenic probe head with Z-gradient system and automatic tuning and matching. All 
experiments were recorded at 310K. Temperature calibration was done prior to each batch 
of measurements using the method of Findeisen et al.1 The duration of the π/2 pulses were 
automatically calibrated for each individual sample using a homonuclear-gated nutation 
experiment on the locked and shimmed samples after automatic tuning and matching of 
the probe head.2
The stored EDTA plasma and serum samples were thawed at 4°C and were mixed by 
inverting the tubes 10 times. Next, samples (300 µL) were mixed with 300 µL 75 mM 
disodium phosphate buffer in H2O/D2O (80/20) with a pH of 7.4 containing 6.15 mM NaN3 
and 4.64 mM sodium 3-[trimethylsilyl] d4-propionate (TSP) using a Gilson 215 liquid handler 
in combination with a Bruker SampleTrack system. Samples were transferred into 5mm 
SampleJet NMR tubes in 96 tube racks using a modified Gilson 215 tube filling station and 
kept at 6°C on a SampleJet sample changer while queued for acquisition.
For water suppression presaturation of the water resonance with an effective field of γB1 = 25 
Hz was applied during the relaxation delay.3 J-resolved spectra (JRES)4 were recorded with a 
relaxation delay of 2 s and a total of one scan for each increment in the indirect dimension. 
A data matrix of 40 x 12,288 data points was collected covering a sweep width of 78 x 10,000 
Hz. A sine-shaped window function was applied and the data was zero-filled to 256 x 16,384 
complex data points prior to Fourier transformation. The resulting data matrix was tilted 
along the rows by shifting each row (k) by 0.4992*(128-k) points and symmetrised about 
the central horizontal lines in order to compensate for the skew of the multiplets in the F1 
dimension. For T2-filtered 1H NMR spectra a standard 1D CPMG (Carr–Purcell–Meiboom–
Gill) pulse sequence,5,6 was used with a relaxation delay of 4 seconds. A pulse train of 128 
refocusing pulses with individual spin echo delays of 0.6 ms were applied resulting in a total 
T2 filtering delay of 78 ms. 73,728 data points covering a spectral width of 12,019 Hz were 
collected using 16 scans. The FID was zero-filled to 131,072 complex data points and an 
exponential window function was applied with a line broadening factor of 1.0  Hz prior to 
Fourier transformation. The spectra were automatically phase and baseline corrected. 
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Quality control, scaling and calibration of the 1H-NMR spectra
Further data processing was performed in Matlab® (R2009a, The Mathworks Inc., Natick, 
MA, USA). The spectra and associated data were converted into Matlab files using in-house 
code. First, the spectra were combined into one file while removing superfluous information. 
For CPMG this included dropping the imaginary part of the spectrum, while for the JRES 
spectra the sum projection along the indirect dimension was taken. Quality control (QC) on 
the set of 1H-NMR spectra was carried out by examining a set of spectroscopic parameters 
such as shim values and intensity of the water signal, and subsequently visually inspecting 
the spectra. The spectra that failed the QC were not included for further analysis. The 
spectra were then scaled with respect to the sensitivity of the receiver coil, as determined 
from the pulse length that was automatically calibrated for each sample.7 After subtracting 
a constant value as a simple baseline correction, the spectra were calibrated with respect 
to the anomeric resonance of α-D-glucose (δ = 5.23 ppm).8 Since there are small deviations 
of the peak position in the different 1H-NMR spectra, alignment was performed using the 
correlation optimized warping algorithm by Tomasi et al.9 This was performed actively for 
the CPMG spectra, after which the same warping was applied to the JRES projection. Peaks 
in the JRES projection were picked by finding the signals that were above the surrounding 
spectral area by more than the estimated noise level. Peaks in different spectra were grouped 
according to similarity in peak position and intensity. The intensity and the position give 
good initial guesses for the deconvolution of the peaks by fitting groups of mixed Gaussian-
Lorentzian line shapes to isolated spectral areas using a Simplex optimization algorithm. As 
the fitting algorithm incidentally fails to converge properly, values further from the median 
than 3 times the interquartile range are discarded. Using PLS regression, the remaining peak 
intensities were used to build a linear model that predicts all intensities directly from the 
non-warped spectrum, yielding also values for the cases where the peak picking failed or 
the deconvolution values were discarded, and eliminating the problem of faulty warping.
For 76 signals, metabolites were assigned using information from previously reported 
plasma/serum metabolites,6,8,10,11 the Human Metabolome Database (HMDB)12 and the 
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Table S1 | An overview of all peaks identified in the 2 dimensional J-resolved 1H-NMR spectrum and their association 
with incident CHD in the primary prospective case-cohort study. 
Cases Sub-cohort Association with CHD
Chemical 
shift
Assignment Mean (sd) Min : Max Mean (sd) Min : Max HR (95% CI) P-value
0.873 ppm* lipids (CH3)† 0.45 (1.48) -0.93 : 6.67 -0.05 (0.94) -0.97 : 6.67 1.40 (1.13-1.74) 0.002
0.929 ppm* isoleucine 0.27 (0.99) -1.60 : 2.89 -0.04 (1.00) -2.02 : 5.08 1.14 (0.90-1.45) 0.282
0.947 ppm* leucine 0.30 (1.05) -1.67 : 3.83 -0.04 (1.00) -1.72 : 4.98 1.23 (0.98-1.55) 0.074
0.952 ppm* unknown 0.01 (1.24) -3.14 : 3.00 0.00 (0.97) -4.29 : 3.21 0.99 (0.77-1.26) 0.921
0.957 ppm* leucine 0.24 (1.00) -1.78 : 2.79 -0.04 (0.99) -2.10 : 4.07 1.17 (0.92-1.50) 0.207
0.965 ppm unknown 0.07 (1.13) -3.56 : 2.45 -0.02 (1.00) -3.56 : 4.76 0.97 (0.75-1.24) 0.780
0.973 ppm* unknown 0.03 (1.00) -2.35 : 2.93 -0.01 (1.00) -3.13 : 3.77 0.93 (0.71-1.20) 0.568
0.981 ppm* valine 0.33 (0.98) -1.65 : 3.26 -0.05 (0.99) -2.37 : 4.43 1.23 (0.97-1.57) 0.090
0.988 ppm* unknown 0.24 (0.87) -1.88 : 2.69 -0.03 (1.01) -7.36 : 4.19 1.22 (0.96-1.55) 0.102
1.000 ppm* isoleucine 0.27 (0.96) -1.79 : 2.48 -0.03 (1.00) -2.07 : 4.31 1.17 (0.92-1.49) 0.214
1.032 ppm* valine 0.29 (1.02) -1.88 : 3.26 -0.04 (0.99) -2.35 : 4.36 1.18 (0.92-1.51) 0.193
1.054 ppm unknown 0.26 (1.38) -1.94 : 5.02 -0.04 (0.93) -1.66 : 3.99 1.21 (0.95-1.55) 0.131
1.063 ppm* ketoisovalerate 0.12 (1.27) -1.89 : 7.24 -0.01 (0.96) -1.90 : 4.89 1.09 (0.84-1.41) 0.509
1.163 ppm* unknown 0.14 (1.77) -0.18 : 15.48 -0.02 (0.83) -0.21 : 14.04 1.11 (0.94-1.31) 0.235
1.174 ppm* ethanol 0.14 (1.63) -0.13 : 14.20 -0.02 (0.87) -0.13 : 14.52 1.10 (0.93-1.29) 0.280
1.191 ppm* 3-hydroxybutyrate 0.08 (0.96) -0.57 : 6.77 -0.02 (1.00) -0.58 : 9.75 1.10 (0.90-1.34) 0.362
1.212 ppm* unknown 0.15 (1.44) -1.33 : 10.34 -0.02 (0.92) -2.03 : 5.48 1.17 (0.91-1.52) 0.228
1.264 ppm* lipids (CH2)† 0.42 (1.39) -0.91 : 5.79 -0.05 (0.95) -0.94 : 6.23 1.36 (1.10-1.69) 0.005
1.319 ppm* lactate 0.20 (1.06) -1.51 : 4.43 -0.02 (0.99) -1.90 : 4.41 1.22 (0.95-1.56) 0.120
1.391 ppm* unknown -0.14 (1.02) -1.99 : 2.69 0.02 (1.00) -2.60 : 4.35 0.78 (0.60-1.00) 0.053
1.407 ppm* unknown 0.01 (1.00) -1.78 : 2.19 0.00 (1.00) -2.53 : 3.24 1.02 (0.79-1.32) 0.904
1.425 ppm* unknown 0.17 (1.06) -1.93 : 2.78 -0.02 (1.00) -1.98 : 3.51 1.18 (0.92-1.52) 0.198
1.471 ppm* alanine 0.22 (0.93) -1.72 : 2.54 -0.03 (1.00) -2.35 : 3.45 1.13 (0.88-1.45) 0.344
1.706 ppm* unknown 0.24 (1.20) -1.77 : 4.62 -0.03 (0.98) -2.67 : 4.62 1.21 (0.92-1.58) 0.172
1.908 ppm* acetate 0.13 (0.88) -0.77 : 3.84 -0.02 (1.01) -0.81 : 16.58 1.04 (0.87-1.24) 0.656
2.001 ppm* lipids (CH*2CH=CH)† 0.49 (1.72) -1.01 : 8.67 -0.05 (0.91) -1.19 : 8.67 1.37 (1.13-1.67) 0.001
2.035 ppm* glycoproteins 0.52 (1.18) -1.51 : 3.85 -0.06 (0.96) -2.05 : 4.88 1.32 (1.03-1.69) 0.028
2.066 ppm* glycoproteins 0.32 (1.12) -1.59 : 4.33 -0.04 (0.99) -2.51 : 4.33 1.20 (0.93-1.55) 0.159
2.099 ppm* glutamine/
glutamate
-0.01 (0.88) -1.85 : 2.77 -0.01 (1.01) -2.43 : 3.58 0.97 (0.76-1.22) 0.773
2.125 ppm* glutamine/
glutamate
0.00 (1.05) -2.41 : 3.66 0.00 (1.01) -2.48 : 3.66 1.03 (0.81-1.32) 0.791
2.221 ppm* lipids (CH2CO)† 0.40 (1.55) -0.76 : 7.24 -0.05 (0.93) -0.84 : 7.24 1.35 (1.10-1.66) 0.004
2.260 ppm* valine 0.11 (1.15) -2.10 : 2.71 -0.02 (0.98) -2.11 : 4.41 1.01 (0.78-1.30) 0.954
2.301 ppm* 3-hydroxybutyrate 0.01 (0.63) -0.55 : 2.71 0.00 (1.03) -0.64 : 11.41 1.04 (0.82-1.30) 0.766
2.349 ppm* glutamate 0.50 (1.21) -0.91 : 4.24 -0.06 (0.96) -1.68 : 4.24 1.38 (1.09-1.75) 0.007
2.364 ppm* pyruvate -0.19 (0.99) -1.47 : 3.13 0.02 (1.00) -1.66 : 3.91 0.96 (0.73-1.26) 0.768
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Cases Sub-cohort Association with CHD
Chemical 
shift
Assignment Mean (sd) Min : Max Mean (sd) Min : Max HR (95% CI) P-value
2.393 ppm* 3-hydroxybutyrate 0.16 (0.86) -0.94 : 3.82 -0.02 (1.01) -0.96 : 10.08 1.13 (0.92-1.39) 0.242
2.412 ppm unknown 0.32 (0.99) -2.37 : 2.67 -0.04 (0.99) -2.64 : 3.11 1.22 (0.96-1.55) 0.110
2.430 ppm* glutamine -0.22 (1.04) -1.69 : 2.10 0.02 (0.99) -1.79 : 3.30 0.81 (0.63-1.05) 0.107
2.530 ppm* citrate -0.10 (0.81) -1.52 : 2.13 0.01 (1.02) -2.56 : 4.43 0.77 (0.59-0.99) 0.045
2.645 ppm* citrate -0.19 (0.76) -1.81 : 1.84 0.02 (1.02) -2.53 : 4.56 0.73 (0.56-0.95) 0.017
2.690 ppm Mg-EDTA 0.11 (1.03) -1.47 : 2.79 -0.01 (0.99) -1.80 : 3.88 1.05 (0.82-1.33) 0.710
2.737 ppm sarcosine 0.44 (1.57) -1.45 : 9.23 -0.05 (0.96) -1.45 : 9.23 1.32 (1.08-1.61) 0.007
2.801 ppm aspartate -0.04 (1.00) -1.70 : 4.01 0.01 (1.00) -2.36 : 4.75 0.84 (0.65-1.09) 0.191
2.858 ppm asparagine 0.13 (0.98) -1.50 : 5.23 -0.02 (1.00) -2.95 : 10.18 1.18 (0.94-1.47) 0.148
2.914 ppm* dimethylglycine 0.17 (1.04) -2.07 : 2.53 -0.02 (0.99) -2.42 : 3.57 1.02 (0.79-1.32) 0.875
3.024 ppm* lysine -0.08 (0.83) -2.04 : 1.85 0.01 (1.02) -2.24 : 3.89 0.81 (0.63-1.06) 0.119
3.034 ppm* creatine + creatinine 0.17 (1.18) -1.72 : 6.82 -0.03 (0.97) -2.05 : 4.07 0.96 (0.75-1.23) 0.754
3.050 ppm* ornithine 0.24 (1.11) -2.03 : 2.55 -0.03 (0.99) -2.49 : 3.42 1.07 (0.82-1.40) 0.614
3.090 ppm Ca-EDTA 0.07 (1.13) -2.09 : 4.19 0.00 (1.01) -2.25 : 4.19 0.95 (0.75-1.22) 0.700
3.117 ppm Ca-EDTA 0.08 (1.12) -3.84 : 4.04 -0.02 (0.99) -3.84 : 4.55 1.01 (0.79-1.28) 0.957
3.145 ppm* unknown 0.02 (1.15) -2.57 : 5.57 -0.01 (0.98) -2.57 : 6.04 0.88 (0.66-1.16) 0.348
3.200 ppm EDTA 0.11 (0.84) -2.88 : 2.04 -0.01 (1.03) -3.39 : 9.57 1.16 (0.91-1.48) 0.228
3.240 ppm* glucose 0.32 (1.49) -1.38 : 9.56 -0.05 (0.90) -2.24 : 7.29 1.20 (0.98-1.47) 0.078
3.252 ppm TMAO 0.32 (0.93) -2.60 : 3.46 -0.04 (1.00) -3.26 : 6.43 1.17 (0.93-1.47) 0.174
3.267 ppm* 1,5-anhydrosorbitol -0.15 (1.07) -5.08 : 1.98 0.01 (0.99) -4.19 : 3.42 1.01 (0.80-1.28) 0.927
3.312 ppm unknown 0.20 (0.88) -1.80 : 3.71 -0.02 (1.01) -2.00 : 11.23 1.09 (0.82-1.44) 0.555
3.333 ppm* proline 0.17 (0.91) -1.44 : 2.67 -0.03 (1.01) -1.80 : 4.80 1.02 (0.80-1.29) 0.902
3.342 ppm* 1,5-anhydrosorbitol -0.16 (0.92) -1.96 : 2.10 0.01 (1.01) -1.85 : 3.53 0.86 (0.66-1.13) 0.287
3.348 ppm unknown -0.02 (0.90) -1.75 : 3.21 0.01 (1.01) -2.67 : 3.57 1.00 (0.79-1.27) 0.978
3.354 ppm* unknown 0.11 (1.53) -1.15 : 10.50 -0.02 (0.90) -1.15 : 9.50 1.21 (0.95-1.53) 0.124
3.362 ppm unknown 0.17 (1.31) -2.79 : 4.62 -0.02 (0.95) -2.79 : 3.72 1.21 (0.93-1.56) 0.154
3.401 ppm* glucose 0.38 (1.48) -1.69 : 9.93 -0.05 (0.90) -1.95 : 7.82 1.23 (1.01-1.49) 0.036
3.458 ppm glucose 0.30 (1.47) -1.53 : 9.22 -0.04 (0.91) -1.71 : 6.45 1.26 (1.01-1.57) 0.040
3.487 ppm* glucose 0.37 (1.43) -1.64 : 9.52 -0.05 (0.91) -2.03 : 7.82 1.22 (1.01-1.47) 0.042
3.531 ppm* glucose 0.39 (1.48) -1.64 : 9.76 -0.05 (0.90) -1.83 : 7.82 1.23 (1.02-1.49) 0.033
3.551 ppm* unknown -0.18 (0.90) -1.53 : 3.77 0.02 (1.01) -4.31 : 4.53 0.81 (0.62-1.05) 0.111
3.599 ppm EDTA 0.12 (0.84) -2.86 : 2.52 -0.01 (1.02) -3.41 : 9.90 1.18 (0.93-1.50) 0.175
3.633 ppm unknown 0.00 (0.51) -2.47 : 0.65 0.00 (1.05) -22.4 : 2.58 0.97 (0.81-1.16) 0.755
3.649 ppm* ethanol 0.13 (1.59) -0.41 : 13.79 -0.02 (0.88) -0.41 : 14.69 1.09 (0.92-1.29) 0.303
3.712 ppm* glucose 0.33 (1.46) -1.71 : 9.30 -0.05 (0.91) -1.76 : 7.51 1.19 (0.98-1.45) 0.078
3.721 ppm* glucose 0.36 (1.45) -1.68 : 9.67 -0.05 (0.91) -2.31 : 7.73 1.23 (1.01-1.49) 0.040
3.735 ppm 3-phosphoglycerate 0.22 (1.12) -1.53 : 3.37 -0.04 (0.98) -1.53 : 2.95 1.19 (0.94-1.52) 0.156
3.747 ppm* unknown 0.12 (1.02) -2.19 : 2.28 -0.01 (1.00) -3.09 : 2.77 1.09 (0.85-1.39) 0.509
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Cases Sub-cohort Association with CHD
Chemical 
shift
Assignment Mean (sd) Min : Max Mean (sd) Min : Max HR (95% CI) P-value
3.759 ppm* glucose 0.32 (1.46) -1.47 : 9.83 -0.04 (0.91) -2.29 : 7.89 1.21 (0.99-1.47) 0.061
3.765 ppm 3-phosphoglycerate 0.25 (1.01) -2.35 : 2.15 -0.04 (0.99) -3.13 : 4.02 1.24 (0.97-1.58) 0.087
3.772 ppm 3-phosphoglycerate 0.23 (1.07) -1.33 : 2.90 -0.03 (0.98) -1.35 : 3.08 1.21 (0.95-1.53) 0.119
3.779 ppm* alanine -0.01 (0.97) -2.80 : 2.26 0.01 (1.01) -3.58 : 3.92 1.00 (0.78-1.27) 0.977
3.818 ppm* unknown 0.04 (1.05) -1.82 : 4.81 0.00 (0.99) -2.09 : 6.76 1.00 (0.79-1.28) 0.983
3.824 ppm* glucose 0.39 (1.40) -2.49 : 7.92 -0.05 (0.92) -1.89 : 6.32 1.29 (1.04-1.59) 0.019
3.838 ppm* glucose 0.37 (1.5) -1.69 : 9.94 -0.05 (0.89) -2.07 : 7.37 1.25 (1.02-1.52) 0.031
3.876 ppm* 1,5-anhydrosorbitol 0.00 (1.23) -5.59 : 2.69 0.00 (0.96) -5.37 : 5.01 1.02 (0.80-1.29) 0.888
3.888 ppm unknown 0.03 (1.10) -2.28 : 4.80 -0.01 (0.99) -2.50 : 3.68 0.96 (0.75-1.23) 0.745
3.893 ppm* glucose 0.36 (1.47) -1.57 : 9.91 -0.05 (0.90) -1.96 : 7.83 1.22 (1.01-1.49) 0.042
3.924 ppm* unknown 0.00 (0.93) -2.30 : 2.62 0.00 (1.01) -2.64 : 3.36 0.78 (0.60-1.01) 0.062
3.959 ppm* unknown -0.04 (0.77) -1.65 : 1.42 0.01 (1.02) -2.11 : 9.13 0.93 (0.71-1.21) 0.570
3.974 ppm* 1,5-anhydrosorbitol -0.10 (1.02) -2.12 : 2.85 0.01 (1.00) -2.85 : 2.98 1.02 (0.78-1.32) 0.897
3.981 ppm Multiple 
metabolites
-0.16 (0.90) -1.87 : 2.73 0.02 (1.01) -2.46 : 5.23 0.86 (0.66-1.12) 0.259
4.044 ppm* creatinine 0.38 (1.47) -1.85 : 10.37 -0.05 (0.90) -2.51 : 4.16 1.35 (1.04-1.76) 0.027
4.103 ppm* lactate 0.20 (1.07) -1.41 : 4.57 -0.02 (0.99) -1.82 : 4.60 1.23 (0.96-1.57) 0.100
4.121 ppm* proline 0.13 (0.93) -2.01 : 2.20 -0.02 (1.01) -2.20 : 4.39 0.97 (0.76-1.25) 0.831
4.167 ppm phosphorylcholine -0.02 (0.87) -1.60 : 2.65 0.00 (1.02) -2.68 : 6.10 0.82 (0.61-1.10) 0.179
4.223 ppm 3-phosphoglycerate -0.01 (0.96) -1.02 : 4.42 0.00 (1.00) -1.20 : 4.84 0.98 (0.76-1.27) 0.894
4.239 ppm* unknown -0.12 (0.88) -1.62 : 2.64 0.02 (1.02) -2.00 : 4.14 0.92 (0.72-1.18) 0.519
4.503 ppm* glucose 0.26 (1.14) -1.52 : 5.96 -0.03 (0.97) -2.54 : 4.61 1.23 (0.98-1.55) 0.074
5.180 ppm* unknown 0.29 (1.42) -2.20 : 7.36 -0.03 (0.94) -2.20 : 5.14 1.27 (1.01-1.60) 0.046
5.230 ppm* glucose 0.38 (1.47) -1.79 : 9.75 -0.05 (0.90) -1.98 : 7.97 1.23 (1.02-1.48) 0.035
5.299 ppm* lipids (CH=CH) † 0.41 (1.65) -0.61 : 7.82 -0.04 (0.91) -0.76 : 7.82 1.37 (1.12-1.67) 0.002
6.890 ppm* tyrosine 0.03 (0.90) -1.74 : 2.89 -0.01 (1.02) -2.38 : 5.14 0.85 (0.66-1.10) 0.212
7.186 ppm* tyrosine 0.05 (1.01) -1.50 : 2.95 -0.01 (1.00) -2.15 : 4.98 0.91 (0.70-1.17) 0.444
8.451 ppm* formate 0.02 (1.03) -1.49 : 4.45 0.00 (1.00) -1.30 : 9.41 0.90 (0.65-1.23) 0.495
Mean is expressed as area under the curve
*Detected and quantified in the confirmation study
†The term in parenthesis indicates the structural feature of the lipid measured by 1H-NMR spectroscopy
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Table S2 | Baseline characteristics of the traditional CHD risk factors in the primary study before removing 
participants with missing data.
Cases (N=125) Sub-cohort (N=738)*
N missing Mean±SD/%(N) N missing Mean±SD/%(N)
Age (years) 0 50.49 ± 7.11 0 44.57 ± 8.23
Total cholesterol (mmol/L) 2 5.91 ± 0.99 13 5.33 ± 0.98
HDL cholesterol (mmol/L) 2 1.11 ± 0.28 13 1.33 ± 0.36
SBP (mmHg) 0 133.18 ± 17.83 1 121.23 ± 14.61
BMI (kg/m2) 0 27.69 ± 4.45 0 25.48 ± 3.87
Men 0 95 (76.0%) 0 323 (43.8%)
Current smoking 2 69 (56.1%) 5 283 (38.6%)
Diabetes 0 6 (4.8%) 0 5 (0.7%)
Parental history of MI 14 58 (52.3%) 68 264 (39.4%)
HDL, high-density lipoprotein; MI, myocardial infarction; SBP, systolic blood pressure; BMI, body mass index
* Including 10 cases
Table S3 | The association between the metabolite score based on 16 1H-NMR signals and the metabolite score 
based on the 13 1H-NMR signals and incident CHD in the primary study.
Univariate analysis* Adjusted for TRF†
HR (95% CI) P-value HR (95% CI) P-value
Metabolite score based on 16 1H-NMR signals 1.93 (1.50-2.48) <0.001 1.58 (1.18-2.12) 0.002
Metabolite score based on 13 1H-NMR signals‡ 1.91 (1.50-2.44 <0.001 1.50 (1.12-2.01) 0.007
HR, hazard ration; TRF, traditional risk factors
*Univariate HR were calculated per unit increase for the metabolite scores. Age in years was used as the time-scale 
variable. 
†The TRF include total cholesterol, HDL cholesterol, SBP, BMI, gender, current smoking, self-reported diabetes and 
parental history of MI. Age in years was used as the time-scale variable.
‡This metabolite score is based on the 13 1H-NMR signals that were also available in the secondary study.
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Table S4 |  Reclassification of participants when the metabolite score was used in addition to a risk score based on 
traditional risk factors (i.e. age, sex, current smoking, total cholesterol, HDL cholesterol, BMI, parental history of MI 
and self-reported diabetes). For reclassification the following risk categories were used: 0-<5%, 5-<10%, 10-<20%, 
≥20%.
Model with TRF + metabolite score
Model with TRF* <5% 5-<10% 10-<20% ≥20% Total
Incident cases
<5% 39 3 1 0 43
5-<10% 5 13 3 1 22
10-<20% 0 2 4 0 6
≥20% 0 0 1 4 5
Total 44 18 9 5 76
Non-cases
<5% 515 7 1 0 523
5-<10% 4 15 2 0 21
10-<20% 0 3 7 0 10
≥20% 0 0 0 0 0
Total 519 25 10 0 554
TRF, traditional risk factors 
*The TRF include age in years, total cholesterol, HDL cholesterol, SBP, BMI, gender, current smoking, self-reported 
diabetes and parental history of MI. 
Table S5 | Improvement in reclassification of incident CHD when using the metabolite score in addition to traditional 
risk factors (i.e. age, sex, current smoking, total cholesterol, HDL cholesterol, BMI, parental history of MI and self-
reported diabetes). For calculating the NRI the following risk categories were used: 0-<5%, 5-<10%, 10-<20%, ≥20%.
Reclassification
P Up P Down NRI Z-score P-value
Event 0.140 0.096 0.044 0.924 0.178
Non-event 0.018 0.013 -0.005 -1.593 0.944
Total … … 0.038 0.809 0.209
P Up, proportion of participants placed into a higher risk category; P Down, proportion of participants placed into 
a lower risk category; NRI, net reclassification index.
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Table S6a | Comparing the predictive power of the single traditional risk factors, all traditional risk factors combined 
with and without the metabolite score in the primary case-cohort study using Harrell’s C index.
TRFs only TRF + MS
C-index (95% CI) C-index (95% CI) Diff (SE) P-value
Age 0.72 (0.66-0.77) 0.79 (0.74-0.84) 0.08 (0.02) <0.001
Total cholesterol 0.66 (0.61-0.72) 0.77 (0.72-0.81) 0.10 (0.03) <0.001
HDL cholesterol 0.67 (0.60-0.73) 0.74 (0.68-0.79) 0.07 (0.02) <0.001
Systolic blood pressure 0.71 (0.65-0.77) 0.79 (0.74-0.84) 0.08 (0.02) <0.001
Body mass index 0.64 (0.58-0.71) 0.74 (0.69-0.80) 0.10 (0.03) <0.001
Male sex 0.66 (0.61-0.71) 0.76 (0.71-0.81) 0.10 (0.02) <0.001
Current smoking 0.57 (0.51-0.62) 0.74 (0.69-0.80) 0.18 (0.03) <0.001
Self-reported diabetes 0.51 (0.49-0.54) 0.76 (0.71-0.81) 0.25 (0.03) <0.001
Parental history of MI 0.55 (0.49-0.60) 0.75 (0.70-0.80) 0.20 (0.03) <0.001
All TRFs combined 0.82 (0.78-0.87) 0.84 (0.80-0.87) 0.01 (0.01) 0.107
TRFs, traditional risk factors; MS, metabolite score; Diff, Difference in C-indices; SE, standard error; HDL, high 
densitity lipoprotein; MI, myocardial infarction
Table S6b | Comparing the predictive power of the metabolite score combined with and without single traditional 
risk factors and all traditional risk factors combined in the primary case-cohort study using Harrell’s Concordance 
index.
C-index (95% CI) Diff (SE) P-value
Metabolite Score only 0.75 (0.74-0.84) - -
Age + MS 0.79 (0.74-0.84) 0.038 (0.022) 0.090
Total cholesterol + MS 0.77 (0.72-0.81) 0.011 (0.008) 0.194
HDL cholesterol +MS 0.74 (0.68-0.79) 0.017 (0.021) 0.412
Systolic blood pressure +MS 0.79 (0.74-0.84) 0.035 (0.019) 0.064
Body mass index +MS 0.74 (0.69-0.80) 0.011 (0.010) 0.308
Male sex +MS 0.76 (0.71-0.81) 0.007 (0.020) 0.720
Current smoking +MS 0.74 (0.69-0.80) 0.011 (0.015) 0.476
Self-reported diabetes +MS 0.76 (0.71-0.81) 0.002 (0.003) 0.453
Parental history of MI +MS 0.75 (0.70-0.80) 0.008 (0.008) 0.970
All TRFs combined 0.84 (0.80-0.87) 0.081 (0.023) <0.001
Diff, Difference in C-indices between the metabolite score only and the traditional risk factor(s) and the metabolite 
score combined; SE, standard error; MS, metabolite score; TRFs, traditional risk factors
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Table S7| Baseline characteristics of the traditional CHD risk factors in the secondary study before removing 
participants with missing data.
Cases (N=174) Controls (N=2170)*
N missing Mean±SD/%(N) N missing Mean±SD/%(N)
Age (years) 0 60.98 (11.73) 0 47.70 (14.02)
Total cholesterol (mmol/L) 1 5.00 (1.07) 12 5.60 (1.06)
HDL cholesterol (mmol/L) 1 1.15 (0.32) 12 1.29 (0.37)
SBP (mmHg) 1 148.31 (22.91) 30 139.18 (19.75)
BMI (kg/m2) 3 28.14 (4.43) 35 26.79 (4.61)
Men 0 108 (62.1%) 0 924 (42.6%)
Current smoking 1 62 (35.8%) 3 844 (38.9%)
Diabetes 0 25 (14.4%) 0 101 (4.7%)
Parental history of MI 69 54 (31.0%) 729 430 (19.9%)
HDL, high-density lipoprotein; MI, myocardial infarction; SBP, systolic blood pressure; BMI, body mass index
Table S8 | The association between the metabolite score and coronary heart disease in the total confirmation study 
(170 cases and 2157 controls) and after excluding statin users (n=299; 77 cases and 1946 controls left for analysis).
Metabolite score Crude OR (95% CI) P-value Adjusted OR (95%CI)* P-value
Total population 2.72 (2.28-3.25) 2.0x10-28 1.59 (1.19-2.13) 0.002
Non statin users 2.78 (2.16-3.57) 1.2x10-15 2.02 (1.33-3.08) 0.001
OR, odds ratio; CI, confidence interval
Odds ratios were calculated per standard deviation increase in metabolite score
* The metabolite score was adjusted for age, total cholesterol, HDL cholesterol, systolic blood pressure, body mass 
index, sex, smoking, diabetes and parental history of myocardial infarction.
Figure S1 | Kernel density plots showing the distribution of the metabolite score in the sub-cohort and in the cases 






Figure S1 | Results from the principal 
component analysis on the 98 
1H-NMR peaks (a/b) and on the 401 
1H-NMR bins (c/d). The black dots 
represent the participants and the 
red numbers represent the peaks or 
the bins. There are three individuals 
with aberrant values for the peak 
located at 1.174 ppm representing 
ethanol (a). After removing this peak, 
there were some individuals with 
high values for peaks representing 
glucose (b). A bin located at 1.17 
was aberrant for the same three 
individuals (c). After removing this 
bin, there were six individuals with 
high values for bins located near 
peaks representing glucose (d). 
The participants with high values 
for peaks or bins representing 
glucose also had high glucose levels 
according to a conventional method 






Statistical analysis for LASSO GRSs
Not all GWAS-identified SNPs may contribute to the risk of future CHD in our population-
based prospective study. Therefore, we selected a sub-set of the most informative SNPs 
from all GWAS identified SNPs using least absolute shrinkage and selection operator (LASSO) 
regression. With LASSO regression it is possible to perform variable selection and shrinkage 
at the same time, which makes it an effective method for finding prediction rules based in 
high dimensional data.1-3 The penalty parameter, which determines the number of variables 
selected for the model, was set by the 10-fold cross-validated partial likelihood. With 10-
fold cross-validation we have addressed the issue of internal validation.4 The resulting SNPs 
and their weights, based on the coefficients resulting from 10-fold cross-validated LASSO 
regression, were then used to construct the LASSO GRS. This approach was used to select 
subsets of informative SNPs from the 29 CHD SNPs (CHD LASSO GRS) and all 179 SNPs (LASSO 
GRS). For this analysis the R package  penalized (version 0.9-32), was used.
References
1. Goeman JJ. L1 penalized estimation in the cox proportional hazards model. Biom.J. 2010;52:70-84
2. Tibshirani R. Regression shrinkage and selection via the lasso. J.R.Statist.Soc.B.1996;58:267-288




Construction the LASSO GRSs and their associations with incident CHD
By performing 10-fold cross-validated LASSO regression on the 29 CHD SNPs, a subset of 
3 SNPs (see supplementary table S7) was selected as the optimal predictor for incident 
CHD in our data-set, namely rs10757278, rs11556924 and rs646776 (see supplementary 
table S7 for locus and nearby genes). When performing LASSO regression on all 179 SNPs, 
a subset of 14 SNPs was selected (see supplementary table S7). Three SNPs (rs10757278, 
rs11556924 and rs646776) were also selected for the CHD LASSO GRS, the remaining 11 SNPs 
were: rs2925979, rs6882076, rs2954029, rs6987702, rs10889352, rs2972146, rs514230, 
rs8050136, rs181362, rs925946 and rs2000999 (for locus and nearby genes see table S7).
Supplementary Tables
Supplementary table S1 can be found online at:
http://circgenetics.ahajournals.org/content/5/2/202/suppl/DC1
Supplementary table S1 | Candidate SNPs (based on the association between CHD and 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































HR (95% CI) HR std†  (95% CI) P
Overall GRS
179 185.4 ± 8.4 182.5 ± 9.4
1.02 (1.01-1.04) 1.25 (1.06-1.46) 0.006
Adjusted for TRF* 1.01 (1.00-1.03) 1.11 (0.96-1.28) 0.152
Risk Factor GRS
153 157.0 ± 8.1 155.3 ± 8.4
1.02 (1.01-1.04) 1.22 (1.05-1.42) 0.011
Adjusted for TRF* 1.01 (0.99-1.03) 1.08 (0.94-1.24) 0.303
CHD GRS
29 31.1 ± 3.2 30.7 ± 3.5
1.05 (1.01-1.09) 1.79 (1.03-1.35) 0.020
Adjusted for TRF* 1.03 (0.97-1.09) 1.12 (0.93-1.36) 0.285
Weighted CHD GRS 
29 11.4 ± 1.3 11.1 ± 1.3
1.23 (1.10-1.37) 1.32 (1.13-1.53) <0.001
Adjusted for TRF* 1.14 (1.01-1.29) 1.19 (1.02-1.40) 0.032
LASSO CHD GRS
3 1.80 ± 0.70 1.63 ± 0.73
1.57 (1.28-1.94) 1.39 (1.20-1.62) <0.001
Adjusted for TRF* 1.39 (1.13-1.71) 1.19 (1.02-1.40) 0.002
LASSO GRS
14 4.1 ± 1.0 3.7 ± 1.0
1.64 (1.36-1.99) 1.65 (1.36-2.00) <0.001
Adjusted for TRF* 1.53 (1.24-1.90) 1.54 (1.24-1.91) <0.001
* Traditional risk factors include sex, current smoking (yes/no), systolic blood pressure,
total cholesterol, HDL cholesterol, self-reported diabetes (yes/no), body mass index and parental history of MI 
parents with MI, one parent with MI, both parents with MI). Age was used as the time scale variable 
† Increase in hazard ratio per standard deviation
HR, hazard ratio; std, standardized; SNPs, single nucleotide polymorphisms; CHD, coronary heart disease; TRF, 
traditional risk factors; GRS, genetic risk score; LASSO, least absolute shrinkage and selection operator
145
Supplement III
Table S4 | Weights for the SNPs selected for their association with CHD. The weights are based on the log odds ratio 
as published in Schunker et al. 2011 or Peden et al 2011.
SNP RA
Subcohort Cases
N RAF N RAF OR Weighting factor* Source
RS107572781 G 1832 0.49 623 0.55 1.29 1.00 Schunkert et al. (2011)
RS10953541 C 1902 0.76 641 0.75 1.08 0.30 Peden et al. (2011)
RS11206510 T 1881 0.81 632 0.81 1.08 0.30 Schunkert et al. (2011)
RS1122608 G 1887 0.76 640 0.76 1.14 0.51 Schunkert et al. (2011)
RS11556924 C 1902 0.60 641 0.64 1.09 0.34 Schunkert et al. (2011)
RS12190287 C 1901 0.64 641 0.65 1.08 0.30 Schunkert et al. (2011)
RS12413409 G 1901 0.92 641 0.90 1.12 0.45 Schunkert et al. (2011)
RS12526453 C 1865 0.66 616 0.65 1.10 0.37 Schunkert et al. (2011)
RS12936587 G 1900 0.56 641 0.58 1.07 0.27 Schunkert et al. (2011)
RS1412444 A 1900 0.33 639 0.35 1.09 0.34 Peden et al. (2011)
RS17114036 A 1890 0.91 635 0.92 1.17 0.62 Schunkert et al. (2011)
RS1746048 C 1838 0.86 622 0.87 1.09 0.34 Schunkert et al. (2011)
RS17465637 C 1880 0.73 636 0.75 1.14 0.51 Schunkert et al. (2011)
RS17609940 G 1897 0.81 637 0.81 1.07 0.27 Schunkert et al. (2011)
RS216172  G 1898 0.35 637 0.35 1.07 0.27 Schunkert et al. (2011)
RS25050832 C 1897 0.41 637 0.43 1.05 0.19 Schunkert et al. (2011)
RS2895811 C 1901 0.41 641 0.41 1.07 0.27 Schunkert et al. (2011)
RS3825807 T 1901 0.58 641 0.57 1.08 0.30 Schunkert et al. (2011)
RS4380028 G 1902 0.61 641 0.6 1.07 0.27 Peden et al. (2011)
RS46522   T 1901 0.54 642 0.55 1.06 0.23 Schunkert et al. (2011)
RS4773144 G 1901 0.45 642 0.46 1.07 0.27 Schunkert et al. (2011)
RS579459  C 1890 0.23 633 0.23 1.10 0.37 Schunkert et al. (2011)
RS646776  A 1887 0.79 641 0.82 1.11 0.41 Schunkert et al. (2011)
RS6725887 G 1811 0.13 611 0.13 1.14 0.51 Schunkert et al. (2011)
RS6922269 A 1866 0.26 615 0.27 1.06 0.23 Schunkert et al. (2011)
RS964184  C 1880 0.14 639 0.14 1.13 0.48 Schunkert et al. (2011)
RS974819  A 1901 0.31 642 0.31 1.07 0.27 Peden et al. (2011)
RS9818870 T 1869 0.17 638 0.16 1.12 0.45 Schunkert et al. (2011)
RS9982601 T 1859 0.13 626 0.15 1.18 0.65 Schunkert et al. (2011)
1 Instead of rs10757278, rs4977574 was selected for replication in Schunkert et al. 
2 Instead of rs2505083, rs7920682 was selected for replication in Schunkert et al.
* The weighting factor is determined by dividing the log odds ratio of a SNP by the log odds ratio of rs10757278 (the 
SNP with the highest log odds ratio).
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Table S5 | The association between the 179 successfully genotyped SNPs and incident CHD in the CAREMA study.
SNP RA
Subcohort Cases CHD CHD adjusted*
N RAF N RAF HR (95% CI) P HR (95% CI) P
SNPs selected for their association with coronary artery diseases
RS10757278 G 1832 0.49 623 0.55 1.34 (1.17-1.53) <0.001 1.29 (1.05-1.59) 0.015
RS10953541 C 1902 0.76 641 0.75 0.98 (0.84-1.14) 0.779 0.87 (0.77-0.99) 0.028
RS11206510 T 1881 0.81 632 0.81 0.99 (0.83-1.17) 0.861 1.02 (0.88-1.17) 0.840
RS1122608 G 1887 0.76 640 0.76 1.01 (0.87-1.18) 0.869 1.01 (0.89-1.15) 0.919
RS11556924 C 1902 0.60 641 0.64 1.16 (1.01-1.32) 0.033 1.23 (0.93-1.63) 0.155
RS12190287 C 1901 0.64 641 0.65 1.05 (0.92-1.21) 0.451 1.06 (0.94-1.20) 0.323
RS12413409 G 1901 0.92 641 0.90 0.88 (0.69-1.14) 0.334 0.86 (0.71-1.04) 0.124
RS12526453 C 1865 0.66 616 0.65 0.92 (0.80-1.06) 0.255 1.00 (0.89-1.13) 0.991
RS12936587 G 1900 0.56 641 0.58 1.08 (0.95-1.24) 0.247 1.04 (0.93-1.17) 0.505
RS1412444 A 1900 0.33 639 0.35 1.07 (0.93-1.24) 0.325 1.15 (0.77-1.73) 0.489
RS17114036 A 1890 0.91 635 0.92 1.06 (0.85-1.33) 0.598 0.99 (0.80-1.23) 0.924
RS1746048 C 1838 0.86 622 0.87 1.01 (0.82-1.23) 0.960 1.05 (0.88-1.25) 0.568
RS17465637 C 1880 0.73 636 0.75 1.14 (0.99-1.32) 0.064 1.04 (0.92-1.17) 0.535
RS17609940 G 1897 0.81 637 0.81 0.99 (0.83-1.17) 0.864 0.88 (0.63-1.24) 0.459
RS216172  G 1898 0.35 637 0.35 1.02 (0.88-1.17) 0.809 1.09 (0.93-1.28) 0.286
RS2505083 C 1897 0.41 637 0.43 1.07 (0.93-1.23) 0.322 1.00 (0.89-1.12) 0.942
RS2895811 C 1901 0.41 641 0.41 0.99 (0.87-1.14) 0.905 0.99 (0.89-1.11) 0.864
RS3825807 T 1901 0.58 641 0.57 1.00 (0.87-1.14) 0.956 1.04 (0.93-1.17) 0.447
RS4380028 G 1902 0.61 641 0.60 0.99 (0.87-1.13) 0.890 1.06 (0.95-1.18) 0.337
RS46522   T 1901 0.54 642 0.55 1.10 (0.96-1.26) 0.168 1.07 (0.94-1.21) 0.327
RS4773144 G 1901 0.45 642 0.46 0.99 (0.87-1.13) 0.846 0.99 (0.88-1.11) 0.818
RS579459  C 1890 0.23 633 0.23 0.97 (0.84-1.13) 0.727 0.99 (0.87-1.12) 0.821
RS646776  A 1887 0.79 641 0.82 1.27 (1.09-1.47) 0.002 1.25 (1.07-1.45) 0.004
RS6725887 G 1811 0.13 611 0.13 1.05 (0.85-1.30) 0.637 1.08 (0.90-1.29) 0.395
RS6922269 A 1866 0.26 615 0.27 1.06 (0.91-1.24) 0.431 1.07 (0.92-1.25) 0.386
RS964184  C 1880 0.14 639 0.14 0.96 (0.8-1.170) 0.704 0.80 (0.56-1.14) 0.215
RS974819  A 1901 0.31 642 0.31 1.02 (0.88-1.18) 0.812 0.96 (0.85-1.09) 0.552
RS9818870 T 1869 0.17 638 0.16 0.94 (0.79-1.11) 0.452 0.92 (0.79-1.07) 0.285
RS9982601 T 1859 0.13 626 0.15 1.19 (0.96-1.49) 0.114 1.16 (0.98-1.37) 0.092
SNPs selected for their association with blood pressure
RS1004467 T 1894 0.91 639 0.90 0.89 (0.70-1.14) 0.347 0.83 (0.69-0.99) 0.038
RS11014166 A 1895 0.66 639 0.68 1.05 (0.91-1.20) 0.526 1.14 (1.00-1.30) 0.051
RS11191548 T 1899 0.92 641 0.91 0.92 (0.72-1.18) 0.523 0.90 (0.75-1.09) 0.282
RS12946454 T 1900 0.26 642 0.24 0.91 (0.79-1.06) 0.218 0.83 (0.68-1.03) 0.084
RS1378942 G 1899 0.32 642 0.34 1.11 (0.96-1.28) 0.163 1.00 (0.88-1.12) 0.937
RS1530440 C 1898 0.18 641 0.18 1.05 (0.88-1.25) 0.622 0.89 (0.77-1.03) 0.112
RS16948048 G 1900 0.38 642 0.39 1.06 (0.93-1.22) 0.390 1.09 (0.97-1.23) 0.132
RS16998073 T 1899 0.29 641 0.31 1.06 (0.91-1.23) 0.460 1.08 (0.95-1.22) 0.250
RS17367504 A 1897 0.15 642 0.15 1.03 (0.85-1.26) 0.735 1.15 (0.98-1.36) 0.082
RS2681472 T 1900 0.84 642 0.84 0.93 (0.77-1.13) 0.464 0.85 (0.73-0.99) 0.038
RS3184504 T 1900 0.51 642 0.50 0.98 (0.86-1.12) 0.731 0.92 (0.81-1.06) 0.241




Subcohort Cases CHD CHD adjusted*
N RAF N RAF HR (95% CI) P HR (95% CI) P
RS9815354 A 1896 0.17 641 0.17 0.99 (0.83-1.17) 0.865 1.06 (0.92-1.22) 0.437
SNPs selected for their association with diabetes type II
RS10811661 T 1874 0.81 622 0.80 0.94 (0.79-1.12) 0.491 0.91 (0.76-1.08) 0.284
RS10923931 A 1821 0.09 620 0.10 1.16 (0.90-1.50) 0.253 1.14 (0.81-1.59) 0.455
RS10946398 C 1861 0.31 624 0.31 1.01 (0.88-1.17) 0.867 1.06 (0.94-1.20) 0.316
RS1111875 C 1861 0.60 622 0.61 1.03 (0.89-1.18) 0.726 1.11 (0.81-1.53) 0.512
RS12779790 G 1818 0.18 613 0.19 1.04 (0.87-1.25) 0.655 1.08 (0.92-1.25) 0.350
RS13266634 C 1871 0.69 620 0.69 1.02 (0.88-1.18) 0.838 0.99 (0.87-1.12) 0.881
RS2237892 C 1831 0.94 619 0.94 0.94 (0.70-1.27) 0.703 0.80 (0.59-1.09) 0.153
RS2237897 C 1848 0.96 613 0.96 0.98 (0.69-1.39) 0.913 0.89 (0.54-1.45) 0.635
RS4402960 A 1880 0.32 638 0.34 1.12 (0.97-1.30) 0.124 1.11 (0.98-1.25) 0.109
RS4506565 T 1847 0.34 631 0.35 1.01 (0.88-1.17) 0.853 0.94 (0.72-1.22) 0.637
RS4607103 C 1870 0.75 618 0.77 1.12 (0.97-1.30) 0.126 1.09 (0.96-1.24) 0.181
RS4689388 A 1900 0.59 641 0.60 1.07 (0.94-1.23) 0.311 1.15 (0.89-1.49) 0.291
RS4712524 G 1838 0.31 617 0.32 1.04 (0.89-1.20) 0.643 1.09 (0.97-1.24) 0.152
RS5215    G 1856 0.37 627 0.36 0.93 (0.81-1.06) 0.270 1.03 (0.92-1.16) 0.639
RS5219    A 1789 0.36 608 0.36 0.94 (0.82-1.09) 0.417 1.06 (0.95-1.20) 0.305
RS6931514 G 1843 0.27 621 0.28 1.02 (0.88-1.19) 0.801 1.09 (0.96-1.23) 0.174
RS7578597 A 1869 0.89 632 0.89 1.03 (0.83-1.27) 0.806 1.05 (0.87-1.26) 0.608
RS7961581 C 1836 0.30 623 0.31 1.08 (0.93-1.26) 0.295 1.04 (0.91-1.19) 0.541
RS8050136 A 1815 0.36 622 0.40 1.19 (1.04-1.38) 0.014 1.20 (1.07-1.34) 0.002
RS864745  T 1857 0.52 631 0.50 0.91 (0.79-1.04) 0.159 0.90 (0.80-1.02) 0.090
SNPs selected for their association with blood lipid levels
RS10401969 A 1888 0.93 641 0.92 0.85 (0.64-1.14) 0.279 0.76 (0.44-1.33) 0.338
RS1042034 A 1901 0.78 641 0.75 0.88 (0.74-1.04) 0.123 0.83 (0.73-0.94) 0.005
RS10468017 C 1863 0.72 625 0.70 0.95 (0.81-1.10) 0.460 1.00 (0.88-1.13) 0.965
RS1084651 T 1898 0.85 637 0.85 0.88 (0.72-1.08) 0.234 0.92 (0.77-1.08) 0.302
RS10889352 A 1882 0.66 637 0.68 1.13 (0.98-1.30) 0.082 1.07 (0.95-1.21) 0.249
RS10903129 G 1820 0.55 620 0.53 0.96 (0.84-1.10) 0.594 1.05 (0.93-1.17) 0.437
RS11206510 T 1881 0.81 632 0.81 0.99 (0.83-1.17) 0.861 1.02 (0.88-1.17) 0.840
RS1167998 T 1877 0.66 633 0.68 1.11 (0.97-1.28) 0.138 1.07 (0.95-1.21) 0.256
RS12272004 A 1855 0.07 606 0.06 0.85 (0.66-1.09) 0.193 0.77 (0.60-0.99) 0.043
RS1260326 T 1863 0.42 615 0.44 1.07 (0.93-1.23) 0.343 0.91 (0.72-1.15) 0.426
RS12670798 C 1888 0.23 640 0.24 1.01 (0.86-1.17) 0.949 0.91 (0.80-1.04) 0.173
RS12678919 A 1857 0.89 625 0.90 1.19 (0.96-1.46) 0.107 1.02 (0.84-1.24) 0.831
RS12740374 C 1854 0.79 626 0.82 1.26 (1.08-1.47) 0.003 1.24 (1.07-1.43) 0.004
RS12916 C 1896 0.43 632 0.41 0.96 (0.84-1.10) 0.562 0.96 (0.85-1.09) 0.528
RS1495741 G 1902 0.23 641 0.24 1.05 (0.89-1.24) 0.534 1.09 (0.95-1.24) 0.233
RS1501908 G 1845 0.63 634 0.66 1.10 (0.96-1.26) 0.194 1.11 (0.99-1.25) 0.085
RS1532085 G 1883 0.62 638 0.60 0.93 (0.81-1.06) 0.276 0.95 (0.84-1.06) 0.355
RS1532624 C 1860 0.57 620 0.57 1.00 (0.88-1.15) 0.973 0.94 (0.83-1.05) 0.270
RS1564348 T 1873 0.85 628 0.86 1.05 (0.88-1.25) 0.624 1.13 (0.97-1.32) 0.123
RS157580  A 1844 0.62 630 0.63 1.01 (0.88-1.17) 0.842 0.99 (0.88-1.12) 0.837




Subcohort Cases CHD CHD adjusted*
N RAF N RAF HR (95% CI) P HR (95% CI) P
RS17216525 C 1846 0.92 633 0.91 1.02 (0.80-1.29) 0.901 0.97 (0.79-1.18) 0.729
RS174547  G 1871 0.33 618 0.33 1.05 (0.90-1.21) 0.555 1.04 (0.62-1.72) 0.896
RS174570  C 1793 0.86 602 0.86 0.95 (0.78-1.16) 0.591 1.02 (0.86-1.20) 0.832
RS1800562 G 1901 0.94 641 0.94 1.03 (0.79-1.34) 0.822 0.77 (0.62-0.96) 0.020
RS1800588 T 1890 0.23 640 0.22 0.97 (0.82-1.13) 0.675 1.00 (0.87-1.16) 0.961
RS1800961 T 1857 0.03 621 0.03 1.15 (0.72-1.85) 0.558 0.80 (0.30-2.14) 0.649
RS181362 T 1890 0.21 634 0.24 1.17 (0.99-1.40) 0.071 1.24 (1.09-1.41) 0.001
RS1883025 A 1836 0.25 609 0.25 1.02 (0.88-1.20) 0.766 0.91 (0.79-1.03) 0.140
RS2000999 A 1901 0.20 642 0.24 1.32 (1.08-1.60) 0.006 1.21 (1.02-1.43) 0.027
RS2068888 G 1896 0.55 637 0.54 0.96 (0.84-1.10) 0.568 0.86 (0.75-0.99) 0.034
RS2072183 G 1890 0.23 635 0.22 1.01 (0.86-1.19) 0.900 0.96 (0.84-1.11) 0.582
RS2075650 G 1859 0.14 624 0.15 1.01 (0.83-1.24) 0.893 1.00 (0.85-1.18) 1.000
RS2081687 T 1901 0.35 641 0.37 1.10 (0.96-1.27) 0.176 1.13 (1.01-1.27) 0.036
RS2083637 A 1874 0.74 622 0.75 1.01 (0.86-1.18) 0.933 0.90 (0.68-1.18) 0.433
RS2228671 C 1883 0.88 640 0.89 1.22 (1.01-1.46) 0.037 1.16 (0.97-1.38) 0.101
RS2240466 G 1873 0.90 621 0.89 0.91 (0.72-1.15) 0.412 0.95 (0.73-1.22) 0.670
RS2255141 T 1902 0.30 641 0.32 1.06 (0.91-1.23) 0.450 1.12 (0.85-1.47) 0.425
RS2271293 A 1817 0.87 620 0.87 1.02 (0.84-1.24) 0.837 0.93 (0.75-1.15) 0.503
RS2277862 C 1901 0.85 642 0.83 0.90 (0.74-1.10) 0.317 0.97 (0.83-1.13) 0.697
RS2290159 G 1895 0.80 637 0.80 0.93 (0.78-1.11) 0.440 0.88 (0.76-1.02) 0.078
RS2293889 A 1890 0.41 635 0.41 1.01 (0.89-1.16) 0.853 1.00 (0.89-1.11) 0.958
RS2304130 A 1886 0.91 640 0.91 1.01 (0.80-1.27) 0.933 0.93 (0.76-1.12) 0.426
rs2241213 G 1834 0.47 623 0.45 0.95 (0.83-1.08) 0.444 0.99 (0.86-1.13) 0.860
RS2412710 A 1901 0.02 641 0.03 1.08 (0.68-1.70) 0.758 0.82 (0.58-1.16) 0.251
RS2479409 G 1895 0.36 635 0.36 0.99 (0.86-1.13) 0.865 0.98 (0.88-1.10) 0.728
RS2650000 A 1839 0.34 623 0.34 1.01 (0.88-1.17) 0.858 1.00 (0.89-1.13) 0.981
RS2652834 A 1886 0.20 633 0.19 0.98 (0.83-1.16) 0.776 0.93 (0.80-1.08) 0.346
RS2737229 T 1901 0.67 642 0.68 1.00 (0.87-1.15) 0.979 0.92 (0.79-1.09) 0.343
RS2814944 T 1890 0.15 635 0.13 0.91 (0.76-1.09) 0.307 0.93 (0.77-1.11) 0.400
RS2814982 G 1902 0.90 641 0.90 0.95 (0.75-1.19) 0.643 0.98 (0.81-1.19) 0.870
RS2902940 A 1890 0.70 635 0.71 1.04 (0.90-1.19) 0.607 1.06 (0.61-1.85) 0.828
RS2923084 G 1890 0.19 635 0.18 0.93 (0.79-1.09) 0.351 0.97 (0.84-1.12) 0.707
RS2925979 T 1890 0.30 635 0.33 1.23 (1.05-1.44) 0.012 1.13 (0.93-1.38) 0.217
RS2929282 A 1901 0.05 641 0.05 0.99 (0.74-1.33) 0.952 1.01 (0.79-1.30) 0.927
RS2954029 A 1870 0.52 619 0.54 1.07 (0.94-1.23) 0.310 1.05 (0.94-1.18) 0.388
RS2972146 T 1898 0.64 637 0.67 1.19 (1.05-1.36) 0.009 1.06 (0.94-1.19) 0.353
RS328     C 1835 0.89 620 0.90 1.17 (0.95-1.44) 0.146 1.03 (0.84-1.26) 0.770
RS3757354 C 1898 0.79 642 0.80 1.05 (0.89-1.23) 0.551 1.00 (0.86-1.17) 0.994
RS3764261 C 1889 0.69 634 0.70 1.09 (0.95-1.25) 0.215 1.06 (0.94-1.20) 0.327
RS3905000 T 1798 0.12 614 0.10 0.87 (0.72-1.06) 0.161 0.86 (0.54-1.39) 0.544
RS4129767 G 1898 0.51 637 0.52 1.01 (0.89-1.16) 0.840 0.97 (0.86-1.09) 0.575
RS4148008 C 1890 0.30 635 0.32 1.13 (0.97-1.31) 0.113 0.97 (0.85-1.10) 0.583
rs6544713 T 1832 0.30 630 0.30 1.06 (0.91-1.23) 0.475 0.96 (0.85-1.08) 0.491




Subcohort Cases CHD CHD adjusted*
N RAF N RAF HR (95% CI) P HR (95% CI) P
RS442177 T 1888 0.59 635 0.59 1.03 (0.90-1.18) 0.622 1.11 (0.99-1.24) 0.086
RS4660293 C 1861 0.25 633 0.25 0.97 (0.83-1.13) 0.686 0.82 (0.72-0.94) 0.003
RS471364  G 1841 0.12 612 0.13 1.08 (0.87-1.34) 0.464 1.08 (0.91-1.28) 0.369
RS4731702 C 1863 0.52 631 0.52 1.01 (0.88-1.15) 0.944 1.01 (0.91-1.13) 0.802
RS4765127 G 1893 0.68 637 0.70 1.04 (0.89-1.20) 0.648 1.02 (0.88-1.17) 0.832
RS4846914 G 1825 0.41 602 0.43 1.08 (0.94-1.25) 0.256 0.98 (0.86-1.11) 0.755
RS492602 G 1899 0.44 640 0.45 1.05 (0.92-1.19) 0.517 1.04 (0.93-1.16) 0.483
RS4939883 C 1777 0.84 602 0.86 1.15 (0.97-1.36) 0.106 1.20 (1.04-1.40) 0.015
RS514230 T 1890 0.52 634 0.54 1.14 (1.00-1.31) 0.051 1.19 (0.94-1.51) 0.151
RS581080 C 1897 0.19 636 0.19 1.01 (0.85-1.19) 0.938 0.97 (0.84-1.12) 0.639
RS6029526 A 1888 0.47 632 0.46 0.97 (0.85-1.11) 0.690 1.01 (0.90-1.13) 0.925
RS629301 A 1897 0.79 639 0.82 1.25 (1.07-1.45) 0.004 1.23 (1.06-1.42) 0.005
RS6450176 T 1893 0.26 633 0.26 0.98 (0.85-1.14) 0.789 0.86 (0.76-0.98) 0.019
RS645040 T 1890 0.79 634 0.79 0.98 (0.83-1.16) 0.808 0.91 (0.80-1.05) 0.195
RS646776  A 1887 0.79 641 0.82 1.27 (1.09-1.47) 0.002 1.25 (1.07-1.45) 0.004
RS6511720 G 1867 0.12 615 0.11 0.80 (0.67-0.95) 0.013 0.85 (0.71-1.01) 0.062
RS6544713 T 1832 0.30 630 0.30 1.06 (0.91-1.23) 0.475 0.96 (0.85-1.08) 0.491
RS6754295 T 1839 0.76 632 0.74 0.92 (0.78-1.08) 0.294 0.85 (0.75-0.97) 0.016
RS6756629 C 1888 0.94 641 0.93 0.97 (0.74-1.27) 0.817 0.81 (0.65-1.01) 0.057
RS6882076 G 1900 0.63 641 0.66 1.11 (0.97-1.27) 0.138 1.13 (1.00-1.27) 0.044
RS693     T 1874 0.48 620 0.48 1.01 (0.89-1.16) 0.860 0.93 (0.83-1.04) 0.191
RS6987702 C 1890 0.72 641 0.75 1.16 (1.01-1.34) 0.038 1.19 (1.04-1.34) 0.008
RS7134375 C 1901 0.59 641 0.60 1.01 (0.88-1.15) 0.912 0.88 (0.79-0.98) 0.019
RS7255436 C 1897 0.49 640 0.51 1.05 (0.93-1.20) 0.439 1.10 (0.89-1.36) 0.375
RS737337 C 1826 0.08 616 0.10 1.12 (0.87-1.45) 0.393 1.11 (0.92-1.33) 0.275
RS7395662 G 1871 0.59 632 0.58 0.89 (0.77-1.02) 0.091 0.88 (0.56-1.38) 0.574
RS7515577 T 1901 0.77 642 0.78 1.05 (0.90-1.23) 0.569 1.03 (0.90-1.18) 0.691
RS7557067 A 1853 0.76 620 0.74 0.92 (0.79-1.08) 0.329 0.87 (0.76-0.99) 0.029
RS7570971 A 1901 0.41 641 0.44 1.09 (0.95-1.24) 0.217 1.14 (1.02-1.27) 0.019
RS7679    C 1807 0.20 622 0.19 1.02 (0.85-1.21) 0.869 1.04 (0.90-1.20) 0.595
RS780093 T 1860 0.41 628 0.44 1.11 (0.96-1.27) 1.530 0.95 (0.85-1.07) 0.426
RS7819412 C 1866 0.51 612 0.49 0.93 (0.81-1.06) 0.271 0.93 (0.82-1.04) 0.194
RS7941030 C 1901 0.38 642 0.39 1.03 (0.89-1.18) 0.725 0.96 (0.86-1.07) 0.463
RS8017377 A 1901 0.46 642 0.46 0.99 (0.86-1.13) 0.855 0.92 (0.82-1.03) 0.158
RS838880 A 1901 0.69 641 0.71 1.03 (0.90-1.19) 0.643 1.01 (0.89-1.14) 0.890
RS9488822 T 1899 0.67 640 0.67 1.00 (0.87-1.15) 0.990 1.09 (0.97-1.23) 0.149
RS964184 C 1880 0.14 639 0.14 0.96 (0.80-1.17) 0.704 0.80 (0.56-1.14) 0.215
RS9686661 T 1902 0.19 641 0.20 1.08 (0.91-1.29) 0.378 1.15 (1.00-1.32) 0.050
RS9987289 A 1896 0.07 639 0.07 0.88 (0.69-1.11) 0.274 0.68 (0.53-0.88) 0.003
SNPs selected for their association with anthropomorphic related traits
RS10146997 G 1900 0.19 642 0.21 1.11 (0.93-1.32) 0.262 1.07 (0.93-1.23) 0.341
RS10838738 C 1813 0.32 612 0.32 1.05 (0.91-1.22) 0.506 1.02 (0.90-1.16) 0.720
RS10913469 G 1764 0.19 599 0.21 1.19 (0.98-1.44) 0.081 1.29 (1.10-1.51) 0.001




Subcohort Cases CHD CHD adjusted*
N RAF N RAF HR (95% CI) P HR (95% CI) P
RS11084753 G 1794 0.68 609 0.67 0.94 (0.81-1.09) 0.389 0.81 (0.70-0.94) 0.004
RS1260326 T 1863 0.42 615 0.44 1.07 (0.93-1.23) 0.343 0.91 (0.72-1.15) 0.426
RS12970134 A 1839 0.26 621 0.28 1.10 (0.94-1.29) 0.239 1.01 (0.89-1.15) 0.833
RS2568958 A 1854 0.61 622 0.61 0.96 (0.84-1.11) 0.572 0.95 (0.83-1.10) 0.495
RS2605100 G 1895 0.70 639 0.71 1.04 (0.90-1.19) 0.616 1.10 (0.98-1.24) 0.115
rs29939 G 1837 0.69 615 0.68 0.91 (0.78-1.06) 0.212 0.79 (0.66-0.93) 0.006
RS3764261 C 1889 0.69 634 0.70 1.09 (0.95-1.25) 0.215 1.06 (0.94-1.20) 0.327
RS6265    G 1792 0.79 612 0.78 0.91 (0.76-1.08) 0.267 0.99 (0.86-1.12) 0.825
RS6499640 G 1841 0.57 614 0.57 1.03 (0.89-1.18) 0.728 1.04 (0.93-1.16) 0.551
RS6548238 C 1831 0.83 618 0.82 0.96 (0.80-1.16) 0.694 0.91 (0.79-1.06) 0.225
RS7498665 G 1859 0.36 626 0.38 1.06 (0.92-1.22) 0.455 1.04 (0.90-1.21) 0.562
RS7561317 G 1767 0.83 596 0.82 0.98 (0.82-1.18) 0.858 0.93 (0.80-1.09) 0.368
RS7647305 G 1824 0.81 602 0.80 1.01 (0.85-1.20) 0.902 0.97 (0.84-1.12) 0.671
RS8050136 A 1815 0.36 622 0.40 1.19 (1.04-1.38) 0.014 1.20 (1.07-1.34) 0.002
RS925946  T 1896 0.28 641 0.30 1.14 (0.98-1.32) 0.091 1.29 (1.10-1.51) 0.002
RS987237  G 1899 0.19 641 0.18 0.95 (0.81-1.12) 0.561 0.96 (0.83-1.12) 0.613
SNP, single nucleotide polymorphism; BP, base pair; RA, risk allele; RAF, risk allele frequency; CHD, coronary heart 
disease; HR, hazard ratio; CI, confidence interval; P, P-value; MI, myocardial infarction; CAD, coronary artery disease 
* Adjusted for sex, current smoking, systolic blood pressure, total cholesterol, HDL cholesterol, body mass index, 
diabetes and family history of MI, age was used as the time scale variable
Table S6a | Reclassification of subjects when a Genetic Risk Score (GRS) composed of all 179 SNPs was used in 
addition to traditional risk factors (age, sex, current smoking, total cholesterol, HDL cholesterol, BMI, parental 
history of MI and self-reported diabetes).
Model without 
Overall GRS
Model with Overall GRS
<5% 5-<10% 10-<20% ≥20% Total
Incident cases
<5% 191 4 0 0 195
5-<10% 1 126 2 0 129
10-<20% 0 4 76 0 80
≥20% 0 0 0 30 30
Total 192 134 78 30 434
Non-cases
<5% 1755 7 0 0 1762
5-<10% 11 157 4 0 172
10-<20% 0 3 61 0 64
≥20% 0 0 0 14 14
Total 1766 167 65 14 2012
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Table S6b | Reclassification of subjects when a Genetic Risk Score (GRS) composed of the 153 CHD risk factor SNPs 
was used in addition to traditional risk factors (age, sex, current smoking, total cholesterol, HDL cholesterol, BMI, 
parental history of MI and self- reported diabetes).
Model without 
Risk Factor GRS
Model with Risk Factor GRS
<5% 5-<10% 10-<20% ≥20% Total
Incident cases
<5% 193 2 0 0 195
5-<10% 1 126 2 0 129
10-<20% 0 1 79 0 80
≥20% 0 0 0 30 30
Total 194 129 81 30 434
Non-cases
<5% 1759 3 0 0 1762
5-<10% 2 169 1 0 172
10-<20% 0 1 63 0 64
≥20% 0 0 0 14 14
Total 1761 173 64 14 2012
Table S6c | Reclassification of subjects when a Genetic Risk Score (GRS) composed of the 29 SNPs previously 
associated with CHD was used in addition to traditional risk factors (age, sex, current smoking, total cholesterol, 
HDL cholesterol, BMI, parental history of MI and self-reported diabetes).
Model without 
CHD GRS
Model with CHD GRS  
<5% 5-<10% 10-<20% ≥20% Total
Incident cases
<5% 190 5 0 0 195
5-<10% 4 116 9 0 129
10-<20% 0 4 73 3 80
≥20% 0 0 4 26 30
Total 194 125 86 29 434
Non-cases
<5% 1751 11 0 0 1762
5-<10% 18 150 4 0 172
10-<20% 0 5 56 3 64
≥20% 0 0 1 13 14
Total 1769 166 61 16 2012
152
Supplement III
Table S6d | Reclassification of subjects when a Genetic Risk Score (GRS) composed of the 29 weighted CHD risk 
SNPs was used in addition to traditional risk factors (age, sex, current smoking, total cholesterol, HDL cholesterol, 
BMI, parental history of MI and self-reported diabetes).
Model without 
weighted CHD GRS
Model with weighted CHD GRS  
<5% 5-<10% 10-<20% ≥20% Total
Incident cases
<5% 183 12 0 0 195
5-<10% 3 114 12 0 129
10-<20% 0 9 68 3 80
≥20% 0 0 4 26 30
Total 186 135 84 29 434
Non-cases
<5% 1748 14 0 0 1762
5-<10% 22 144 6 0 172
10-<20% 0 8 51 5 64
≥20% 0 0 1 13 14
Total 1770 166 58 18 2012
Table S6e | Reclassification of subjects when a weighted Genetic Risk Score (GRS) composed of 3 SNPs selected 
using LASSO regression on the 29 SNPs previously associated to CHD was used in addition to traditional risk 




Model with weighted CHD GRS  
<5% 5-<10% 10-<20% ≥20% Total
Incident cases
<5% 180 15 0 0 195
5-<10% 11 104 14 0 129
10-<20% 0 10 65 5 80
≥20% 0 0 5 25 30
Total 191 129 84 30 434
Non-cases
<5% 1743 19 0 0 1762
5-<10% 29 134 9 0 172
10-<20% 0 10 52 2 64
≥20% 0 0 2 12 14
Total 1772 163 63 14 2012
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Table S6f | Reclassification of subjects when a weighted Genetic Risk Score (GRS) composed of 14 SNPs selected 
using LASSO regression on all 179 SNPs was used in addition to traditional risk factors (age, sex, current smoking, 
total cholesterol, HDL cholesterol, BMI, parental history of MI and self-reported diabetes).
Model 
without LASSO GRS
Model with LASSO GRS  
<5% 5-<10% 10-<20% ≥20% Total
Incident cases
<5% 173 22 0 0 195
5-<10% 15 83 31 0 129
10-<20% 1 17 53 9 80
≥20% 0 0 4 26 30
Total 189 122 88 35 434
Non-cases
<5% 1730 32 0 0 1762
5-<10% 47 113 12 0 172
10-<20% 0 17 42 5 64
≥20% 0 0 4 10 14
Total 1777 162 58 15 2012
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Table S8 | Information about the subsets of SNPs, their coefficients and the appropriate weighting factors. The 
subsets of SNPs were selected using 10-fold cross-validated LASSO regression on only the 29 SNPs previously 
associated with CHD and all 179 SNPs. 




LASSO regression on the 29 CHD SNPs
RS10757278 9p21.3 CDKN2A, CDKN2B 0.160 1.000 CHD
RS11556924 7q32.2 ZC3HC1 0.038 0.238 CAD
RS646776 1p13.3 CELSR2, PSRC1, SORT1 0.041 0.256 MI
LASSO regression on all 179 SNPs
rs10757278 9p21.3 CDKN2A, CDKN2B 0.159 1.000 CHD
rs2925979 16q23.2 CMIP 0.066 0.414 HDL
rs6882076 5q33.3 TIMD4 0.006 0.039 TC
rs2954029 8q24.13 TRIB1 0.001 0.007 TG
rs6987702 8q24.13 TRIB1 0.011 0.067 TC
rs10889352 1p31.1 DOCK7 0.023 0.142 TC
rs2972146 2q36.3 IRS1 0.050 0.316 HDL-C
rs11556924 7q32.2 ZC3HC1 0.031 0.198 CAD
rs514230 1q42.3 IRF2BP2 0.021 0.135 TC
rs8050136 16q12.2 FTO 0.063 0.394 DM2, DMI
rs181362 22q11.21 UBE2L3 0.015 0.096 HDL
rs646776 1p13.3 CELSR2, PSRC1, SORT1 0.065 0.406 MI, LDL-C
rs925946 11p14.1 BDNF 0.022 0.136 BMI
rs2000999 16q22.2 HPR 0.128 0.804 TC









Quintile of δ-5 desaturase activity1 P value 
for trend2
First Second Third Fourth Fifth
AA
(n = 205)
13 0.61 (0.27-1.41) 0.35 (0.15-0.79) 0.36 (0.16-0.80) 0.25 (0.11-0.54) <0.0001
14 0.60 (0.25-1.43) 0.35 (0.15-0.83) 0.48 (0.21-1.11) 0.35 (0.15-0.81) 0.022
15 0.63 (0.26-1.53) 0.40 (0.17-0.97) 0.55 (0.24-1.27) 0.44 (0.19-1.04) 0.087
AG/GG
(n = 276)
13 0.69 (0.46-1.03) 0.62 (0.38-1.00) 0.54 (0.31-0.93) 1.15 (0.57-2.33) 0.0276
14 0.62 (0.39-0.98) 0.71 (0.42-1.21) 0.72 (0.40-1.30) 1.64 (0.76-3.53) 0.463
15 0.63 (0.40-1.02) 0.75 (0.44-1.27) 0.78 (0.43-1.41) 1.86 (0.84-4.12) 0.649
1 δ-5 desaturase activity was assessed by the ratio of C20:4n-6 to C20:3n-6 in plasma cholesteryl esters.
2 From models with desaturase activity included as a continuous variable.
3 Model was adjusted for age, sex, systolic blood pressure, hypertensive medication use, current smoking, and 
diabetes.
4 Model was adjusted for age, sex, systolic blood pressure, hypertensive medication use, current smoking, diabetes, 
total cholesterol, and high-density lipoprotein cholesterol.
5 Model was adjusted for age, sex, systolic blood pressure, hypertensive medication use, current smoking, diabetes, 
total cholesterol, high-density lipoprotein cholesterol, and percentages of C22:6n-3 (DHA) in plasma cholesteryl 
esters.
6 Hazard ratio per unit desaturase activity (95% confidence interval) = 0.89 (0.80-0.99).




Incident CHD, n 234 259 56 -
Model 12 1.0 1.00 (0.80-1.26) 0.96 (0.67-1.37) 0.99 (0.84-1.16)
Model 23 1.0 1.15 (0.88-1.49) 0.91 (0.60-1.39) 1.02 (0.85-1.22)
1 The model assumes that each copy of the G allele contributes equally to coronary heart disease risk.
2 Model 1 was adjusted for age and sex. 
3 Model 2 was adjusted for age, sex, systolic blood pressure, hypertensive medication use, current smoking, 
diabetes, total cholesterol, and high-density lipoprotein cholesterol.
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Table S3 | Association between baseline n-6 PUFA in plasma cholesteryl esters (precursors and products of δ5- or 
δ6-desaturase) and incident coronary heart disease (CHD)
Quintile of C18:2n-6 (linoleic acid) P value 
for trend1
First Second Third Fourth Fifth
Incident CHD, n 127 125 102 97 86
Model 12 1 1.11 (0.80-1.54) 1.02 (0.72-1.44) 1.10 (0.78-1.56) 0.80 (0.57-1.13)  0.247
Model 23 1 1.16 (0.81-1.66) 1.27 (0.88-1.83) 1.30 (0.89-1.89) 0.91 (0.62-1.32) 0.861
Model 34 1 1.09 (0.74-1.60) 1.34 (0.91-1.96) 1.38 (0.92-2.09) 1.01 (0.68-1.48) 0.395
Model 45 1 1.09 (0.74-1.61) 1.34 (0.91-1.96) 1.39 (0.92-2.09) 1.01 (0.69-1.49) 0.389
Quintile of C18:3n-6 P value 
for trend1
First Second Third Fourth Fifth
Incident CHD, n 93 109 100 107 128
Model 12 1 1.05 (0.74-1.50) 0.89 (0.62-1.28) 0.92 (0.64-1.32) 1.00 (0.71-1.41) 0.706
Model 23 1 1.12 (0.76-1.64) 0.90 (0.61-1.33) 1.02 (0.69-1.50) 0.93 (0.64-1.37) 0.867
Model 34 1 1.13 (0.75-1.72) 0.90 (0.58-1.38) 1.01 (0.66-1.53) 1.05 (0.70-1.57) 0.605
Model 45 1 1.14 (0.75-1.73) 0.90 (0.58-1.39) 1.02 (0.67-1.56) 1.06 (0.70-1.61) 0.536
Quintile of C20:3n-6 P value 
for trend1
First Second Third Fourth Fifth
Incident CHD, n 88 80 107 125 137
Model 12 1 0.98 (0.68-1.43) 1.14 (0.80-1.64) 1.29 (0.91-1.82) 1.39 (0.99-1.96) 0.024
Model 23 1 0.91 (0.61-1.34) 1.06 (0.73-1.55) 1.14 (0.78-1.66) 1.43 (1.00-2.05) 0.011
Model 34 1 0.94 (0.61-1.45) 1.13 (0.75-1.69) 1.00 (0.67-1.50) 1.11 (0.75-1.67) 0.494
Model 45 1 0.95 (0.62-1.47) 1.15 (0.76-1.73) 1.03 (0.67-1.57) 1.14 (0.75-1.74) 0.420
Quintile of C20:4n-6 (arachidonic acid) P value 
for trend1
First Second Third Fourth Fifth
Incident CHD, n 127 107 120 79 104
Model 12 1 0.89 (0.63-1.24) 0.96 (0.70-1.34) 0.65 (0.45-0.92) 0.76 (0.54-1.06) 0.031
Model 23 1 0.86 (0.60-1.22) 0.92 (0.65-1.31) 0.64 (0.43-0.94) 0.77 (0.53-1.10) 0.088
Model 34 1 1.06 (0.72-1.56) 1.09 (0.74-1.60) 0.79 (0.51-1.21) 0.86 (0.58-1.28) 0.163
Model 45 1 1.04 (0.70-1.55) 1.07 (0.73-1.58) 0.76 (0.48-1.20) 0.83 (0.53-1.28) 0.150
1 From models with fatty acids included as continuous variables.
2 Model 1 is adjusted for age and sex. 
3 Model 2 is adjusted for age, sex, systolic blood pressure, hypertensive medication use, current smoking, and 
diabetes.
4 Model 3 is adjusted for all covariates in model 2, total cholesterol, and high-density lipoprotein cholesterol.
5 Model 4 is adjusted for all covariates in model 3 and baseline n-3 PUFA in plasma cholesteryl esters. 
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Table S4 | Association of baseline C20:5n-3 (EPA) and C22:6n-3 (DHA) in plasma cholesteryl esters with incident 
coronary heart disease (CHD)












Incident CHD, n 96 100 104 114 123
Model 13 1 0.81 (0.57-1.16) 0.88 (0.62-1.26) 0.82 (0.57-1.16) 0.82 (0.58-1.17) 0.348
Model 24 1 0.86 (0.59-1.24) 0.91 (0.62-1.33) 0.88 (0.61-1.27) 0.76 (0.52-1.11) 0.243
Model 35 1 0.90 (0.60-1.34) 0.90 (0.59-1.39) 0.79 (0.52-1.20) 0.89 (0.58-1.35) 0.733
Model 46 1 0.90 (0.60-1.35) 0.90 (0.59-1.39) 0.80 (0.52-1.22) 0.89 (0.58-1.35) 0.724












Incident CHD, n 89 139 93 112 104
Model 13 1 1.45 (1.03-2.05) 0.87 (0.60-1.25) 1.07 (0.74-1.53) 0.93 (0.65-1.34) 0.286
Model 24 1 1.49 (1.05-2.13) 0.84 (0.58-1.24) 1.13 (0.77-1.67) 0.86 (0.58-1.29) 0.268
Model 35 1 0.96 (0.65-1.43) 0.61 (0.41-0.92) 0.89 (0.59-1.34) 0.65 (0.42-0.99) 0.049
Model 46 1 0.95 (0.64-1.40) 0.57 (0.38-0.87) 0.82 (0.53-1.26) 0.59 (0.37-0.93) 0.027
1 Median percentages of EPA and DHA in each quintile are listed between brackets.
2 From models with fatty acids included as continuous variables. 
3 Model 1 is adjusted for age and sex. 
4 Model 2 is adjusted for age, sex, systolic blood pressure, hypertensive medication use, current smoking, and 
diabetes.
5 Model 3 is adjusted for all covariates in model 2, total cholesterol, and high-density lipoprotein cholesterol.
6 Model 4 is adjusted for all covariates in model 3 and baseline n-6 PUFA in plasma cholesteryl esters. 
Supplementary Note S1
Analysis of intermediate factors of coronary heart disease (CHD)
To explore whether δ-5 desaturase activity might exert its protective effect against CHD 
through known intermediate risk (or protective) factors of CHD (total and HDL cholesterol 
levels, systolic blood pressure, diabetes mellitus, EPA and DHA), we regressed these 
factors against δ-5 desaturase activity with adjustment for age and sex. It seems some of 
these intermediate factors (HDL cholesterol levels, EPA and DHA) might be involved in the 
protective effects of δ-5 desaturase activity against CHD risk (See Table S5).
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Table S5 | Association between intermediate risk (protective) factors for coronary heart disease and δ-5 desaturase 
activity at baseline in a random subcohort (n = 1263).1
Covariates B P
Total cholesterol (mmol/L)2 -0.021 ± 0.011 0.076
HDL cholesterol (mmol/L)2 0.020 ± 0.003 < 0.0001
Systolic blood pressure (mmHg)2 -0.29 ± 0.17 0.078
EPA (%)2 0.044 ± 0.004 < 0.0001
DHA (%)2 0.023 ± 0.002 < 0.0001
Diabetes mellitus (Yes/no)3 -0.020 ± 0.12 0.86
1 δ-5 desaturase activity was assessed by the ratio of C20:4n-6 to C20:3n-6 in plasma cholesteryl esters.
2 B and P are β regression coefficients ± SE and corresponding p values obtained by using a regression model 
adjusted for age and sex.
 3 B and P are β regression coefficient ± SE and corresponding p value obtained by using a logistic model adjusted 




Het is zeven jaar geleden dat ik naar Leiden kwam. Nu heb ik mijn proefschrift afgerond 
en is het tijd voor een nieuwe stap in mijn carrière. Eén van de dingen die ik geleerd heb 
tijdens die zeven jaren is dat je wetenschap samen doet en niet alleen. Daarom wil ik graag 
diegenen bedanken die het voor mij mogelijk hebben gemaakt dit proefschrift te schrijven. 
Om te beginnen bij mijn promotor Professor Eline Slagboom. Hartelijk bedankt voor de tijd 
die jij in mij hebt gestoken om dit proefschrift tot een goed einde te brengen. Daarnaast 
wil ik mijn co-promotor Bas Heijmans bedanken voor zijn inzet en de discussies die hebben 
geleid tot beter proefschrift. 
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R-scriptjes was Stefan een grote steun voor mij. Ook wil ik Jolanda bedanken voor haar 
uitleg over het case-cohort design en de CAREMA studie.
Zonder data geen proefschrift. Dennis en Eka bedankt voor jullie steun en hulp op het 
lab. Aswin, Sibel, Axel en André ik heb jullie hulp met betrekking tot het uitvoeren van de 
1H-NMR  experimenten en het interpreteren van de spectra zeer gewaardeerd. 
Claudia, onze samenwerking heeft geleid tot een beter artikel en daar ben ik heel blij mee. 
Yingchang thank you for your collaboration on this NHS project which resulted in this thesis. 
Ook wil ik mijn collega’s bedanken, niet alleen voor de wetenschappelijke discussies, maar 
ook voor de gezelligheid bij ons op de afdeling. Ik denk dat de stelling “Werken en feesten 
maakt schoone geesten” zeker van toepassing is op onze afdeling.
 Ana ik vond het erg leuk om jouw paranimf te zijn tijdens je promotie. Hierdoor weet ik al 
een beetje hoe het voelt om als promotie kandidaat aan tafel te zitten. 
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Naast werken moet er ook tijd zijn voor ontspanning. Die ontspanning heb ik gevonden in de 
vele leuke uitjes die ik samen met mijn vrienden heb ondernomen. 
Acrobatiek doe je samen, niet alleen. De gezelligheid van mijn mede-acrobaten en hun 
belangstelling voor mijn proefschrift heb ik zeer gewaardeerd. 
Ook wil ik mijn ouders en broer bedanken voor hun steun en interesse tijdens mijn 
promotietraject. 
Annemieke, zonder jou had ik Bob nooit leren kennen en dit brengt mij bij mijn allerlaatste 
bedankje. Dankjewel lieve Bob voor jouw steun tijdens het schrijven van dit proefschrift.
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